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1.1. History 
In 1955 a virus was isolated by Morris et al. from a chimpanzee with an upper respiratory 
tract infection (80). This apparently new virus was originally called chimpanzee coryza 
agent. Soon aftclwards, when it was isolated from children with respiratory disease, it 
became clear that this virus was a major human pathogen (18-20). The virus was from then 
onward called respiratory syncytial virus (RSV) because of its ability to caLise respiratory 
disease and to induce large syncytia in cell culture. RSV is now known as the single l11os1 
common cause of severe respiratory tract infection in childhood. In fact up to 70% of hos-
pital admissions of infants for respiratory infections during the winter season may be caused 
by RSV alone (37). 
Soon after RSV was found to be a significant cause of morbidity and 1ll00iaiity in childhood 
the search for a vaccine began. During the sixties a formalin inactivated RSV (FI-RSV) can-
didate vaccine, known as "lotI 00", was developed and administered to children of two to 
seven years old. This vaccine, in stead of protecting vaccinees against RSV infection, pre-
disposed for more severe disease upon natural infection in the following RSV season. 
Hospitalization rates were as high as 80% and two of the vaccinces died (22,34,69). 
At this moment, despite considerable research efforts, no licensed vaccine is available 
against this important pathogen. Development ofa vaccine against RSV is one of the prior-
ities of the Global Program for Vaccines of the World Health Organization (27). 
1.2. Virology 
RSV is a member of the family of Paramyxoviridae. It belongs to the genus PnCU1l10VilUS, 
together with bovine RSV - which causes a disease in calves similar to the severe manifes-
tations of human RSV in infants - the turkey rhinotracheitisvirus and the pneumonia virus 
of mice (Table 1.1.). The virion contains one single-stranded negative-sense RNA genome, 
of 15.222 base pairs long, which contains the genetic information for the ten known RSV 
proteins (61). The RSV genome is enclosed within the nucleocapsid of about 13.5 11111 in 
diameter, which is encapsulated by a lipid bilayer envelope of 120-300 11m. The members 
of the genus Pneulllovims differ from other paramyxQvirusscs by having envelope proteins 
without hemaglutinin or neuraminidase activity and also by having a second matrix protein 
(24). 
RSV contains 8 structural proteins. The two main envelope glycoproteins, the fusion pro-
tein (F) and the glycoproteIn (G) form the spikes which are visible as a fuzzy layer by elec-
tron microscopy (see also Figure 1.1.). The F protein of about 70kD mediates both viral 
penetration and cell to cell spread by fusion of membranes. This protein contains N linked 
oligosacharidc groups and is composed of 2 disulfide-linked subunits of 47kD (FI) and 
20kD (F2). The larger envelope protein G of about 90kD serves a function corresponding to 
Table 1.1. Classification of Paramyxoviridae 
Subfamily 
genlls virus 
Subfamily Paramyxovirinae 
Paral11yxuvil'us 
Rub/IIC/vil'us 
JvJorhillivirus 
tentative new genlls 
human parainfluenzavirus type 1 
human parainfluenzavirus type 3 
sendai virus (mouse parainHuenzavirus type 1) 
bovine parainHuenza virus type 3 
simian parainfluenzavirus type 1 () 
human parainfluenzavirus type 2 
human parainfluenzavirus type 4 A and B 
mumpsvirus 
porcine rubulavirus 
simian virus 5 (canine paraintluenzavirus type2) 
newcastle disease virus (avian para myxovirus 1) 
Yucaipavirus (avian paramyxovirus 2) 
avian paramyxovirus 3 to 9 
measiesvirlls 
canine distemper virus 
rinderpest virus 
peste-des-petit-ruminant virus 
phoeine distemper virus 
dolphin morbillivims 
porpoise distempervims 
Hcndra vints 
Nipah virus 
Menangle virus 
Subfamily Pneumovirinac 
PnelllllUvil'lIS human respiratory syncytial vims 
bovine respiratory syncytial virus 
mouse pneumonia virus 
turkey rhinotraeheitis virus 
Data obtained hom references 23,54,72,76,89 
CHAPTER 1 13 
disease in humans 
common cold, croup 
common cold, croup, 
pneumonia 
common cold, croup 
mumps 
measles 
respiratory symptoms 
flu-like symptoms, 
encephalitis 
common cold, 
bronchiolitis, pneumonia 
14 INTRODUCTION 
Envelope proteins 
F (70kD) -=====~,~ G (90kO) . 
S H {14kO} -:::::::=::=::==:J 
Nucleocapside proteins 
L (250kO) -::==::j~::::;~~===~==-N (42kO) ~ 
P (27kO) 
Matrix proteins 
M (28kO) 
M2 (22kD) 
structural proteins 
18 (14kO) 
1C (15kO) 
F;''Slfre 1.1. Negative contrast electron micrograph (A) and schematic diagram (8) of the RSV 
virion showing the different RSV proteins. (The elcctron micrograph was a kind gill tl'om dI'. 1.1. 
IIahova of the department of Virology of the Erasmus Medical Center Rotterdam). 
the host cell attachment of the hcmaglutinin of othcr paramyxovirusses. It is heavily gly-
cosilated with both 0- and N-linked oligosacharide groups. In fact more than 60% of the 
molecular weight of the G protein consists of sugar moieties. RSV contains one smaller 
envelope glycoprotein, the SH or 1A protein of about 14kO, of which the function is essen-
tially unknown. There are two matrix proteins, M of about 28kO and M2 of about 22kD. 
RSV contains 3 nucleocapsid-associated proteins; the nucleoprotein (N) of about 42kD, the 
phosphoprotein (P) of about 27kD and the large protein (L) orabout 250kD, which harbors 
the RNA polymerase function. Furthermore, RSV contains two small non-structural pro-
teins; the 1 Band 1 C protein of about 14 and 15kD respectivcly, of which the functions are 
unknown. 
Antigenic diversity in RSV strains is extensivc, especially for the G protein, the most vari-
able protein of the virus (66). RSV strains can be divided into two main groups, RSV-A and 
-B, by their reaction patterns with monoclonal antibody panels (4,81,82) and on the basis of 
the nucleotide sequence differences between several of their genes (13,65,10],103). 
Between the two groups antigenic homology is found to bc about 25%. For the F protein it 
is about 50%. For the G protein amino acid hOl11ology has been found to be as low as 53% 
and antigenic homology only 5(%, between the two groups. This makes the G protein the 
protein 1110st tolerable to mutations without loss off function known in nature (24,59,66). 
The two antigenic catcgories ofRSV have variously been described in literature as groups, 
subgroups, types or subtypes. The term "groupl! is currently used most frequently (102). 
Figure 1.2. Annual incidence or RSV group A and B isolations as detected at the department of 
Virology or the Erasmus Medical Center Rotterdam ti-om 1990 to 1998 (kindly provided by G. 
Aaron and Dr. Ph.II. Rothbmth). 
The RSV groups A and B circulate independently in the population with group A being 
somewhat more prevalent (2,60':-S1,106). Figure 1.2. illustrates this by showing the number 
of isolates of groups A and B over eight years in the Erasmus Medical Center Rotterdam. 
Also within the two groups several lineages can be identified, mainly on the basis of differ-
ences in the G protein. These strains also seem to co-circulate independently in the popula-
tion (l 0, I 01). 
1.3. Epidemiology 
RSV infections have a wortdwide geographical distribution. Wherever studies have been 
performed, RSV was found to be the main cause of severe lower respiratory tract infection 
in young children (24,37,113). Tn temperate climate zones RSV infections occur virtually 
only during the winter season during yearly epidemics (24), as is illustrated in Figure 1.3. 
Epidemics usually last for about 5 months but 40% of infections are usually found during 
one peak month, being mostly December or January. In tropical climates a different pattern 
is found. Infections may be detected year round with peaks oftcn found during the rainy sea-
son (113). In some years mainly group A viruses are isolated, whereas in others mainly 
group B viruses are found. In some years a co-circulation of both group A and B viruses is 
observed (sec also Figure 1.2.). 
RSV is spread via infected respiratory secretions. Transmission occurs mainly through 
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Figure J. 3. Monthly RSV it-lolaLions as detected at the department of Virology of the Erasmus 
Medical Center Rotterdam from 1991 to 1998 illustrating the yearly winter outbreaks of RSV in 
our setting (kindly provided by G. Aaron and dr. Ph.H. Rothbarth). 
direct close contact with infected individuals or contact with surfaces contaminated with 
respiratory secretions and subsequent f!sclf-infection" via contaminated hands to nasal and 
conjunctival mucosa. Transmission does not occur via small particle aerosols (46). RSV can 
survive on clothes for about 30 minutes and on smooth surfaces like countcliops and stetho-
scopes for several hours (9,49). 
RSV causes rcspiratOlY tract infections of patients of any age. Clinically severe RSV infec-
tions are mainly found in the very young, presumably at their first infection. The highest 
morbidity of RSV infections is seen in infants between six weeks and six months of age 
(3X,40,50,88). 
Reinfections with RSV are common. They tend to have a milder clinical course and usual-
ly remain limited to the upper rcspiratOlY tract. In a study of Hall et al about 25% of adult 
volunteers could be reinfected with RSV of the same group two months after natural infec-
tion (52). Frequent reinfections enable RSV to remain highly prevalent in the population. At 
least 50% of children are infected during their first winter. By two years of age almost all 
children will have been infected at least once and over 50% will have been infected twice 
(58). 
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1.4. Clinical manifestations of RSV infection 
RSV infection usually starts with upper respiratory tract infection characterized by rhinitis, 
cough and a low-grade fever. Two to five days later lower respiratory tract involvement may 
develop characterized by tachypnea, chest retractions and sometimes wheezing. Often 
hypoxemia and hypercapnia is observed. Only in a minority of children [ever is found at that 
stage. A high percentage (up to 40%) of young children infected with RSV for the first time 
will show signs of lower respiratory tract involvement (39,67,100), but only some will be 
so severely affected that hospital admission is necessary. Apnea is found in 10 - 20 % of 
infants hospitalized for RSV and in the very young apnea may be the only presenting symp-
tom of RSV infection. An estimated 0.5 - 2% of all infants are hospitalized with an RSV 
infection in their tirst year of life (38,40.50,75,85) and 7% - 21 % of these hospitalized 
infants will develop respiratoty insufficiency that requires ventilatoty support (11,12,105). 
Especially at risk for a severe clinical course of RSV infection are infants with underlying 
risk factors such as prematurity (85), bronchopulmonary dysplasia (41), congenital heart 
disease with pulmonaty hypertension (74) or immune deticiency (51). However, most chil-
dren admitted to hospital because of a RSV infection do not posses one or more oUhese risk 
factors. 
The most common clinical presentation of RSV infection in older children and adults is a 
mild upper respiratory infection. Although RSV is described mainly as a cause oflower res-
piratOlY tract infection in young infants, in recent years more and more reports of severe 
RSV infections in adults are seen (6,32,73,114). Severe clinical RSV infection is seen in 
immune compromised adults, especially shortly after bone marrow transplantation, where 
high mortality rates are found (33,55). During outbreaks among institutionalized elderly, 
RSV infections are tl-equently complicated by pneumonia and mortality rates of 2 to 20% 
have been described (43,56)S7,97). RSV infections have also been related to community 
acquired pneumonia and excacerbations ofCOPD in adult patients (44,98,108). 
1.5. Humoral immune response 
Tn response to RSV injection, antibodies to most RSV proteins develop (36,107.109·111). 
Neutralizing antibodies are mainly directed to the envelope glycoproteins and are involved 
in protection. Reinfection however, is readily possible (52,58) also in adults, indicating that 
protection is incomplete even when high levels of neutralizing antibodies are present. 
Antibodies detected locally in the respiratory tract are related to protection against infection 
or reinfection. Presence of neutralizing antibodies in the respiratOlY tract was described to 
correlate with relative protection against experimental infection in human adults (79,84) and 
development of local IgA has been found to coincide with virus clearance (77). 
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In the past antibodies have often been incriminated as playing a role in the pathology of 
RSV lower respiratory tract infection mainly based on two facts. 0) Most severe infections 
arc seen at an age when infants still have maternally derived antibodies (39,68), and (ii) the 
FI-RSV candidate vaccine, which predisposed for more severe disease upon subsequent 
infection, induced high levels of antibodies (22,83). I Iowever it has become apparent since, 
that RSV specific antibodies do not playa role in pathogenesis of severe lower respiratOlY 
tract disease. In fact RSV neutralizing antibodies induce protection to infection, although 
high titers are necessatY- This protective effect of high titers ofRSV neutralizing antibodies 
is found both in animal models (90) and in infants in which higher levels of maternally 
derived antibodies have been found to correlate with a relative protection to the develop-
ment of lower respiratory tract infection (38). Furthermore in recent years passive adminis-
tration of antibodies to high-risk children has been found to be valuable in decreasing the 
chance to develop severe clinical disease upon RSV infection (42,57,96). Recently RSV 
hyperimmuneglobulin (RespiGamC(Il) and a humanized monoclonal antibody directed to thc 
F protein (PaiuvizumabC13)) have been licensed for prophylactic usc in high-risk infants 
(1,78,94) 
1.6. Cellular immune response 
RSV specific cellular immune response is considered to playa major role in clearance of 
the virus and recove!y from infection. This is iI1ustrated by the observation that normal chil-
dren stop shedding virus within 1 to 3 weeks but T cell immune compromised children can 
shed virus for many months (17,51). Also in mouse models, T cell depleted animals can 
shed RSV for prolonged periods of time, whereas the administration ofRSV specific CD4+ 
and/or CDX+ cells can induce clearance of the virus in these animals. Interestingly the 
administration of these cells also tends to increase lung damage (3,16,26). 
Especially RSV specitic cytotoxic T cells (CTL) are found to play an important role in clear-
ing the virus (3,15,71,104). CTL against most RSV proteins can be readily detected after 
infection in several animal models (3,7,14,15,71,86,104) and in humans (7,8,14,21,62). 
However, no CTL response to the RSV G protein has yet been demonstrated (7). 
Apart from being important in protection, RSV specific T cell responses also playa role in 
the induction of lung pathology. In mouse models, upon challenge with live virus animals 
vaccinated with FI-RSV, a striking type 2 T cell response is induced which correlates with 
enhanced lung disease largely characterized by eosinophilia (3,25,26). This type 2 T cell 
response proved to correlate with the absence of a cytotoxic T cell response (95,99). 
Measurement of cellular immune memory response in peripheral blood mononuclear celts 
(PBMC) li'om normal children and adults sbowed a type I like T cell response (5). 
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Indications for a type 2 like T cell response are also found in humans. 1n vitro stimulation 
of PBMC from normal humans, with live RSV, FI-RSV or RSV proteins was shown to 
induce a type I like response for live RSV and the F prolein whereas FI-RSV and the G pro-
tein induced predominantly a type 2 like T cell response (63). Moreover lype 2 like 
cytokincs have been detected in supernatants of PBMC from children who experienced a 
RSV bronchiolitis at an early age (93), indicating a direct relationship between severe RSV 
lower respiratory tract infection and T cell responses. 
1.7. Pathogenesis ofRSV and the possible role of the immune response 
ill pathogenesis 
In experimental and natural settings the incubation period for RSV was found to be about 4 
to 5 days (46.64,67,70.100). At the beginning ofthe infection RSV primarily replicates in 
the epithelial cells of the nasophatynx (53), inducing signs of upper respiratory tract infec-
tion. The mechanism by which RSV sprcads to thc lower respiratory tract is essentially 
unknown, but it is thought that spread occurs mainly by the aspiration of nasopharingeaJ 
secretions. RSV may also spread directly from ce]J to cell. It is however unlikely that, in the 
natural situation, this is an important route for viral spread to the lower respiratory tract, 
because in certain animal studies the tracheal epithelium shows only a patchy infection at 
any time (31,91). RSV infections usually stay limited to the respiratory tract and do not 
become systemic even in severely affected children (24,35). No culturable virus is found in 
blood samples of immunologically competent patients, although RSV genome may be 
detected in bloodsamplcs of infecled young children (29,92). Signs of lower respiratory 
tract involvement, like tachypnea, usually start 1 to 3 days after the onsct of disease, prob-
ably indicating viral sprcad to the lower respiratory tract (24). 
Pathologic findings in severe RSV infection resemble those observed in severe infections 
by other respiratory viruses. In these cases destruction of epithelial cells is found and cell 
debris is released into the bronchiolar space, which is accompanied by enhanced mucus 
secretion. In addition a peri-bronchiolar inflammatory response is found, characterized by a 
cellular infiltrate mainly consisting of mononuclear cells. Also edema of the mucosa and 
submucosa develops. Mucosal necrosis and IllUCUS secretion togcther with swelling of sub-
mucosal tissllc may induce obstruction of the bronchioli, leading to hyperinflation and 
atelectasis of parts of the lungs, contributing to the classical signs and symptoms of RSV 
lower respiratOlY tract infection (24). 
Clinical severity of lower respiratory tract involvement in RSV infection is, at least partial-
ly, determined by the direct cytopathic effect of the virus infection on lung tissue. A role for 
an aberrant immunological response, occurring in part of the infected children, which 
increases the inflammatory process, has long been suspected. These speCUlations were based 
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on several observations. (i) Most importantly, the vaccine debacle, predisposing for a more 
severe disease upon subsequent infection (22,34,69). (ii) Severe infections found at an age 
when maternal antibodies are still present. (iii) Clinical signs that have been reported to 
diminish while virus excretion from the nasopharynx continued (47,48). (iv) Children who 
experienced a clinically scvcre RSV infection at a young age have higher chance of devel-
oping recurrent wheezing later in childhood (30,45,112). 
Enhanced disease after vaccination with FI-RSV has, in the mouse model, convincingly 
been related to an abenant type 2 like T cell response leading to more severe lung disease. 
Newborn infants still have an immature immune response and are known to be more prone 
to produce a type 2 like T cell response upon infection (28), possibly leading to more severe 
inflammation in these children upon RSV infection. The presence of type 2 cytokines in 
supernatants ofPBMC from children who experienced a RSV infection at an early age have 
been reported (93). 
1.8. Scope of this thesis 
Although for many years RSV has been recognized as the most prevalent cause of severe 
respiratory infection in young infants, the development of effective preventive and thera-
peutic strategies has been hampered by the lack of understanding of the pathogenesis of 
lower respiratory tract involvement occurring in part of the RSV infected infants. 
As outlined above it has long been suspected that an immune pathologic phenomenon may 
be at the basis of the development of severe RSV lower respiratory tract infection. However 
other factors related to the virus, the patient or the environment may have an impact on the 
clinical outcome of naturally occurring RSV infection in young infants. 
In this thesis the role of viral (chapter 2), environmental (chapter 3) and immunological fac-
tors (chapter 4 and 5) are studied in relation to the clinical sevcrity of RSV infection. The 
goal of these studies was to obtain more insight in factors related to the cl in ical severity of 
RSV lower respiratory tract infection. This knowledge will be valuable for the rational 
development of preventive and therapeutic intervention strategies for RSV infection in 
young infants. 
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Summary 
We investigated whether a relationship bet\veen clinical severity of RSV infection and dis-
tribution of subtype A or B could be demonstrated. The data of 232 children, who were 
admitted to or diagnosed with RSV infection in the outpatient department of the Sophia 
Children's Hospital, Rotterdam between 1992 and 1995, were studied. The diagnosis of 
RSV was confirmed by a direct immunofluorescence assay. SUbtyping was performed by an 
indirect immunofluorescence assay using specific monoclonal antibodies. Gender, age at 
diagnosis, gestational age and birthweight, the presence of underlying diseases, impaired 
feeding, the presence of wheezing and retractions, respiratory rate, temperature, clinical 
diagnosis at presentation, Sa02, pCO} and pH, characteristics of hospitalisation and the 
need for mechanical ventilation were observed. Analysis was performed on data from all 
patients diagnosed with RSV infection in the period between 1992 and 1995 spanning three 
RSV seasons, and seperately on the RSV season 1993 - 1994. The outcome of the three year 
analysis (150 (64.7%) subtype A vs. 82 (35.3%) subtype B) was compared with the oulcome 
of the season 1993 - 1994, a mixcd epidemic with 37 (60.7%,) subtype A and 24 (39.3'Yo) 
subtype B isolates. None of the variables observed in the season 1993 - J 994 differed sig-
nificantly bet\veen RSV-subtype 1\ and B. Similar results were obtained from the analysis in 
the period 1992 until 1995, with the exception of pC02 (a more high pC02 was found in 
subtype A, p < 0.001) and retractions (more retractions were noted in patients with subtype 
i\, p = 0.03). After correcting for possible confounders using regression analysis, these dif-
ferences were not significant anymore. 
Our data indicate that there is no relationship between clinical severity ofRSV infection and 
sUbtype. 
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Introduction 
Respiratory syncytial virus (RSV) if) the 1110St common cause of respiratory tract infections 
in infants and young children. The clinical presentation can vary from a mild upper respira-
tory tract infection to severe bronchiolitis. The incidence of RSV bronchiolitis reaches a 
maximulll at the age of two months and declines within the first year oflifc (13). The major-
ity of infections have a mild clinical course. A minority of infants, 0.5 to 2%, has to be 
admitted to the hospital. Between 7% and 21 % of these patients will need mechanical ven-
tilation (4,5). 
Severe infections may occur in premature infants or patients sutfering from an underlying 
disease, sLlch as congenital heart disease (CHD), bronchopulmonary dysplasia (BPD) or T-
cell-immunodeficiency (3). The mOJiality ofinifmts hospitalised with RSV is approximate-
ly 0.5% to 1.5%. In infants with an underlying disease higher mortality rates are found (7,8). 
Two major antigenic groups of RSV, subtype A and subtype B, can be identified by specif-
ic monoclonal antibodies (1). The antigenic diversity between these two subtypes is deter-
mined mainly by G-proteins, which are responsible for attachment of the virus and to a less-
er extent by the fusion proteins, the F-proteins. The two subtypes can circulate independ-
ently from each other, but they may also cocirculate during one cpidemic (2). The identifi-
cation of the two subtypes has led to the speculation that there might bc a relationship 
between clinical severity of infection and RSV subtype. A limited number of studies were 
carried out to establish such a relationship (6,9,10,14). These studies provide conflicting 
results. 
The objective of our study was to investigate whether a relationship between clinical sever-
ity of RSV infection and subtype could be demonstrated in children younger than 12 
1110nths. 
Patients and methods 
Patients younger than 12 months who either were admitted to the Sophia Children's Hospital 
or visited the outpatient department due to RSV infection in the period between 1992 and 
1995, were included in this study. The Sophia Children's Hospital is a combined secondary-
tertiary care university hospital. 
RSV infection was confirmed by a positive direct immunofluorescent assay (IFA) using 
FlTC labeled monoclonal antibodies against RSV (DAKO, Ely, UK) performed on cells of 
nasophmyngeal washing and/or a positive viral culture on HEp-2 cells (11). In 97.4% (n = 
226) both DIFA and viral culture were positive, in 1.3% (n = 3) only the DIFA was positive 
and in 1.3% (n = 3) only the viral culture was positive. RSV sUbtyping was performed using 
RSV subtype specific monoclonal antibodies (MAB) in an immunofluorescence assay on 
cells of nasopharyngeal washings as described by Taylor et. ai. (15). MABs used were 92-
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Table 2.1.1. Patient characteristics 
subtype A subtype B 
(n~ 150) (n ~ 82) 
(%) (%) 
Boys 63.3 67.1 
Girls 36.7 32.9 
Mean age (months) 3.5 ± 3.0 3.6 ± 2.9 
Patients < 3 1110nths 48.0 47.6 
3 - 6 months 26.7 26.8 
> 6 months 25.3 25.6 
Mean gestational age (weeks) 37.3 ± 3.8 37.8 ± 3.3 
Gestational age < 35 weeks 18.4 12.7 
35 - 37 weeks 10.3 12.7 
> 37 weeks 71.3 74.6 
Mean birthweight (g) 2936 ± 875 3023 ± 804 
Underlying disease state 16.3 11.0 
Prematurity and BPD (n) 10 4 
CHD (n) 14 3 
BPD (n) 0 2 
No significant dilTerences between RSV subtype A and l3 were found. 
Data expressed as percentages unless stated otherwise. 
BPD : bronchopulmonary dysplasia; OlD : congenital heart disease 
llC for subtype A and 1 02-10B for subtype B (Chemieon, Temecula USA) (I). Briefly, cells 
of nasopharyngeal washings were fixed on glass slides in acetone. RSV SUbtype specific 
MAB!s were incubated for 30 minutes at 3]'> C. After washing three times in PBS the slides 
were incubated with the conjugate anti-mouse FITC (Oako, Ely,UK). When the IFA was 
negative and viral culture was positive, the subtype specific immunofluorescence was per-
formed on RSV infected HEp-2 cells. 
Epidemiological and clinical data were retrospectively obtained from the medical chal1s. 
Patient characteristics include gender, age at diagnosis, birth weight, gestational age and the 
presence of underlying disease (congenital heart diseasc with hemodynamic consequences 
i.e. Icftlright shunt, bronchopulmonary disease and T-cell immune deiiciency). Clinical 
observations at presentation include impaired feeding (defined as norl11al feeding, slow 
feeding with normal volume, decreased volume and no oral ieeding), the presence ofwheez-
ing and retractions, and temperature. The usc of mechanical ventilation was registered dur-
ing admission. The decision for leU admission and mechanical ventilation was made before 
subtype was known. Other clinical parameters include characteristics of hospitalisation: 
Table 2.1.2. Clinical parameters at presentation 
Impaired fceding 
Wheezing 
Retractions 
Mean respiratOlY rate (min-I) 
Mean temperature (Oe) 
Mean Sa02 (%) 
Mean pCO, 
Mean pH 
subtype A 
(n ~ 150) 
(%) 
71.6 
36.0 
58.0 
52 ± 18 
37.8 ± 1.0 
90.3 ± 11.3 
6.8 ± 2.2 
7.35 ± 0.1 
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subtype B 
(11 ~ 82) 
(%) 
64.6 
34.1 
41.8 
51 ± 13 
38.0 ± 0.8 
90.4 ± 9.2 
5.8 ± 1.0 
7.37 ± O. 
No significant differences between RSV subtype A and 8 were found, except for the presence of 
retractions (p '"" 0.03) and pC02 (p < 0.001). 
Data expressed as cpercentages unless stated otherwise. 
number of admissions and length of stay in hospital and number of intensive care unit (leU) 
admissions and length of stay in leU. 
Laboratory parameters measured at presentation included measurement of oxygen satura-
tion (Sa02), peo2 and pH. Sa02 was measured transcutaneously with the llse of a pulse 
oximeter, pC02 was measured on capillary blood samples. All parameters wcre measured 
irrcspectivc of severity of disease. 
Three diagnostic categories were defined: bronchiolitis/pneumonia (lower respiratory tract 
infection, LRTI), upper respiratory tract infection (URTI) and apnoea. The diagnosis bron-
chiolitis was based on clinical features and hypertranslucency, atelectasis or bronchial thick-
ening on chest radiograph. URTT was defined as coughing and/or rhinitis, with no abnor-
malities on chest radiograph. Apnoea at presentation was defined as a cessation of respira-
tion for a period over 15 seconds and/or bradycardia with accompanying cyanosis. The 
diagnosis pneumonia was based on cl inical features and the presence of an infiltrate on chest 
radiograph. 
Statistical analysis was performed using the X2 test, the student's t-test and the Mann-
Whitney U test. P-value < 0.05 was considered significant. In order to examine the indepent 
effect of virus subtype on the severity of disease we adjusted for gender, age in months, pre-
maturity (gestational age ~ 37 weeks), the presence of underlying disease and year of diag-
nosis with logistic and linear regression analysis. Linear regression was used to investigate 
if there were differences between the two virus subtypes in Sa02 or pC02. Logistic regres-
sion was performed with dichotomous outcome variables sllch as impaired feeding, the 
presence of wheezing and retractions, the clinical diagnosis (bronchiolitis/pneumonia or 
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Table 2.1.3. Clinical diagnosis at presentation 
Apnoea ± URT[ 
URTl 
suhtype A 
(n ~ [50) 
(%) 
5.3 
24.7 
Bronchiolitis/pneumonia 3.3 
with URTJ 52.0 
with apnoea and URT[ 14.7 
No significant difTerences between subtype A and B were found. 
URTI : upper respiratory traet infection 
subtype B 
(n ~ 82) 
(%) 
3.7 
28.0 
2.4 
56.1 
9.8 
upper respiratOlY tract infection), need of mechanical ventilation and TCU admission. 
Results 
[n the period between 1992 and 1995 covering three RSV seasons, 232 children with RSV 
infection visited our hospital. In 1992 - 1993 a predominance of subtype B was found. Ten 
out of68 children were infected with subtype A (14.7%) versus 58 children with subtype B 
(85.3%). The season 1993 ~ [994 showed a mixed epidemic: 37 children were infected with 
subtype A (60.7%) and 24 children were infected with subtype B (39.3%). The season 1994 
- 1995 showed a epidemic in which all 103 children were infected with subtype A. 
Based upon the subtype distribution, two analysis were pertomed: one on the the entire peri-
od from 1992 until 1995, covering three RSV seasons and one on the mixed A/B season 
1993 - 1994. The results of the outcome of the analysis of the period [992 - 1995 were 
compared with the outcome of the analysis of the season 1993 - 1994. 
Al1alysis oflhe dalafi'Oll1 Ihe period 1992 I1l1lil 1995 
This period included 232 children: 150 (64.7%) werc infected with subtype A, 82 (35.3%) 
with subtype B. The malc/female ratio was 1.8 (150/82). Table 2.1.1. shows the population 
characteristics. 
Clinical parameters are shown in Table 2.1.2. No significant differences were found regard-
ing impaired feeding, the presence of wheezing, respiratory rate, temperature, Sa02 and pH. 
Significant differences were found regarding pC02 and the presence of retractions. The 
average peo, for subtype A is 6.8 kPa against 5.8 kPa for subtype B (1' < 0.00 I). 
Retractions were noted in 84 childrens infected with subtype A and in 28 children infected 
with subtype B (p ~ 0.03). No significant differences were found regarding underlying dis-
ease. Table 2.1.3. shows the clinical diagnosis at presentation. Tn Table 2.1.4. the character-
istics of hospitalisation are shown. 
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The pC02 was measured in 213 children: 136 (90.1%) samples were collected in patients 
with subtype A and 77 (94.0%) lor subtype B. We noted in the season 1994 - 1995 more 
children with a high peol (above 10.0 kPa) than in the other two seasons. We also found in 
the season 1994 - 1995 a significant difference ill the number of children < 2 months of age 
(in the first two seasons 19.4% against 34.0% of the children in the season 1994 - 1995, P 
= 0.01). Furthermore we found a significantly higher peol in children < 2 months of age 
(7.5 kPa vs. 6.0 lePa for children 2: 2 months of age, p < 0.001). This also applies to all three 
seasons separately. 
Twenty-eight (12.1 %) children required mechanical ventilation. Twenty-one of these were 
infected with subtype A, 7 with sUbtype B (1' ~ 0.22). Two children died. One ofthel11 was 
infected with subtype A, the other child was infected with subtype B. 
Table 2.1.4. Characteristics of hospitalisation 
Number of admissions 
Mean length of stay (days) 
Number of lCU admissions 
Mean length of stay in ICU (days) 
Mechanical ventilation 
subtype A 
(n ~ 150) 
(%) 
76.7 
10.4(6.2) 
34.0 
6.2(8.3) 
14.0 
subtype B 
(n ~ 82) 
(%) 
85.4 
9.3(4.8) 
23.2 
5.9(5.0) 
8.5 
No significant ditferences between RSV subtype A and B were found. 
Data expressed as percentages unless staled otherwise. 
leu: intensive care unit 
Adjustment for confounders with regression analysis did not reveil a significant difference 
between subtype A and B for any of the disease outcome parameters such as impaired feed-
ing, presence of wheezing, presence of retractions, Sa02 and pC02• lower respiratory tract 
infection, rCU-admission and mechanical ventilation. 
Analys;s of/he season 1993 - 1994 (lnd comparison Q(bofh analysis 
This period included 61 patients. The male/female ratio was 1.3 (35/26). We did not find a 
significant difference in the studied population characteristics between subtype A and sub-
type B. No significant ditferences were found between subtype A and subtype B for all the 
observed variables. 
The outcome of the analysis of the data from the season 1993 - 1994 was equal to the out-
come of the analysis of the data from the period 1992 - 1995, covering three seperate RSV 
seasons, except for pC02 and the presence of retractions. 
38 CUN1CAL SEVERITY OF RSV INFECTION AND SUBTYPE 
Discussion 
We investigated whether a relationship between clinical severity ofRSV infection and sub-
type A or B could be demonstrated. The results of our study indicate that such a relationship 
docs not ex ist. 
Two analysis were performed: one on data from the whole period between 1992 and 1995, 
covering three RSV seasons, and one on data of the season 1993 - 1994. By comparing the 
outcome of one season with the outcome of three seasons, the possible effect of confound-
ing variables fi'om a particular season was ruled out. 
As strong indicators for severity of infection in this study were Llsed oxygen saturation 
(Sa02), pC02, clinical diagnosis (upper respiratory tract infection versus lower respiratory 
tract infection), ICU-admission and the need for mechanical ventilation. These indicators 
arc strongly related to pulmonary dysfunction (6,16). 
None of the variables observed in the season 1993 1994 were significantly different 
between patients infected with subtype A and subtype B. This was also found in the analy-
sis of the period 1992 - 1995, except for the presence of retractions and pC02. More retrac-
tions were noted in patients with subtype A than in patients with subtype B. Howcver, the 
association did not hold after correcting for confounders using logistic regression analysis. 
Thc othcr variable that showed a significant difference is pC02. This is due to a relationship 
between young age and high pCG" as has been demonstrated by Mulholland et al.(12). Tn 
the season 1994 - 1995 (a season with only subtype A infections) significantly more chil-
dren younger than two months of agc were admitted with RSV than in the two preceding 
epidemics. The mean pe02 of these children was significantly higher than the mean pC02 
of children ~ 2 months. This influences the l11ean pe02 for subtype A in the whole period 
covering the three seperate RSV-seasons. After correcting for age, the association between 
high pCG, and subtype A did not hold. 
Several studies investigated the possible relationship between clinical severity of RSV 
infection and subtype. McConnochie et al. conclude that subtype A is related to a more 
severe disease (9). They analysed data from 157 patients with known subtype, using arbi-
trary cut-off values at which a variable was to be considered severe. Significant differences 
were observed in pC02 > 45 111111 Hg, Sa02 < 87% and respiratory rate> 72 min-i. A sig-
nificant difference was also observed between subtype A and subtype B regarding mechan-
ical ventilation. Straliotto et a1. concluded that subtype B is related to a more severe disease, 
but their popUlation was rather small: 29 patients (14). The results of both these studies are 
conflicting with those from our study. McIntosh et al. concluded that there is no difference 
in severity between subtype A and subtype B. They analysed their data using a severity 
index consisting of three groups: severe, moderate and mild (10). 
In conclusion, the outcome of the analysis of the data obtained in our study indicate that 
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there is no relationship between clinical severity of RSV infection and subtype A or B. 
lIenee it is 110t necessary to determine subtype at presentation, because there arc no conse-
quences for clinical management. The outcome of our study also implies that the develop-
ment of a vaccine has to be aimed in the direction of a vaccine which protects for subtype 
I\. as well as subtype 13. 
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Summary 
Respiratory syncytial virus group A strain variations of 28 isolates from The Netherlands 
collected during three consecutive seasons were studied by analyzing G protein sequences. 
Several lineages circulated repeatedly and simultaneously during the respective seasons. No 
relationships were found between lineages on the one hand and clinical severity or age on 
the other. 
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Respiratory syncytial virus (RSV) call be divided into two groups, A and B, on the basis of 
the reaction with monoclonal antibodies directed against the F and G protein (1,23) and 
nucleotide sequence differences of several genes (5,16,30,31). These two groups circulate 
independently in the hl1l11an population, with group A being the most prevalent (14,23). 
Also, within the two groups substantial strain differences have been described, mainly asso-
ciated with the divergence in the gene encoding the G protein (17), which is the 1110st vari-
able protein of the virus. Several lineages within groups A and B also seem to co-circulate 
simultaneously in the population (3,30). Studies on RSV strains show an accumulation of 
amino acid changes over the years, suggesting antigenic drift-based immunity-mediated 
selection (4,5,8,15,27). 
One of the most interesting features of RSV is its ability to cause repeated infections 
throughout life (9,11). This enables RSV to remain present at high levels in the population, 
and it has been estimated that at least 50% of children encounter their first RSV infection 
during their tirst winter season. S train variation is thought to contribute to its abil ity to cause 
frequent reinfections (4,8,32). 
The clinical severity of RSV infection is associated with epidemiological and host factors, 
which include socioeconomic status (26), age (26), prematurity (25), and underlying heart 
and/or lung disease (10,19). Several studies have evaluated differences in clinical severity 
between groups A and B. Tn about half of these studies no differences in clinical severity 
were detected between groups involved (14,18,21,22,28,34,37) and in the other studies 
group A seemed to be associated with more severe clinical disease (12,13,20,23,29,33,36). 
It has been suggested that virus variants within group A are responsible for this discrepan-
cy (7,12,36). 
To further address this issue, we selected group A strains from three consecutive winter sea-
sons and subjected isolates of these strains to sequence analyses of part of the G protein. The 
strains were isolated from children for whom standardized clinical data were available from 
our previous study concerning RSV-A versus RSV-B and clinical severity (18). 
RSV isolates (n --= 293) found in routine diagnostics during three consecutive winter seasons 
were typed by performing direct imlllune fluorescence on cells from nasopharyngeal wash-
ings using specific monoclonal antibodies MAB 92-11 C for group A and MAE 109-1 OB for 
group B (Chemicon, Temecula, CA) as previously described (2). Twenty-eight RSV group 
A isolates were selected for sequence analysis. 
AI! five group A strains available from the first season (1992-93) were included. Eleven 
from the second season (1993-94) and twelve from the third season (1994-95) were select-
ed from children who had experienced either a mild infection (not admitted) or a severe 
infection as determined by clinical parameters upon admission (see below). 
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Demographic and clinical data on the children during the acute phase and at the time of the 
control visit were collected in a previous study (18). Briefly, the data included gender, age, 
duration of pregnancy, underlying disease, feeding difliculties, history of apnea, the pres-
ence of retractions, respiratory rale, oxygen saturation (SaO}) in room air, pmiiai CO2 pres-
sure (peOl ), pH, abnormalities on X ray, admission to an intensive care unit, and the need 
for artificial ventilation. Severe RSV infection was defined as meeting onc or more of the 
following criteria: peo2 > 6.6 kPa Sa02 < 90%, and/or the need for artificial ventilation. 
Viral RNA extraction and amplification orthe viral RNA by reverse transcriptasc peR was 
carried out as described previously (35). Briefly, RNA was extracted ii'om 100 ILl of culture 
supernatant using a guanidiniull1 isothiocyanate solution and was collected by precipitation 
with isopropanol. The viral RNA was then amplified by reverse transcriptase peR using 
oligonucleotide primers G(A)-I73s (GGCAATGATAATCTCAACTTC) and G(A)-525as 
(TGAATATGCTGCAGGGTACT), which resulted in an amplified fragment of392 bp span-
niog the lirst hypervariable region of the G protein (AA 100-132). The amplified products 
were subjected to nucleotide sequence analysis by cycle sequencing using an ABl dye ter-
minator sequencing system and analysis on an ABI Prism 377 DNA sequencer (PE Applied 
Biosystems, Nieuwerkerk aid Hssel, The Netherlands). Alignment of the nucleotide 
sequences of the G protein gene of the RSV isolates was carried out using the GCG pack-
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Figure 2.2.1. Number of RSV isolates per week during the three seasons studied as recorded by 
the combined Dutch Virology Laboratories. (Published with permission or the Dutch Working 
Group 011 Clinical Virology.). 
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age (Madison, Wiscon.). Multiple sequence files were analysed by DNA PARS in the 
PHYLIP package (6). Subsequently, phenograms were generated using the DRAWGRAM 
program. 
Clinical data of patients from the respective seasons were compared in a X2 test, Fisher's 
exact, or Mann-Whitney U test when applicable. 
During the three winter seasons 232 children younger than 12 months of age were diagnosed 
with a RSV infection by direct immune fluorescence and/or virus isolation. In 1992-93 a 
predominance of group B viruses was found, season 1993-94 showed a 111 ixcd epidemic, and 
in season 1994-95 all children were infected with group A viruses (18). Figure 2.2.1. shows 
the numbers of RSV isolates in The Netherlands per week during the three seasons. in the 
1994-95 season, a short steep peak in the first weeks of December was observed. During 
this third season, more children younger than 1 month of age were admitted. Children in the 
third season had a higher mean pC02 and lower pH (Table 2.2.1.) than children in the first 
two seasons. No other differences in parameters known to con'elate with clinical severity 
could be objectively measured. 
G protein amplicons of 28 RSV group A isolates divided over the three seasons were stud-
ied by sequence analysis and a phenogram was generated (Figure 2.2.2.). Season of infec-
Table 2.2.1 . Clinical parameters of RSV-inCected patients during three consecutive 
seasons 
Patient variable 1992-1993 1994-1995 po 
and 1993-1994 
No. of children 130 102 NS 
No. (%) <37 gestation 37 (28.5) 21 (20.5) NS 
No. ('!o) <1 month 9 (6.9) 17 (16.7) 0.035 
Mean (SO) respiratory rate 51.9 (13.4) 51,6 (20.3) NS 
No. (%) with hstory of apnea 23 (17.7) 23 (22.5) NS 
No. (%) wheezing 47(36.1) 34 (33.2) NS 
Mean (SD) pCO, 6.1 (1.4) 6.93 (2.35) 0.027 
Mean (SD) pH 7.36 (0.07) 7.33 (0.11) 0.040 
Mean (SD) Sa02 90.7 (8.7) 89.9 (12.2) NS 
No. (%) on miificial ventilation 13 (10.0) 15 (14.7) NS 
No. (%) with severe RSVb 51 (39.2) 46(45.1) NS 
a. Clinical data of patients were compared in a X2 test, Fisher's exact test, or Mann-Whitney U 
test when applicable. NS - no statistical diHcrence. 
b. Severe RSV in rection was defined as meeting one or more of the lallowing criteria: peo2 > 
6.6 kPa Sa02 < 90% and/or on artificial ventilation. 
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Season severly a.v. apn. age 
RSV-A2 
! Rs25 1 s + 44 
Rs12 3 s + 96 
Rs19 3 m 79 
RsIS 3 m 79 
3 m 98 
Rs24 1 m 150 
Rs02 2 s + 53 
RsID 2 m 157 
Rs04 2 s + 106 
I Rs27 1 m 275 
Rs16 3 m 148 
3 m 197 
Rs13 3 s + 68 
3 m + 197 
I Rs09 2 s 93 
, RsI? 3 s + + 65 
Rsll 2 m 121 
Rs22 3 m 46 
Rs21 3 s 59 
Rs20 3 s + + 43 
[ Rs26 1 m 122 Rs23 1 s + 9 
RsOl 2 s 13 
RsDS 2 m 143 
RsO? 2 s 47 
Rs06 2 m 75 
RsDS 2 s 34 
i Rs03 2 m 151 
Figure 2.2.2. Phylogenetic dendrogram showing relatedness or group A isolates determined by 
sequence analyses of the rirst hypervariable region of the G protein. Isolates were selected from 
three consecutive seasons ill the Sophia Children's Hospital Rotterdam. Seasons are indicated as 
follows: I; 1992-1993; 2,1993-1994; 3,1994-1995. For each isolate the following patient char-
acteristics are indicated. Severity of RSV intection: s, severe, 111, mild. Severe was defined as 
meeting one or more of the rollowing criLeria: peo) > 6.6 kPa, SaO) < 90%, and for arLil'icial 
venLilaLion a.v., the need lor arLilicial venLilaLion. apI1., a history of al)neaS; age, the age in days 
upon admission. 
tion, age upon diagnosis, and clinical paramctcrs - severity score, aliificial ventilation, and 
apnea - are indicated in the phenogram. 
Sevcrallineages of RSV were found to be present during the three seasons studied, and sev-
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era! lineages could be identified during all three seasons. Closely related strains were also 
found to occur in subsequent seasons. The observed clustering of the RSV isolates proved 
to be independent of season or patient related parameters (Figure 2.2.2.). 
Thus, several lineages of RSV~A cocirculated during the three seasons studied, and clini-
cally severe as well as milder cases were evenly distributed over the different lineages 
found. 
RSV infections are usually found during several months in the winter season. In the 1994-
95 season, a relatively high incidence ofRSV infections during a relatively short period was 
found. In the 1994-95 season, more children from the very young age group were admitted. 
The only clinical parameters objectively found to be more severe in the 1994-95 season 
were the pC02 and the pH. These parameters may be directly related to the younger age of 
the children involved, since a significant relation between pC02 and age has been previ-
ollsly described (24). 
The RSV-G protein is the most variable of the RSV proteins; therefore, we choose to 
sequence a variable part of the RSV-G protein to study strain variation within subgroup A. 
However, it is not known where on the RSV genome putative virulence tactors would be 
located. Since we sequenced only a small paIi of the genome, it cannot be fully excluded 
that mutations important for virulence elsewhere on the RSV genome were missed. 
The isolates t1'om the 1994-95 season were all of group A. We investigated whether this 
peak represented a single, possibly more virulent, strain ofRSV-A. Despite the limited num-
ber of strains that were sequenced, it was clear that in the 1994-95 season, as well as in the 
other two seasons, several different strains cocirculated, and severe infections or younger 
age proved not to be related to one particular strain. Tn addition, closely related strains were 
found during different seasons as has been described previously (3,X,30). 
Collectively, Ollr data show that during a winter season when relatively many children are 
admitted during a relatively short period, several strains may cocirculatc in the population. 
In addition, it was shown that clinically more severe cases were found spread over the 
branches ofthe phylogenetic tree. Therefore, severity of infection could not be attributed to 
patiicular lineages of RSV. 
We thank Conny Kruyssen for assistance in preparing the manuscript. 
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Summary 
Respiratory syncytial virus (RSV) lower respiratory tract infections are considered to be a 
serious disease in centres such as the Sophia Children's Hospital (Rotterdam, the 
Netherlands), but as more benign infections in others such as the Geneva Children's 
Hospital (Switzerland). To assess the clinical severity ofRSV infections at the two sites, 151 
infants primarily admitted with a virologically confirmed RSV infection were studied 
prospectively (1994-5) and retrospectively (1993-4) (55 infants in Gcneva and 96 in 
Rotterdam). Parameters ofRSV morbidity which were more severe in Rotterdam during the 
two winter seasons were apnoea (1.8 v 23.9%), the rate of admission to the intensive care 
L1nit (3.6 v 28.1 %), mcchanical ventilation (0 v 7.3%), and length of stay in hospital (6.8 v 
9.1 days). In Geneva higher respiratory rates (59.2 v 51.2), more wheezing (65.5 v 28.8%), 
and more retractions (81.8 v 63.3%) were recorded. Fewer infants younger than 4 months 
(54.9 v 68.7'10), but more breast fed infants (94.1 v 38.5%), were admitted in Geneva, 
although the morbidity parameters remained different after correction for these two vari-
ables in multivariate analyses. Thus unidentified local factors influence the pattern and 
severity of RSV infection and may affect the results of multicentre prophylactic and thera-
peutic studies. 
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Introduction 
RespiratOlY syncytial virus (RSV) is the most COlllmon cause of lower respiratory tract 
infection (for example, bronchiolitis, pneumonia) in young children. RSV infections occur 
in yearly winter epidemics and 1110st children arc infected before the age of 2 years (5,13). 
The highest morbidity ofRSV disease is seen in infants aged less than 6 months (4,6,8,23) 
and in children with risk factors such as prematurity (22), bronchopulmonalY dysplasia (7), 
congenital heart disease with pulmonary hypertension (17), or immune deficiency (9). An 
estimated 0.5-2% of all infants with RSV infection are admitted to hospital (4,6,8,18,22) 
and 7-21% of these infants will develop respiratory insufficiency and require respiratory 
suppOl1 (2,3,29). The proportion of infants eventually dying from RSV infection has been 
estimated at 0.5-1.5% of all infants admitted to hospital, and higher mortality is seen III 
infants with underlying disease (15-17). 
This classically described RSV morbidity, however, does not reflect the RSV morbidity 
observed in the Geneva Children's Hospital (Switzerland), where RSV bronchiolitis is con-
sidered a common, but relatively benign, disease, in spite of an annual bilih cohort includ-
ing all defined risk groups. Over the past 10 years few infants admitted to hospital in Geneva 
with an RSV infection developed respiratory insufficiency requiring respiratory suppOli, 
and no death directly attributable to RSV was reported. In contrast, RSV disease is consid-
ered a serious, sometimes life threatening, disease at the Sophia Children's Hospital 
(Rotterdam, the Netherlands). 
In the present study we compared the clinical characteristics and outcome of disease in 
infants admitted to hospital with RSV infections in these two centres (a) to objectively 
assess the morbidity of RSV infections at each site and thus the local potential for preven-
tive or therapeutic measures and (b) to evaluate whether known parameters of disease sever-
ity explain the local variability of clinical characteristics and outcome of RSV disease in 
infants. 
Patients and methods 
All children less thall 12 months of age admitted to the Geneva Children's Hospital or the 
Sophia Children's Hospital, Rotterdam with a virologically confimled RSV infection in the 
winter seasons j 993-4 and 1994-5 were included in the study. The study was approved by 
institutional ethical committees from the two hospitals. The RSV infection was defined as a 
positive result in direct immune fluorescence assay performed on cells from nasophalyngeal 
washings using fluorescein isothiocyanate labelled RSV specific monoclonal antibodies 
(DAKO, Ely) or detection ofthc viral antigen by indirect ELISA (24) and subsequent con-
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firmation by viral culture. Duplicate samples collected in Geneva were frozen and sent to 
the department of virology of Erasmus University for confirmation analyses. Children 
referred by other hospitals and nosocomially infected children were excluded from the 
analyses to minimise the potential intluence of different referral systems. 
The Geneva Children's Hospital is a university hospital providing primary, secondary, and 
tertiary care for a population of approximately 500000 inhabitants with an annual cohort of 
5800 bilihs in 1994. As it is the only children's hospital it admits all infants [rom this defined 
area, including all prematurely born infants. The Sophia Children's Hospital, Rotterdam is 
a university hospital with a combined secondmy-teliiary care function. As one of several 
hospitals in the area it admits only some of the children from the Rotterdam area requiring 
admission to hospital. Most patients seen in the emergency care outpatient clinic of the 
Sophia Children's Hospital receive basic paediatric care (90%) and only 17% come from 
outside the Rotterdam area (30). 
Epidemiological and clinical variables were prospectively obtained on admission and dis-
charge or at a control visit for the season 1994-5, and retrospectively from the patient charts 
for the season 1993-4. Demographic and clinical data were recorded on a standardised form 
with common definitions for all items. The demographic variables included gender, age, 
duration of pregnancy, existence of underlying disease (defined as congenital hemi disease, 
bronchopulmonary dysplasia, or T cell immune deficiency), breast feeding, a positive fam-
ily history of asthma or eczema, number of children in the household, day care attendance, 
and smoking in the household. The clinical data included the number of days with breath-
ing problems before admission, feeding difficulties (defined as an increase of time required 
for feeding or a decrease in feeding volume), a positive histOlY of apnoea (defined as either 
a history ofrespiratOty arrest with cyanosis or an observation of respiratory arrest for a peri-
od of more than 20 seconds andlor bradycardia with accompanying cyanosis in the paedi-
atric emergency room or during hospital admission), respiratory rate, the presence ofwheez-
ing (scored positive if wheezing could be heard without lIsing a stethoscope) and retractions, 
fever (defined as a rectal temperature higher than 38.5°C), oxygen saturation (Sa02) in 
room air, carbon dioxide tension (pe02), pH, and abnormalities on a radiograph (hyperin-
flation, consolidation, or atelectasis) as described by the radiologist. Sa02 was measured 
transcutaneously with the use of a pulse oximeter (Hewlett Packard Neonatal (Rotterdam), 
Ncllcor N-l 80 (Geneva». Intubation was indicated in both centres in the case of (a) respi-
ratory insufficiency with hypercapnia (PCO, > 8 kPa and pH < 7.2), (b) hypoxia (SaO, 
<85% with a fractional inspired oxygen >60%), (c) prolonged episodes of apnoea leading 
to severe bradycardia requiring stimulation or hand bag ventilation, or (d) sudden clinical 
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deterioration. Discharge from either hospital required an adequate fluid intake for age, cor-
rection of tachypnea, and no oxygen requirement. 
Data collected on the course of the disease and treatment included the occurrence of addi-
tional apnoea during the hospital stay, the maximum respiratory rate, the length of stay in 
hospital, admission to and length of stay in the intensive care unit, use of mechanical ven-
tilation, administration of oxygen, bronchodilators, ribavirinc and/or antibiotics, and num-
ber of deaths. 
The clinical data from the Geneva and Rotterdam patients were compared in a X2 test, 
Fisher's exact test, or Mann-Whitney U test when applicable. Differences in the clinical 
manifestations between Geneva and Rotterdam were tested again with multiple regression 
analysis, adjusting for possible confounders. Linear regression was used for continuous 
variables and logistic regression for dichotomous variables. The clinical parameters were 
entered in the regression model as dependent variables, and the confounders and location 
were entered as independent variables. Statistical significance was accepted at p < 0.05. To 
check for seasonal differences in clinical severity the analyses were also performed sepa-
rately for the two winter seasons. 
Results 
Rates aloe/mission fo hospital in Genevo 
We calculated the rates of admission to hospital for RSV infection in the Geneva Children's 
Hospital for both term (n ~ 58(0) and pretenn (gestation <37 weeks, n ~ 312) infants 
younger than 12 months of age. The rate of admission to hospital was 5.3/1000 for term and 
2211 000 for preterm infants lor the 1994-5 winter season. The rate of admission to hospital 
in Rotterdam could not be reliably calculated as the size of the attachment population for 
the Sophia Children's Hospital cannot be precisely defined. 
Demographics 
A total 0[208 children younger than 12 months of age (61 in Geneva, 147 in Rotterdam) 
were admitted to hospital with a diagnosis of RSV infection. A predominance of RSV sub-
group A was found in nasophatyngeal specimens in the two centres (Rotterdam, 1993-4 
60'10 subgroup A, 1994-5 100% subgroup 1\; Geneva, 1993-4, data not available, 1994-5 
75% subgroup A). Six infants in Geneva (one secondary referral and five nosocomial infec-
tions) and 51 in Rotterdam (27 secondary referrals and 24 nosocomial infections) were 
excluded from the analysis. 
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Table 3.1.1. Demographic characteristics of patients 
Geneva 
(n~55) 
Gender (boys: girls) 34: 21 
Age in days upon admission 10S111-341 
(medianlrange) 
Gestational age (weeks )± SD 3g.2 ± 3.3 
Risk factors : 
Gestation < 37 weeks 10 (1S.2) 
Age < 6 weeks 9 (16.4) 
Cardiac malformation 2 (3.6) 
Bronchopulmonary dysplasia 2 (3.6) 
T cell immune deficiency 0 
No risk factors 34 (6I.S) 
Breast feeding> 1 month 35 (70.0) 
Breast feeding upon admission 25 (50.0) 
Asthma in family * S (25.S) 
Eczema in family * 2 (6.5) 
N. of children in the household* 211 - 4 
(medianlrange) 
Daycare attendance * 3 (9.7) 
Rotterdam 
(IF96) 
55: 41 
79/9-256 
3S.0 ±3.0 
23 (24.0) 
23 (24.0) 
3 (3.1) 
4 (4.2) 
0 
53 (55.2) 
23 (29.1) 
24 (31.2) 
14 (26.4) 
10 (lg.5) 
211 - S 
3 (5.7) 
P-value 
0.71 
0.17 
079 
0.53 
0.37 
0.53 
0.0001 
0.051 
1.00 
0.20 
1.00 
0.67 
Smoking in the household 12 (40.0) 23 (46.9) 0.64 
* Data hom the prospectively collected cohort (s.eason 1994/95) only. 
Percentages arc shown in brackets. 
DilTerences between Geneva and Rottcrdam cohorts were tested by the X2 test or Fisher's exact 
test for dichotomous variables and by Manll-Whitney U test ror continuous variables. 
Table 3.1.1. summarises the demographic data on the 151 children included in the study. 
Significant differences between centres were only noted for breast feeding (Table 3.1.1.) and 
age at admission (Figure 3.l.1.): 55% of children admitted in Geneva and 69% of those 
admitted in Rotterdam were younger than 4 months (X2 test; p = 0.03). 
Disease severity at admission 
Several disease severity parameters were reported differently by the two centres (Table 
3.1.2.). Rotterdam infants were more often admitted with a history of apnoea and had a 
lower Sa02 and a higher PC02 at the time of admission than the subset of Geneva infants 
for whom PC02 values were available. Geneva infants, in contrast, had a higher mean res-
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piratory rate and more often presented with wheezing and chest retractions. Feeding dilli-
culties and chest retractions were the most common presenting symptoms in the two cen-
tres, 
Course of dis'ease and treatment 
Treatment in the two centres included supplementary oxygen, empirical bronchodilator 
administration, and the use of antibiotics but no corticosteroids (Table 3.1.3.). Ribavirin was 
only used for a subset of infants in Rotterdam. Additional episodes of apnoea (two infants) 
were only reported in Rotterdam, as well as the death of a 4 week old infant with no known 
RSV risk factors who had been admitted with cardiorespiratory arrest after recurrent 
apnoea. The total length of stay in hospital was shorter in Geneva than in Rotterdam, where 
more children were admitted to the intensive care unit and required mechanical ventilation. 
~)'epaf'{/te analysis o.lseasons 
To evaluate the influence of seasonal variability on the clinical severity of RSV, statistical 
analyses were performed independently for the prospectively studied 1994-5 winter season 
and the retrospective 1993-4 season. For the 1994-5 season, no difference in pre-existing 
risk factors was observed between Geneva (n = 31) and Rotterdam (n = 59) infants. 
Significant differences for Geneva infants were higher rates of breast feeding >1 month 
25 
III Geneva ( n = 55 ) 
20 0 Rotterdam ( n = 96 ) 
~ 15 
c 
.s 
" ~ 10 ;;; 
i5 
5 
Il 
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Table 3.1.2. Clinical parameters at admission. 
Fever 
Days with breathing problems 
Geneva 
(IF55) 
15 (27.2) 
3/0 - 13 
before admission* (median/range) 
Feeding problems 42 (76.4) 
Retractions 
whcczing* 
Respiratory rate/min ± SD 
Apnea 
O2 saturation (%) ± SD 
pCO, (kPa) ± SD 
45 (81.8) 
19(65.5) 
59.7 ± 12.2 
I (1.8) 
92.5 ± 8.2 
5.8 ± 1.3 
(n~15) 
Rotterdam 
(n~96) 
22 (23.4) 
2/0 - 9 
82 (92.1) 
57 (63.3) 
17 (28.8) 
51.2 ± 19 
23 (23.9) 
90.8 ± 9.0 
6.7 ± 1.9 
(IF94) 
Abnormality on X-ray 40 (74.0) 56(59.6) 
P-value 
0.74 
0.09 
0.17 
0.029 
0.001 
00002 
0.0008 
0.0039 
0.032 
0.10 
* Data from the prospectively collected cohort (season 1994/95) only. 
Percentages are shown in brackets. 
Differences between Geneva and Rotterdam cohorts were tested by the X2 lest or Fisher's exact 
lest for dichotomous variables and by Mann-Whitney U test for continuolls variables. 
(74.2 V 30.6%, P < 0.001), higher respiratory rates (60.3 v 51.3, p ~ 0.(19), a lower he-
quency ofapnoca (3.2 v 23.7'10, p ~ 0.013), lower PC 0, (5.65 v 6.91, P ~ 0.019), a shorter 
length of hospital stay (6.0 v 8.4 days, p ~ 0.01), and a lower rate ofadl11ission to the inten-
sive care unit (6.5 v 32.2%, p < 0.001). Tn this small sample of90 infants differences in the 
tl·equency of chest retractions, mean Sa02, and requirement for respiratory support did not 
reach statistical significance. The same trends were found for the 1993-4 season (24 infants 
in Geneva and 37 in Rotterdam). SignifIcant differences for the Geneva infants were a high-
er rate of breast feeding> I month (73.4 v 21.8%, p = 0.002), a higher mean respiratOlY rate 
(59.5 v 51.1, P ~ 0.03), a lowcrfrequency of apnoea (0 v 24.3%, p ~ 0.009), a shOiter length 
of hospital stay (7.3 v 9.9 days, p = 0.02), and a lower rate of admission to the intensive care 
unit (0 v 21.6%, p ~ 0.02). 
i\I[ultivariate analysis 
Clinical parameters whieh differed significantly between Geneva and Rotterdam were again 
compared by multivariate analysis, adjusting for the identitied epidemiological factors that 
differed between the two centresnamely, age and breast feeding. After correction for these 
potential confounders a higher percentage of apnoeas, a higher rate of admission to the 
intensive care unit, and a longer duration of hospital stay were still observed in Rotterdam, 
Tahle 3.1.3. Course of disease and treatment 
Geneva 
(n~55) 
Oxygen administration 43 (78.8) 
Brollchodilators 49(89.1) 
Ribavirine 0 
Antibiotics 32 (58.2) 
Maximal Respiratory rate ± SD 63.3±12.3 
Additional children with apnea 0 
Patients in ICU 2 (3.6) 
Patients requiring mechanical 0 
ventilation 
Deaths 0 
Hospital stay (days) 6.5/1-19 
(median/range) 
Pereenlagcs arc shown in brackets. 
Rotterdam 
(n~96) 
59 (68.6) 
79 (84,(1) 
16(17.2) 
34 (38.2) 
58.7±15.4 
2 (2.1) 
27(28.1) 
7 (7.3) 
1 (10) 
9/1-29 
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P-value 
0.30 
0.54 
0.03 
0.026 
0.0005 
0.048 
0.0011 
Differences between Geneva and Rotterdam cohorts were tested by the X2 test or fisher's exact 
test for dichotomolls variables and by Mann-Whitney U test tor continuolls variables. 
whereas a higher rcspiratOl), rate and higher percentage of wheezing on admission in 
Geneva remained significant. 
Discussion 
In this study we confirmed that the course of RSV infections is significantly more benign in 
Geneva than Rotterdam. Infants admitted to hospital in Geneva less often presented with 
apnoea or respiratory insufficiency and thus less often required admission to the intensive 
care unit or respiratory suppOtt than infants admitted in Rotterdam. Their more benign sta-
tus was also reOected by a significantly shOlier length of stay in hospitaL This demonstra-
tion of a local variability of RSV disease severity is not restricted to the two centres stud-
ied. it is in accordance with at least two previous published observations. A striking differ-
ence in RSV morbidity was first reported in 1961 in two nearby nursery groups (12). More 
recently, a significant association between the hospital centre and parameters of clinical 
severity wa.s reported in a l11ulticentre study of RSV outcome in Canada (31). Furthermore, 
paediatricians from various European centres have subjectively recognised either of the two 
distinct clinical patterns ofRSV disease presented here as representative of the situation pre-
vailing in their area (personal communications to C.A. Siegrist at ESPTD meeting, June 
1996). Importantly, this study also shows (as 35 years ago (12)) that a detailed comparison 
of all the parameters previously reported as affecting disease severity does not identify the 
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factors responsible for the observed differences in RSV disease severity. 
The more benign course of RSV infection in Geneva does not appear to depend on a lower 
incidence of RSV infections in the first year of life. The rate of admission to hospital for an 
RSV infection during the first winter season at 5.311 000 lies within the previously repOlied 
rates of admission to hospital of 1-2011 000 children (4,27). This rate of admission to hospi-
tal in Geneva is little affected by the variable severity of the RSV winter epidemic. 
Comparison of the two consecutive seasons of children admitted to hospital confirmed that 
the disease pattern and severity also remain constant. As rates of admission to hospital have 
been reported to be influenced by socioeconomic status, influencing the age at exposure and 
access to medical care (11,27,28), the potentially higher socioeconomic status of parents in 
Geneva would be expected to result in a reduction of rates of admission to hospital rather 
than ofRSV disease severity. Thus the more benign course ofRSV disease in Geneva than 
in Rotterdam essentially reflects a reduced severity of disease in the most severely sick 
infants who require admission to hospital. 
Disease severity and the outcome of infants admitted to hospital is related to their pre-exist-
ing status such as prematurity, age less than 6 weeks, congenital heart disease, bronchopul-
monary dysplasia, or immune deficiency (9,17,22). The lower severity of RSV infections in 
Geneva than Rotterdam is, however, not explained by a lower number of infants presenting 
with these underlying risk factors. Two factors found to differ between the two cohorts were 
a smaller percentage of children aged less than 4 months at admission and a higher per-
centage of breast feeding in Geneva. Interestingly, the percentage of breast fed infants in the 
Rotterdam cohort was also significantly lower than the overall rate of breast feeding in the 
Netherlands (65% at 1 month and 55% at 3 months of age (1». As minimal or no breast 
feeding has been reported to increase the risk of admission to hospital for respiratory infec-
tions (27), mucosal protection could p31iicipate in the observed reduction of disease sever-
ity. COiTecting for breast feeding and age in llluitivariate analyses did not correct the differ-
ences in disease severity, however. 
Differences in subtype virulence have also been suggested to explain the yearly variation of 
disease severity (10,19), although no relation betvveen clinical severity and RSV subtypes 
was found in a study in Rotterdam (14). In the present study a predominance of subtype A 
was observed in Geneva and in Rotterdam. Although virulence could still differ within 
strains of the same subtype, strain virulence differences are unlikely to result in a higher 
morbidity in the sallle centre over two consecutive winter seasons. 
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Other epidemiological factors that could explain the reported variation in disease severity 
(sec under methods) were carefully compared and found to be similar in the two cohorts. 
Differences in referral systems werc minimised in our study by only including primarily 
referred infants to either centre, but differences in hospital policies still affect rates of 
admission 10 the intensive care unit. In Rotterdam all RSV infected children less than 2 
months of age or born prematurely are initially monitored in the intensive care unit, where-
as admission to the Geneva intensive care unit depends exclusively on the clinical status. 
These hospital policies cannot, however, explain the differences in clinical parameters at 
admission or indication for mechanical ventilation. 
Unexpectedly, we recognised two different disease patterns in our two cohorts: respiratory 
rate and frequency of wheezing and chest retractions were significantly higher in the 
Geneva infants. In contrast, respiratory insufficiency was more common in Rotterdam, 
although the duration of reported respiratOlY symptoms before admission was sholier. We 
postulate that the effIcacy of compensatory hyperventilation in response to lung disease 
could be a critical factor distinguishing the two cohOlis. This dissociation between an 
increased respiratory effort (previously described as a poor predictor of clinical severity 
(21)) and the clinical outcome suggests that environmental factors such as air quality may 
exert an influence on RSV morbidity by modulating the infant's capacity to respond to pul-
monary disease by compensatory hyperventilation. Parental smoking (similar in the two 
cohorts) and the usc of wood burning stoves (20,28,32) have been shown to increase the risk 
and severity ofRSV infections. It is impottant to define the role of air humidity or temper-
ature, either indoors or outdoors, or of industrial air pollution, which is responsible for an 
excess of cardiovascular deaths among adult or elderly patients (26) and which could also 
affect the capacity of young infants to cope with respiratOlY infections (25). A relatively pre-
served air quality in medium sized cities such as Geneva compared with large industrialised 
urban agglomerations such as Rotterdam could \vell contribute 10 a lower morbidity of 
infant respiratory diseases. Air quality could thus contribute to the high RSV morbidity 
reported by large American or European centres, mostly located in dense urban environ-
ments. 
Tn conclusion, parameters to be col1ected in multicentre studies assessing RSV disease 
severity have not yet all been identified. Whether air quality affects RSV disease in infants 
and elderly patients should be specifIcally addressed through prospective studies collecting 
air samples. Until these additional factors responsible for the geographical variations of 
RSV morbidity are identifIed, the many prophylactic or therapeutic strategies planned for 
the next decade should probably take into careful account the existence of different local 
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disease patterns. 
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Summary 
The decline of maternal respiratory syncytial virus (RSV) specific serum antibodies was 
studied in 45 children during the first six months of life, using a virus neutralization assay 
and competition ELlS As measuring fusion protein and glycoprotein specific antibodies. In 
all children RSV neutralizing antibodies eould be demonstrated at birth, with titers ranging 
from 33 to 1382. The calculated mean half life of these antibodies was 26 days. 
Furthermore, in a group of 38 children with sllspected RSV infection, all younger than six 
months of age upon admission, the diagnostic value of serological assays was evaluated. In 
32 children RSV infection was contirmed by virus isolation, direct immune fluorescence 
and RT-PCR analyses. In seven individuals of this graup a significant titer rise in virus neu-
tralization assay could be demonstrated. Six additional RSV infected children could be iden-
tified, by showing the presence of RSV-specific IgM or IgA serum antibodies or by show-
ing an increase in fusion protein or glycoprotein specific antibodies. All serological tests 
together identified 13 (41%) of the 32 RSV infected patients. 
It was concluded that in children in this age group, which represent the majority of patients 
hospitalized with RSV infections, serological assays not only have a limited diagnostic 
value, but are also of limited value for sera-epidemiological studies. 
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Introduction 
Tn developed cOllntries respiratory syncytial virus (RSV) is the most important cause of 
severe respiratory tract infections in children under two years of age (4,9). Severe RSV 
infection related disease is predominantly seen in children between six weeks and six 
months of age, when 1110st infants still have RSV specific maternal serum antibodies. 
Vaccination with a formalin inactivated candidate RSV vaccine, inducing high titers ofRSV 
specific antibodies, gave rise to more severe clinical disease upon subsequent exposure to 
the virus (3,15). Therefore antibodies have been incriminated as a factor in more severe clin-
ical outcome of the infection. Especially the presence of RSV specific IgE has been sug-
gested to be a contributing factor in RSV bronchiolitis (2,23). On the other hand there is evi-
dence ±l'om both human and laboratory animal studies that high titered virus neutralizing 
(VN) antibodies may be protective against RSV infection (7,10,17,20). Here we present data 
on the decline of RSV specific maternal serum antibodics in 45 children, and the develop-
ment of specific serum antibodies upon infection with RSV in 32 children, all younger than 
six months of age. In this study, existing and newly developed assays were used to meas-
ure RSV specific antibodies of different classes, isotypes and protein specificities. 
Patients and methods 
Pat;en/s and Sera 
Group I: Serum samples collected during the years 19R9-1991, from 45 healthy children 
participating in a hepatitis B vaccination trial were used to study the decline of maternal 
RSV specific antibodies. Sera were taken at birth, at 3 months and at 6 months. Children 
born in the months March until June were selected to minimize the chance of RSV infec-
tion in these first 6 months. 
Group II: Serum samples frolll 38 children, all younger than six Illonths of age, seen at the 
Sophia1s children hospital during the period November 1993 to April 1994, with a respira-
tory infection suspected of RSV, were collected in the acute stage of the disease and three 
to four weeks later. Demographic and clinical data of these children were collected on 
admission and at control visit. They included gender, age, duration of pregnancy, presence 
of underlying disease (defined as congenital heart disease, bronchopulmonary dysplasia or 
immune deficiency), feeding difficulties (defined as an increase of time required for feed-
ing or a decrease of feeding volume), a positive history for apnea (defined as either a histo-
ry of respiratolY alTest with cyanosis or an observation of respiratory arrest for a period of 
more than 20 seconds and/or bradycardia with accompanying cyanosis in the pediatric 
emergency room or during hospital admission), the presence of retractions, respiratOlY rate, 
oxygen saturation (Sa02) in rool11 air, pC02, pH and abnormalities on X-ray (hyperinflation, 
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consolidation or atelectasis) as described by a radiologist, admission to an intensive care 
unit and the need for artificial ventilation. 
Virus preparation 
The A2 strain of human RSV (ATCC VR1302) was used in serological tests. The virus was 
passaged in HEp-2 cells and cultured until the majority of the monolayer exhibited cyto-
pathic changes. The supcrnatant was cleared of cell debris by ccntrifugation for 10 minutes 
at 1000 G and subsequently aliquoted and fl'ozen at -70°C until use in virus neutralization 
assays (VN). For all virus neutralization tests the same stock of RSV was used. 
Vims for competition ELiSAs and IgM and IgA capture ELISAs was partially purified by 
polyethylene glycol precipitation of the supernatant of infectcd cells and subsequently cen-
trifuged for 2 hours at 25000 rpm through a discontinuous 30-60% (w/w) sucrose gradient 
in a Beclanan SW28 rotor. The resulting opaque virus containing band was collected, 
aliquoted and frozen at _70°C until usc. 
Virus iso/ation(VI) and d;rect imnnme/luorescence assay (DJFA) 
Nasopharyngeal washings were taken from the children of group 11. The samples were dilut-
ed with 5 ml DMEM, h0111ogenated, and centrifuged for 10 minutes at 1000 rp111. The super-
natant was used for DIFA. The pellet was pipetted onto 111uitispot slides, dried at ro0111 tem-
perature and fixed with acetone. These slides were used for DitA as previously described 
(19), using fluorescein isothiocyanate (FITC) labeled RSV specific monoclonal antibodies 
(DAKO, Ely, UK). For RSV subtyping, monoclonal antibodies against subtype A (MAB 92, 
Ilc, Chemicon, Temecula, USA) or subtype B (MAB 109,IOB, Chemicou, Temecula, USA) 
were pi petted on the slides and incubated for 30 minutes at 37°C. After washing three times 
with phosphate bufTered saline pH 7.2 (PBS) a FITC labeled anti mouse conjugate (DAKO, 
Ely, UK) was applied and incubated for 30 minutes at 37°C. After washing three times with 
PBS and once in distilled water the slides were examined under a epifluorescencc micro-
scope using a 620 11m filter. Slides were scored positive when a typical granular fluores-
cence was observed in the cytoplasm of cells. 
Revers'e fran\'cripfase pO~Vl11e!'ase chain reaction (RT-PCR) 
RT-PCR was performed on nasophmyngeal washings of the children as previously 
described (22). In short, total RNA of nasopharyngeal washings was extracted using guani-
diniulll isothiocyanaat and phenol/chloroform. RNA peR was performed in two steps. For 
cDNA synthesis, 10 ~I of the RNA template and I ~Ll (containing 10 p11101) eDNA primer 
were heated to XO°C for 2 minutes and put on ice. Then 14 ~L1 of a eDNA reaction mixture 
was added, which made a solution containing 50 mM Tris,HCL pH 8.3, 37.5 mM KCl 3 
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mM MgCI" 10 lllM OTT, 0.5mM of each ofthc dNTP's (dATP, dCTP, dGTP and dTTP), 
1.6 U RNAsin (Promega, Leiden, The Netherlands) and 8 U 11101011Y murine leukemia virus 
(M-MLV) reverse transcriptase (Gibco-BRL, Breda, the Netherlands). The mixture was 
incubated at 42°C for 45 minutes, heated at 95°C and put on icc. Then 75 ~ll of the peR mix 
was added resulting in a 100 fLi PCR solution containing 10 mM Tris-HCI pH X.8, 50 lllM 
KCI, 1.5 lllM MgCI" 0.1% Triton-X-IOO, 0.2 lllM o[each of the dNTP's, 20 pmol eDNA 
primer, 20 pmol reverse primer and 1 U of Taq polymerase (Promcga, Leiden, The 
Netherlands), A peR program containing 36 cycles of 3 steps (1 min at 95°C, 1 minute at 
52°e, 1 minute at 74°C) was used. 
For analysis of the amplified products 25~li of the peR products were electrophoresed in a 
1.5% agarosc gel. The gel was then denatured for 10 minutes in 0.4 N NaOH and the ampli-
fied products were transferred to nylon membrane using a semidry blotter (Biorad, 
Cahfol11ia USA) at 3 mA/cm2, for southel11 blot analysis. Southel11 blots were hybridized 
overnight using subtype A and B specific 32P labeled oligonucleotides. 
Virus neutralization (VN) assqy 
SOp I serially diluted sera were incubated with 50~Li DMEM containing 100 TCID50 ofRSV-
A2 for one hour at 37°C in 96 well tissue culture microtiter plates (Costar plastics, 
Badhoevedorp, the Netherlands). Control wells contained no serum (positive or virus 
growth control) or only DMEM (negative or cell control). Then I IEp-2 cells were added to 
all wells and incubated for three days at 37°C 5% CO2 , Subsequently the cells were washed 
once carefully with PBS and fixed in ethanol at -70°C for 30 minutes. 
The expression of viral antigen on the HEp-2 cells was detected in an ELISA system; the 
plates were blocked with I 00 ~Li 10;;) gelatin in PBS for 30 minutes and washed five times 
with PBS 0.05%) tween 20 (PBST). 50 ~L1 of an RSV fbsion protein specific mouse mono-
clonal (MAS 92-11 C, Chcmicoll, Temecula USA) was added to the cells and incubated for 
2 hours at 37°C. Aller washing five times, I--IRPO labeled rabbit anti-mollse (DAKO, Ely, 
UK) was used as conjugate, incubated for one hour at 37°C, washed five times and shaken 
dry. Then the substrate, tetramethylbenzidine/I--li)2 was added. The reaction was stopped 
after 10 minutes with 2 M I1,SO,. The optical density (00) was read at450 11111. The per-
centage virus neutralization was calculated by the following formula: 
experimental OD - ccil control 00 
virus control 00 - cell control OD 
x 100% 
The titer of the serum was defined as the reciprocal of the dilution which gave 50 % virus 
neutralization. A significant rise in titer to confirm infection was arbitrarily defined as a 
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greater than a threefold titer rise. 
CompeNtiol1 ELISA 
To measure antibodies against separate RSV membrane proteins, competition ELISAs for 
RSV fusion proteiu (comp-F ELISA) and glycoprotein (comp-G ELISA) were carried out 
essentially according to methods which we have previously described for Hantavirus serol-
ogy (5). Brielly, antigen was coated (2 ng/well) to 96 well ELISA plates (Costar plastics, 
Badhoevedorp, The Netherlands) overnight at 4°C. 100 J1l of a tenfold serum dilution in 
ELISA butrer (PBS with 3% NaCI, 0.1 % BSA, 0.1 % milk powder, 5%) normal rabbit serum 
and 1 % fetal calf serum) were pi petted into the wells. For the negative control (0% inhibi-
tion) ELISA buffer containing no serum was used. For the positive control (100% inhibi-
tion) ELISA buffer containing no serum was used, and ELISA buffer containing no mono-
clonal antibody was used in the second step. After incubation for 2 hours at room tempera-
ture half (50 J11) ofthe serum dilution was removed and replaced by 50 ~d of a mouse mon-
oelonal anti-fusion protein (133IlH, Chemicon MAB 858-1, Temecula, CA) or anti- glyco-
protein (l31/2G, Chemic on MAS 858-2, Temecula, CAl RSV dilution in ELISA buffer and 
incubated for one hour at 3rc. Specificity of these lllonoelonals has been described pre-
viously (I). Subsequently the plates were washed 3 times in PEST HRPO labeled rabbit 
anti-mouse (DAKO, Ely, UK) was used as the conjugate and incubated for one hour at 
37°C, washed three times and shaken dlY. Then 100 )11 tetramethylbenzidinei H20 2 sub-
strate was added. The reaction was stopped after 10 minutes with 2 M H2S04, The OD was 
spectrophotometrically read at 450 nm. Percentage inhibition was calculated by the formu-
la: 
experimental OD - OD 100%inhibition 
ODO%inhihitioll - OD100'YiJinhibitioll 
= %inhibition 
A significant rise in inhibition to confirm infection was arbitrarily detined as a greater than 
threefold rise in inhibition percentage. 
Sera proved negative tested in a 1: 1 0 dilution in this assay never reached inhibition levels 
above 10%. 
RSV specific 19A and l..gA;f detection in serulIl 
RSV specific antibodies of the IgA and IgM class were detected in sera by capture ELISA 
essentially as previously described for hantavirus serology (5). Positive results were COll-
firmed with an indirect immune fluorescence assay as previously described (6). 
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For capture ELISA, goat anti-human IgA or IgM was coated to 96 well ELISA plates 
overnight at 4°C. 1 00 ~Ll of a hundredfold serum dilution, in ELISA butfer, was pi petted in 
the wells and incubated for one hour at 37°C. Subsequently the plates were washed three 
times in PBST. The optimal dilution of RSV antigen was pipctted in the wells and incubat-
ed for one hour at 37°C and the plates were washed three times in PBST. Subsequently 50 
~d of biotinilatcd polyclonai goat anti-RSV (Chemicoll, Temecula, CA) was added to the 
cells, incubated for one hour at 37°C, washed three times in PBST and shaken dty. 
Strcptavidinc-HRPO (Amcrsham, Little Chalfont, UK) was llsed as conjugate, incubated for 
30 minutes at ro0111 temperature, washed three times and shaken dly. Then 1 OO~I tctram-
cthylbenzidine/H20 2 substrate was added. The reaction was stopped after 10 minutes with 
2 M H2S04 , OD was measured at 450 nm. An OD exceeding more than 2 times the OD of 
the negative control was considered positive. 
For confirmation of positive results in an indirect immune fluorescense assay, cells infect-
ed with RSV were mixed with un infected HEp-2 cells and spotted on 12 well l11ultispot 
slides. The slides were dried at room temperature and the cells were fixed with ethanol at-
70°C. Sera were pre-incubated with sheep anti-human Fc gamma globulin (RIVM, 
Bilthoven, The Netherlands). Pre-incubated sera (1:16 end dilution) were pipetted on the 
wells with RSV infected cells and incubated 2 hours at 37°C. Subsequently the slides were 
washed three times for five minutes in PBS and 1 minute in distilled water. Then FITC 
labeled anti-human IgM or IgA (DAKO, Ely, UK) was pipettcd on the slides and incubated 
for 30 minutes at 37°C. After washing, the slides were examined in an epifluorescence 
microscope using a 620 11m filter. Results were considered positive when a characteristic 
granular fluorescence pattern in the cytoplasm of the cells was observed. 
Complemel7tfi."fatiol7 assay (CF) 
The CF assay was carried out as previously described (8). Briefly, serum was inactivated at 
56°C for 30 minutes. A 2 log titration of the serum starting at 1:7 was made. The working 
dilution of first RSV antigen (Bio-Withakker, Walkersville Maryland) and then complement 
(Bio-Withakker, Walkersville Maryland), were added to each serum dilution. After incuba-
tion of 18 hours at 4°C, sheep red blood cells, sensitized with hemolysin (Bio- Withak.ker, 
Walkersville MD), were added and incubated for one hour at 3TC. After settling of the red 
blood cells titers were read at 50% end point. 
Statistical analyses 
For statistical analyses, geometric mean titers (GMT) were calculated for the VN assay. For 
the competition ELISAs, mean inhibition percentages were calculated. For comparison of 
mean rise in antibodies in infected and non-infected children a 2-tailed student's t-test for 
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Figure 4.1.1. Decline oi'maternal RSV specitic serum antibodies in 45 children (Group 1). Sera 
\vcrc taken at birth, three months and six months of age. Individual and mean Lest results are incti-
cated. 
Mean inhibition percentages for comp-F and comp-G ELlSAs and geometric mcan titers for the 
VN assay arc indicated with horizontal bars. 
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paired samples was used. For comparing RSV specific titers upon admission with pat'amc-
ters of clinical severity a 2-tailed student's t-test for independent samples was used. 
Results 
Decline q( maternal RSV specffic antibodies 
The decline of RSV specific maternal antibodies during the first six months of life was mon-
itored in 45 children (Group J) using the VN assay and cnmpetition ELISAs (Figure 4.1.1.). 
At birth VN antibodies were present in the scra of all 45 children with titers ranging from 
33 to 1382 and a geometric mean titer of301. Geometric mean titers at three and six months 
were 24 and 10 respectively. In the majority of scra taken at six months after birth, no VN 
antibodies could be demonstrated. Comparison of mean inhibition percentages measured in 
comp-F ELISA and comp-G ELISA at birth, at three and at six months showed a linear 
decline 86%, 43% and 21 % in the comp-F ELISA and 91 %, 58% and 21 % in the comp G-
ELISA respectively. Two of the 45 children tested showed a significant titer rise in VN 
between three and six months after birth (from < 10 to 48 and from 22 to 132 respectively), 
indicating that these infants had been infected with RSV during this period. In these paired 
sera a rise in inhibition percentage was found from H.4% to 38.9% and 43.0% to 63.7% 
respectively in the comp F-ELISA. However, no rise was observed in the comp-G ELISA. 
From the comparison of the VN serum antibody titers at birth with those fOLlnd three months 
later, a mean half-live of maternally derived serum antibodies of 26 days was calculated. 
Kinetics of RSV spec~fic antibodies after infection 
Of the 38 infants with a suspected RSV infection (group II), 32 indeed proved to be infect-
ed with RSV. This was shown by VI, DIFA and RT-PCR analyses. No other viral infections 
were found in any of the 38 infants. Individual titers and GMT of RSV infected and non-
infccted children arc shown in Figurc 4.1.2. Comparing the serum antibody titers measured 
in the \TN assay upon admission and three to four weeks later showed a significant mean 
antibody titer rise mcasured in children with a confirmcd infection (GMTl = 51; GMT2 = 
75; p~O.OJ) and a decline in antibody titer in llninfected children (GMT! ~ 48, GMT2 ~ 30; 
p=0.06). The mean titer rise in infected children was significantly diflerent from the mean 
titer decline of noninfected children (L'>T-infccted: 30, L'>T-noninfected ~ -44; p~O.04). No 
significant changes in mean inhibition levels werc found between infected and un infected 
children when using the comp-F and comp-G ELISA. 
Comparison oj'diagnostic tes/results ofindivhlual patients with slispected RSV il?fectiol1 
The results of all diagnostic tests carried out with specimens of the 38 patients with SLlS-
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Figure 4.1.2. Development of serum antibody titers ill 38 children with respiratory disease sus-
pect for RSV infection (group II). Individual and mean test results arc indicated. 
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Tahle 4.1.1. Summary of diagnostic analyses in 38 children, < 6 months of age, 
clinically suspected of RSV infection 
patient VI DIFA RT-PCR VN* competition capture CF* 
subtype subtype ELISA'" ELISA 
anti-F anti-G IgM 19A 
1 , A A + + + 
2 + A A + + 
3 + A A + + 
4 + !I. !I. + + 
5 B B + + 
6 + B B + + 
7 + !I. A + 
8 + A A + + 
9 + A A + 
10 + A A + 
II + A A + 
12 + A A + 
13 + !I. A + 
14-19 (n~6) + A A 
20-32 (IF13) + B B 
33-3~ (IF6) 
VI virus isolation, DIl·A direct immune nuorescence on cells or nasopharingeal washings 
using subtype A and B specific monoclonal antibodies, RT-PCR = Reversed LranscripLase poly-
merase chain reaction llsing subtype A and B specifIc probes. VN ~ virus neutralization assay, 
anti-F 0 .. anti fusion protein antibodies, anti-G = anti glycoprotein antibodies. CF = complement 
fixation test. 
* A three rold rise in antibody level was considered positive in VN, CF, and anti rand G com-
petition ELISA. 
peeted RSV infection are presented in Table 4.1.1. The results of VI, D1FA and RT-PCR 
assays were in complete agreement: in 32 patients an RSV infection was identified, of which 
17 were of subtype A and 15 of subtype B as shown with D1FA and RT-PCR. Analyses of 
paired sera, in the VN assay allowed the identification of seven (22%) RSV infected infants 
by showing a greater than threefold titer rise. With the comp-F and comp-G ELISA one 
(3%) and seven (22%) RSV infected infants could be identified respectively. Detection of 
RSV specific IgM and IgA in single serum samples identified one (3%) and five (16%) RSV 
intected infants respectively. With a CF assay no RSV infected infants were detected. All 
serological tests together only identified 13 (41 %) of the 32 RS V infected patients. 
As shown in Figure 4.1.3., a greater than threefold rise in RSV specific serum antibody rise 
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F;glfre 4.1.3. Rise in antibody levels in 32 children with a confirmed RSV infection plotted 
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was predominantly found in RSV infected children older than three months. 
Comparison qf'VN fifer lIpon admission with disease severity 
In order to evaluate whether a relationship exists between the presence of RSV specific 
maternal antibodies on onc hand and severity ofRSV related disease on the other, antibody 
titers measured in the VN assay and inhibition percentages in the cOlllp-F and comp-G 
ELISA were related to parameters of clinical severity (pC02, Sa02, leU admission, artifi-
cial ventilation). 
Children with a higher peo2 lIpon admission had significantly higher tilers in the VN assay 
(p = 0.(5). A higher peo2 also correlated strongly with a younger age upon admission. No 
correlation could be found between Sa02, leU admission, or artificial ventilation and VN 
titers or percentage inhibition in the competition ELISAs (data not shown). 
Discussion 
In the present paper we have shown that in children under six months of age the diagnostic 
value of RSV serology is limited and by far inferior to the direct detection methods for RSV 
antigen or viral RNA. This may, at least in part, be caused by the relative inability of thc 
young intants to mount a specific antibody response upon infection. This is best illustrated 
by the virtual absence ofRSV specific JgM, which is not vertically transmitted via the pla-
centa. Furthermore preexisting maternal antibodies may interiere with the antibody 
response upon infection and may also hinder the interpretation of serological results. 
The detection of IgM, IgG, and IgA antibodies for the serodiagnosis of RSV in young 
infants is known to be relatively insensitive as a diagnostic tool. However, we investigated 
whether antibody recognition of different structural RSV proteins, would be a useful param-
eter for the diagnosis of RSV infection. This is a well established approach for other virus 
infections, like those with HIV (16) and hantavims (5). 
All children in group I had detectable maternal antibodies at birth, which deelined with a 
half-liie of 26 days in the first months oflife. This value is in agreement with normal half-
live values of passively acquired antibodies, which is estimated to be three to four weeks 
(13). The presence of RSV specific antibodies has been shown to correlate with protection 
against severe RSV iniection in mice (17) and in children (7), although relatively high titers 
seemed to be required for protection. Studies in children have shown that the administration 
of high titered anti RSV immune gJobulines may protect young children from developing a 
severe RSV infection with the involvement of the lower respiratory tract (7,] I). This allows 
speculation about the protective value ofmaternai antibodies, which may provide sufficient 
protection against severe disease development after birth. However, with a half-life of 26 
days antibody levels may be expected to drop relatively fast to unprotective levels. 
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With the exception of pC02 levels, which correlated with VN titers upon admission, non of 
the parameters of clinical scverity correlated with antibody levels upon admission in group 
II. However, the correlation of pC02 levels with VN titers may probably be explained by 
the higher pC02 usually found in younger infants with RSV infection (14), at which age 
higher maternal antibody levels are also present. Thus no causal relationship between RSV 
specific antibody titers and severity of infection was detected in this study. 
The discrepancy between the data generated in the VN assay and the competition ELISi\s 
may be explained by the fact that the inhibition percentages of maternal antibodies found in 
noninfected children are relatively high, as compared to VN antibodies. Therefore maternal 
antibodies should be expected to cause more interference in competition ELISAs than in the 
VN assay. This would result in the absence of a demonstrable rise in inhibition percentages 
upon infection. 
We L1sed a 1:10 dilution of the serum sample in our competition ELISA although we real-
ized that sLlch a low dilution might cause nonspecific binding. When the RSV competition 
ELISA was established we tested several negative serum samples at a 1: 1 0 dilution. None 
of these sera caused nonspccific reduction of the absorbance. Furthermore the LIse of the 
principle of a competition ELISA with 1:10 diluted serum samples has becn investigated 
extensively by LIS in several other systems, including infections with hantavirus (5), 
rabiesvirLis (21) and Borrelia burgdorfcri (1 S). 
At different intervals after infection or reinfection, serum antibodies have different aflinities 
for the respective epitopes. Especially in the acute phase of RSV infection, antibodies with 
low affinity may be present (12). In the competition ELISA the monoclonal antibodies 
which have a relative high affinity may interfere with the binding of the serum antibodies, 
especially whcn the whole sample is removed. We therefore removed half of the sample 
only and replaced it with 50 ~d of the respective monoclonal antibody preparation. 
Although the children with a proved subtype A infection showed more often a serological 
response in the assays used than children with a subtype B infection, the number of indi-
viduals studied is too small to conclude that this may have been due to the LIse of a subtype 
A strain in the assays. 
Taken together, the data presented in this study show that VI, DIFA, and RT-PCR arc more 
reliable tools for the diagnosis of RSV infections than serological methods. For practical 
reasons, the use of DIFA, followed by confirmatory VI, is probably the best option at pres-
ent for the rapid and accurate diagnosis of RSV infection. 
The overall poor performance of the serological assays used, indicates the limited diagnos-
tic value of serology in these young children. FUlihermore it shows that serology cannot be 
used for sero-epidemiological studies, at least in the age group of children younger than six 
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1110nths, which comprises more than 50% of all patients hospitalized for RSV infection. 
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Summary 
Peptides deduced [rom the central conserved region (residues 15X to 189) of protein G of 
human respiratory syncytial virus (HRSV) subtypes A and B were used as antigens in sub-
type-specitic cnzyme-linked immunosorbenl assays (G-peptide ELlSAs). These G-peplide 
ELlSAs were compared with seven other serological assays to detect HRSV infection: 
ELISAs based on complete protein G, on fusion protein F, and on nucleoprotein N; a com-
plement fixation assay; a virus neutralization test; and ELlSAs for the detection of 
immunoglobulin A (IgA) or IgM antibodies specific for HRSV. In paired serum samples 
from patients with HRSV infection, more infections were diagnosed by the G-peptide 
ELISA (67%) than by all other serological tests eombincd (4X'Yo). Furthennore, for 16 of 18 
patients (89(Yo), the G-peptide ELISAs were able to differentiate between antibodies against 
HRSV subtypes A and B. This study shows that peptides conesponding to the central con-
served region of the attachment protein G ofHRSV can successfully be used as antigens in 
immunoassays. The G-peptide ELISA appeared to be more sensitive than conventional tests 
for the detection ofHRSV antibody titer rises. 
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Introduction 
Human respiratOlY syncytial virus (HRSV) is the 1110St impOliant causative agent of bron-
chiolitis and pneumonia in young children. The virus is classified within the Pneumovirus 
genlls of the Paramyxoviridae. Efficacious vaccines against respiratory syncytial virus 
(RSV) arc not available. Because different antigenic subtypes arc described for HRSV (6), 
it is important for epidemiological studies and vaccine developments to monitor the pre-
vailing subtypes in a population. However, the available iml11UllOassays (11) arc based on 
whole virus or complete proteins that do not discriminate between subtypes of HRSV or 
betweeu different RSV typcs. 
The highly variable attachment protein G has limited homology between HRSV subtypes 
(53% amino acid homology) (6). However, within the subtypes the amino acid homology is 
much larger: >80% within HRSV subtype A (HRSV-A) strains (3) and >90% within HRSV-
B strains (10). Therefore, protein G is a good candidate antigen for a discriminatory assay. 
We proposed that the ectodomain of protein G contains a central, conserved, relatively 
hydrophobic region bounded by two hydrophilic, polymeric mucin-like regions (8). The 
central conserved region of HRSV, bovine RSV, and ovine RSV is a major antigenic site, 
and peptides cOlTesponding to this region can be used as antigens in immunoassays (I ,7-9). 
In a previous study, it was shown that conventional serology does not provide an adequate 
diagnostic tool for RSV infection in children younger than 6 months of age (2). In this study, 
the data obtained by these conventional serological tests were compared with those obtained 
by enzyme-linked immunosorbent assays (ELISAs) based on peptides corresponding to the 
central conserved region of HRSV-A and HRSV-B. furthermore, we demonstrated the 
applicability of the peptide-based ELlSA for subtype-specific diagnosis. 
Materials and methods 
Peptide jynfhesis. 
Peptides cOlTesponding to the central conserved regions of protein G (residues 158 to 189) 
Figure 4.2.1. Schematic representation of primary structure of HRSV-G. Shaded box, trans-
membrane region (TM). The primary structure of the synthesized peptides corresponding to the 
central conserved region oCthe ectodol11llin is shown. 
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of HRSV-A (12) and HRSV-B (6) were synthesized (Figure 4.2.1.). Peptide synthesis has 
been described previously (7). 
Serum samples and specimens. 
Paired serum specimens fl'om 33 different children (age, 0 to 6 months) with respiratory 
tract disease and suspected of having RSV infection were taken in the acute phase and 3 to 
4 weeks later. Twenty-seven of these patients were contirmed to have an RSV infection by 
direct immunofluorescence of cells from nasopharyngeal washings, virus isolation on HEp-
2 cells, and reverse transcription PCR (2). The RSV subtype was identified by usiog RSV 
subtype-specific monoclonal antibodies (MAbs; MAb 92-11 C for HRSV-A and MAb 109-
lOB for HRSV-B; Chcmicon) in an immunofluorescence assay with infected IIEp-2 cells 
(2). Paired serum specimens frol11 the 27 patients confirmed to be RSV positive were used 
to distinguish between antibody reactivity against the HRSV-A G peptide or the HRSV-8 G 
peptide. Paired serum specimens from 14 mothers of the 14 HRSV-A-infected children 
described above were taken at the same time that specimens were taken from their children. 
These sera were tested in the HRSV-A G-peptide ELISA to measure maternal antibody 
titers. 
As a negative control, paired serum samples fi.·om six additional patients with acute infec-
tions caused by influenza virus type A, Chlamydia psiltaci, and Mycoplasma pneumoniae, 
but not HRSV, were tested in the G-peptide ELlSAs. Two serum samples (samples 2369 and 
2219) f1'om two individuals (ages 2 and 3 years, respectively) positive for HRSV-specific 
antibodies collected during the 1993 to 1994 RSV epidemic were a kind gift ofJ. A. Melero, 
National Centre for Microbiology (Madrid, Spain). These two serum specimens were test-
ed by Pepscan analysis. 
Pepscan analysis. 
Peptides were synthesized on funetionalized polyethylene rods and were tested for their 
reactivity with polyclonal antisera in an ELISA by established procedures (4). Forty-seven 
overlapping dodecapeptidcs of the ectodomain of the G protein of HRSV-A (12) between 
amino acids 153 and 211 were synthesized. This set of peptides includes all peptides COITe-
sponding to the central conserved region. 
Neutf'alization {est. 
Twofold dilutions (starting at LID) of test sera were incubated with 100 5(YYO tissue culture 
infective doses of HRSV-A2 for 1 h at 37°C in 96-well tissue culture microtiter plates. HEp-
2 cells were added to all wells, and the plates were inctlbated for 3 days at 37°C in 5% CO2, 
The expression of viral antigen on the HEp-2 cells was detected by ELISA with an F-pro-
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tein-specific MAb (MAb 92-IIC; Chcmicon) and antimollSC horseradish peroxidase 
(HRPO; Dako, Glostrup, Denmark). Both incubations were [or 1 h at 37°C. 
Tetramethylbenzidinc-H20 2 was used as the substrate. The reaction was stopped after 10 
min with 0.2 M H2S04, Absorption was read at 450 11m. The percent virus neutralization 
was calculated by the following formula: (experimental 00 - cell control OO)/(virus con-
trol 00 - cell control 00) x 100, where 00 is optical density. The titer of the serum was 
defined as the dilution which gave 50% virus neutralization. Threefold titer rises were con-
sidered indicative of RSV infection. 
Competition ELISAs. 
Competition ELISAs for RSV fusion protein F, attachment protein G, and nucleoprotein N 
were performed as described previously (5). Partially purified RSV-A2 was coated (2 
fLg/well) onto 96-well ELISA plates (Costar) overnight at 4°C. Dilutions of 100 fLI of test 
sera (diluted 1 :10 and 1 :1(0) were incubated in the wells for 2 h at room temperature. A 
highly positive serum sample was used as the positive control (100% inhibition), and 
ELISA buffer (phosphate-buffered saline, 3% extra Nael, 0.1 % bovine serum albumin, 
0.1 % milk powder, 5% normal rabbit serum, 1 % fetal calf serum) was used as a negative 
control (0% inhibition). Subsequently, 50 /-11 of the serum dilution was discarded and 50 /-11 
of aLlti-F (13311 H; Chemicon MAb 858-1), anti-G (131/2G; Chemicon MAb 858-2), or anti-
N (23A3; Biosotl MAb 213-88) was added and the mixture was incubated for 1 h at 37°C. 
Next, the wells were incubated with HRPO-conjugated rabbit anti-mouse (Dako) for 1 hat 
37°C. All dilutions were made in ELISA buffer. Tetramethylbenzidine-H20 2 was used as the 
substrate. The reaction was stopped after 10 min with 0.2 M H2S04, Absorption was read at 
450 l1I11. Percent inhibition was calculated by the following fonllula: (experimental OD -
00 for 100% inhibition)/(OO for 0% inhibition - 00 for 100'10 inhibition)" 100. Threefold 
rises in the percentage of inhibition were considered indicative of RSV infection, 
IgA and IgM caplure ELISA. 
Anti-human immunoglobulin A (IgA) or JgM was coated onto the wells of 96-wcll ELISA 
plates (Costar) overnight at 4°C. Test sera (1: 1 00), paLiially purified RSV, 50 fLI of rabbit 
polyclonal anti-RSV serum (Oako), and HRPO-conjugated goat auti-rabbit (Oako) were 
each subsequently incubated for 1 hat 3rc. Tetramethylbenzidine-I-I20 2 was used as the 
substrate. The reaction was stopped after 10 min with 0.2 M H2S04 , Absorption was read at 
450 nm. The cutoff value for positivity was more than two times the OD of a negative sam-
ple. A positive reaction was confirmed by immunofluorescence lest. 
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Table 4.2.1. Antibody titers in paired serum specimens from patients with a respi-
ratory infection determined by both G-peptide ELiSAs 
Titer by the following G-peptide ELISA': 
Patient no. RSV type Peptide A Peptide B 
2 A <10,40 <10,<10 
6 A 10,80 <10,<10 
9 A 20, 160 <10, <10 
11 A 80,40 <10,<10 
17 A 10,160 <20,<10 
18 A 10, 10 <10,<10 
19 A 10,20 <10, <10 
26 A <10,40 <10, <10 
27 A 10, 10 <10, <10 
28 A <10,40 <10, <10 
30 A <10,20 <10, <10 
36 A <10,640 <10, <10 
37 A <10,320 <10, <10 
41 A 40, 80 <10, <10 
7 B <10,20 10,<10 
8 B 10, <10 <10,20 
10 B 40,<10 <10,40 
13 B 20, <10 <10,20 
15 B <10,10 <10, <10 
21 B 10, <10 <10,40 
23 B 10, 10 <10,80 
24 B 10,20 <10, 10 
25 B 10, <10 <10,<10 
35 B 10, <10 <10,40 
38 B 10,40 <10, 10 
39 B 10, 10 <10, <10 
40 B <10, <10 <10,20 
1 <10,<10 <10, <10 
4 <10,40 <10, <10 
5 <10, <10 <10,<10 
12 <10, <10 <10,<10 
14 <10, <10 <10, <10 
29 <10, <10 <10,<10 
a The pairs of values in each column are for the paired scra from each patient. Titers in boldracc 
represent defined titer rises. 
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Table 4.2.2. Antibody titers in paired serum specimens from patients with a nOll-
RSV infection determined by both G-peptide ELISAs' 
Patient Non-HRSV 
infection 
WA Influenza virus type A 
B C. psi/laci 
G Influenza virus type A 
WB Influenza virus type A 
H Ai. pncul110niae 
Non-HRSV 
titer rise 
7, 32 
<16, >64 
7,>96 
12,RO 
<6,32 
Titcr by the following 
G-peptide ELISA 
Peptide A 
320, 160 
RO, 80 
40, 20 
80, 80 
Pcptide B 
80, 80 
<10,<10 
10, <10 
10, 10 
20,10 10, <10 
V M pneumoniae <6, 64 640, 320 20, 20 
a The pairs of values in the last three columns are for the paired sera hom each patient. 
Indirec! G-peptide ELISA procedure. 
The G-peptide ELISA was pcrformed as described previously (7), but with a modification 
in the coating procedure. One hundred fifty nanograms of crude oxidized peptide in 50 III 
of carbonate buffer (0.05 M; pH 9.6) was coated per well (high-binding-capacity flat-bot-
tom microplate; Greiner) at 37°C ovemight until all water was evaporated. Twofold dilu-
tions of test sera (starting at 1:10) and anti-human HRPO 0:1,000; Dako) were incubated 
for I hat 37"C io ELISA buffer (8.1 mM Na,HP04, 2.79 mM KH2P04, 0.5 M NaCl, 2.68 
mM KCI, I mM disodium EDTA, 0.05% [vol/vol] Tween 80 [pH 7.2]) containing 4% horse 
serum. The substrate chromogen solution consisted of 10 mM sodium phosphate buffer (pH 
6.8), 0.1 mM EDTA, 0.1 % (wtlvol) 5-aminosalicylic acid, and freshly added 0.005% 
(vol/vol) H20 2, Incubation with substrate solution was perfomlcd overnight at 4°C. Color 
dcvelnpment was measured at 450 nm (Titertek MUltiscan). Absorbance values higher than 
two times the average background value aftest serum in control wells without peptide were 
considered positive. Fourfold titer rises or seroconversion «IOta >=20) in paired serum 
specimens arc designated defined titer rises and were considered indicative of RS V infec-
tion. 
Results 
The reactivity of a panel of paired SCi"um specimens was tested in the HRSV-A and HRSV-
B peptide ELiSAs described in Materials and Methods (Table 4.2.1.). To evaluate the HRSV 
specificity of the ELISAs, the reactivities of paired serum specimens, which showed anti-
body titer rises against other agents, were tested in both peptide ELiSAs (Table 4.2.2.). No 
titer rises were observed for the negative controls. 
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Table 4.2.3. Antibody titers in paired serum specimens [rom mothers of patients 
with a respiratory infection by HRSV-A G-peptide ELISA 
Mother Titer by G-peptide ELISA for peptide A" 
2 10,20 
6 10,80 
9 160,160 
U b 160,40 
17 20,20 
18 20,20 
19 40,40 
26 40,40 
27 20, 80 
28 160, 160 
30 _c,20 
36 10,10 
37 10, 10 
41 40,40 
a The pairs of values are for the paired sera from each mother. 
b Numbers in boldface represent mothers of t:hiluren with a high acule-phase serum tiler. 
c serum was not available. 
In Table 4.2.1., titer rises may be missed because of the high titer orthe aCLIte-phase serum. 
Because a high titer in the acute-phase serum may be due to maternal antibodies, the paired 
serum specimens from some of the mothers were tested in the IIRSV-A peptide ELISA 
(Table 4.2.3.). No significant association was found for the maternal antibody titer and the 
corresponding titer in the acute-phase serum ti-om the child (p=O.13, according to Fisher1s 
exact test for two-way tables). 
Discussion 
Detection of RSV infection in young children hy conventional serological tests as described 
in a previous study (2) was compared with detection ofRSV intection with the aid of novel 
G-pcptidc ELISAs (Table 4.2.4.). Tn summary, 1801'27,601'27,001'27,0 of27, 6 01'27, 
5 of27, 0 of27, and 0 of27 specimens scored positive in the G-peptide ELISA, protein-G 
ELISA, protein-F ELISA, protein-N ELISA, neutralization test, IgA ELISA, IgM ELISA, 
and complement fixation test, respectively (Table 4.2.4.). The G-peptide ELlSAs performed 
even better (18 of 27 specimens) than the combination of all other serological tests (12 of 
27 specimens) (Table 4.2.4.). Statistical analyses of the sensitivity of different assays are 
presented in Table 4.2.5. In 6 of the 33 patients, no virus or antigen could be detected (see 
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Table 4.2.4. Detection ofHRSV infection by several serological tests 
Palient RSV Peptide A Peptide H Prnlein-G Protein F Protein N Ncutraliza 19i\ IgM Complement 
no. type ELISA I':USA ELISA" ELiSN ELISA" lion lest" ELISA" ELISA" tixation tcst" 
2 A +b ,- + 
6 A + 
9 A + + + 
11 A 
17 A + 
18 A + 
19 A 
26 A + 
27 A + 
28 A + + 
30 A + + + 
36 A + + + 
37 A + + 
41 A 
7 B + 
8 B -, 
10 B + + 
13 B + 
15 B 
21 B + + + 
23 B + 
24 I3 + 
25 B 
35 I3 + 
38 B + 
39 B 
40 B + 
Id + 
4" + 
5" 
12d 
14d 
29" 
a Data obtained !i'om Brandenburg ct al. (2). 
b +, defined antibody titer rise indicative of HRSV infection. 
C -, no defined antibody titer rise. 
d Paired sera Ihllll patients in which no virus or antigen could be detected. 
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Materials and Methods) (2). In paired serum specimens from these six patients not con-
firmed to be infected with RSV, one RSV-spccific antibody titer rise was detected in the 
neutralization test (Table 4.2.4.). Tn another patient not confirmed to be infected with RSV, 
a titer rise was observed in the I IRSV-A G-peptide ELISA. The latter two findings may sug-
gest that these sera reacted aspccifically. However, it may also be possible that the virus or 
antigen detection test was false negative or that the virus was already cleared from the body 
before the patients entered the hospital. No titer rises were detected in paired serum speci-
mens tl'om patients infected with other agents (Table 4.2.2.). 
The IIRSV-A and HRSV-B G-peptidc ELlSAs are selective for the subtypc-specific detec-
tion ofI-lRSV infection. Patients infected with HRSV-Awere only diagnosed positive by the 
HRSV-A G-peptide ELISA. Patients infected with HRSV-8 were diagnosed positive seven 
times by the HRSV-B G-peptide ELISA and twicc by the HRSV-A G-peptidc ELISA. The 
reactivities of two paired serum specimens from supposedly HRSV-B-infccted children in 
the I-lRSV-A peptide ELISA is puzzling. Several explanations can be conceived for this 
observation. First, the MAb-based subtype was wrong. This explanation seems unlikely 
because the MAb-based subtype was confirmcd by subtype-specific peR. Second, the child 
was infected with both virus types, and an antibody response was developed only against 
subtype A. Third, the cross-reactive sera are directed against an epitope conserved in HRSV 
subtypes A and B, and this epitope is better exposed in the HRSV-A peptide. We do have 
some examples of sera that bind to a conserved epitope in the N-terminal part of the HRSV-
A peptide (Figure 4.2.2.). Pepscan analysis showed two examples of human sera that bound 
to five successive overlapping peptidcs which shared the amino acid sequcnce DFI-IFEYFN 
(amino acids 162 to 169). This sequence is conserved in I-IRSV-B except for the mutation 
ofF to Y at position 163 (Figure 4.2.1.). It is possible that this relatively conserved epitope 
is responsible for cross-reactivity in the peptide ELISA. Therefore, a smaller peptide, which 
TaMe 4.2.5. Two-sided 95% confidence intervals for different assay 
Serological test Interval (%) 
G-peptide ELISA 46< P< X3 
Protcin-G ELISA 9 < P < 41 
Protein-F ELISA O<P<13 
Protein-N ELISA 0< P < 13 
Neutralization test 9 < P < 41 
IgAELISA 6 < P < 38 
IgM ELISA 0< P < 13 
Complement fixation test 0< P < 13 
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Figure 4.2.2. Reactivities of two positive control serum samples from infected children wilh 
overlapping pcptides of the cctodomain ofHRSV-G (12) between amino acids 153 and 211. (a) 
reactivity of serum sample 2369 (dilution, 1: 1 00). (b) Reactivity or serum sample 2219 (dilution, 
I: 100). Numbers on the horizontal axis correspond to the N-terll1inal amino acid ofLhe 12-residue 
peptide. Absorbances at 405 11m ohtained with each peptide in an ELISA arc plotted vertically. 
Reactive peptides arc listed in the graph, and the shared amino acids are boxed. 
only contains the more variable C-tcrminal part ofthc central conserved region, would seem 
more useful for subtype-specific diagnosis. However, a 16-residue peptide ELISA based on 
the shorter C-terminal peptide (residues 174 to 189) without the conserved part was signif-
icantly less sensitive than the 32-rcsiduc peptide used in the assays (7). Pcrhaps investiga-
tors will be able to find new imlTIunodominant peptidcs, which can be combined with the 
16-rcsidue peptidc, to develop an ELISA that is 100% subtype specific. However, such pep-
tides, derived from the highly variable mucin-like regions, are probably strain specific and 
not completely SUbtype specific. 
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Tn the sera of nine patients we did 110t detcct a defined titer rise in the I-IRSV-A orthe HRSV-
B peptide ELISA. In the case of patients 11 and 41, this may be dtlC to the high titer in the 
first serum sample (Table 4.2.1.). Perhaps the first sampling date was too latc for these two 
patients. We presumed that the high titer of the acute-phase serum was probably not caused 
by maternal antibodies since no evident association between the antibody titer in the moth-
er's serum and the titer in the acutcphase serum from the child was observed. The inability 
to diagnose an RSV infection in the seven other patients may be explained by a low or no 
antibody response in these children. The patients were young or prematurely born children 
and therefore may not have been fully immunocompetent. Two of the five serum samples 
that did not react in the peptide ELISA gave a positive response in the IgA ELISA only. 
Therefore, the sensitivity of the peptide ELISA may be increased when the reactivities of 
IgA antibodies are also tested. 
The complete G-protein ELISA uses HRSV-A protein G as thc antigen. Fewer infections 
were detected by the ELISA based on the complete HRSV-A protein G than by the ELISA 
based on the HRSV-A G peptide. The higher sensitivity of the HRSV-A G-peptide ELISA 
compared with that of the complete protein-G ELISA may be explained partly by the dilc 
ferent format of the assays and the definition of a defined titer rise. Imp011ant advantages of 
a peptide-based ELISA are the low cost, the ease of production and the unvarying quality of 
the peptide, and the coated mierotiter plates. Furthermore, the peptide-based RSV ELISA 
described in this study performs better than conventional serological assays with sera from 
these young children. Compared with other imiTIunoassays, the peptide-based ELISA is a 
sensitive immunoassay for the detection of RSV infections. Despite considerable amino 
acid sequence homology between the central conserved regions of HRSV-A and HRSV-B 
proteins G, the peptide ELISA is specific for RSV subtype A and selective for subtype B-
specific antibody detection. 
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Summary 
The immunological response of infants younger than six months to infection with respira-
tory syncytial virus (RSV) was studied in relation to clinical severity. IL-6 and IL-X were 
found more frequently and at higher levels in the plasma samples of more severely ill 
patients and no significant differences were found in the levels of cytokines differentiating 
between Type 1 and Type 2 responses. Cellular infiltrates in nasopharyngeal washings con-
sisted mainly ofpoiymorphol111Clear granulocytes and l11011ocytes. Eosinophils, IgE positive 
cells and tryptase positive cells were found sporadically. 
Analyses of RSV stimulated T cell cultures established from peripheral blood mononuclear 
cells, for intracellular and secreted cytokines showed that, irrespective of clinical severity, 
the responses were dominated by the production of IFN-y, and that only low levels of TL-4 
and IL-J 0 were detectable. Collectively these data do not indicate an association between 
clinical severity and a Type 2-1ike T cell response. 
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Introduction 
Respiratory syncytial virus (RSV) infections arc the most common cause of severe respira-
tory disease in young children, leading to the hospitalisation of up to 2% of children in their 
first year of life (16,17,19,29). The clinical presentation may vary from a mild upper respi-
ratory tract infection to severe bronchiolitis or pneumonia. The highest morbidity of RSV 
disease is seen below the age of 6 months (16,17,19,32). Although there are several known 
clinical risk factors for developing severe RSV infection slIch as prematurity (30), bron-
chopulmonary dysplasia (1 X), congenital heart disease with pulmonary hypettcnsion (27) 
and T cell immune deficiency (20), most children admitted with a severe RSV bronchiolitis 
do not have any of these risk factors. 
It has been hypothesised that an aberrant virus specific immune response in these children 
may playa role in the pathogenesis of bronchiolitis. This was partly based on the observa-
tion that children vaccinated with an experimental formaldehyde inactivated RSV vaccine 
(FI-RSV) developed enhanced clinical disease upon subsequent infection (8,14,24,25). The 
hospitalisation ratc for lower respiratory tract infection in vaccinees was up to 80% in one 
study, and hvo of the vaccinated children died (8). In rodent models vaccination with 
formaldehyde inactivated RSV preparations is associated with enhanced lung pathology, 
characterised by a striking eosinophilic infiltrate correlating with a Type 2 T cell response 
(31,43). 
Whether a similar immune pathological mechanism plays a role in naturally occurring RSV 
bronchiolitis in infants remains elusive. To address this question inflammatory responses in 
infants younger than six months of age, with RSV infections of different clinical severities 
were studied. Inflammatory mediators in plasma samples, inflammatory cells in nasal wash-
ings and virus specific responses in T cell cultures established from peripheral blood 
mononuclear cells (PBMCs) of these children were identitied. 
Materials and methods 
Patients and samplei'!' 
One hundred and eleven children, younger than six months of age, seen at the Sophia!s chil-
dren hospital during the winter seasons 1993/94 and 1994/95, with a respiratory infection 
suspected of RSV, were included in the study. The study was approved by the ethical com-
mittee of the hospital. After informed consent was obtained from the parents, clinical data 
and blood samples were collected in the acute and the convalescent phase (3 to 4 weeks 
later) of the disease. Plasma samples were stored at -70°C until use. PBMCs were isolated 
by Lymphoprep (Nycomed@) gradient centrifugation and frozen at -135°C until use as pre-
viously described (40). Nasopharyngeal washings taken in the acute phase for diagnostic 
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purposes were llsed to study cellular infiltrates. 
Demographic and clinical data collected included: gender, age, duration of pregnancy, pres-
ence of underlying disease (defined as congenital heart disease, bronchopulmonary dyspla-
sia or immune deficiency), a history for apnoea (defined as either a history of respiratory 
arrest with cyanosis or an observation of respiratory arrest for a period of more than 20 sec-
onds and/or bradycardia with accompanying cyanosis in the paediatric emergency room or 
during hospital admission), the presence of wheezing (scored positive if wheezing could be 
heard without using a stethoscope), the presence of retractions, respiratory rate, oxygen sat-
uration (Sa02) in ro0111 air, pC02, pH and abnormalities on X-ray (hyperinflation, consoli-
dation or atelectasis) as described by a radiologist, admission to an intensive care unit and 
artificial ventilation. 
Severe RSV infection was defined as meeting one or more of the following criteria: pC02 
> 6,6kPa, Sa02 < 90% or artificial ventilation. 
RSV c/;agnosis 
Nasopharyngeal washings (± I ml) were diluted with 5 ml DMEM, homogenated, and ccn-
trifuged for 10 minutes at 1000 rpm. The pellet was spotted onto multispot slides, dried at 
room temperature and fixed with acetone. The supernatant was used for virus isolation. The 
pellet was pi petted onto multispot slides, dried at room tcmperature and fixed with acetone. 
These slides were Llsed for direkt antigen detection as described previously (35), using flu-
orescein isothiocyanate (FITC) labelled RSV-specitic monoclonal antibodies (DAKO, Ely, 
UK). 
C)!tokine assays 
Cytokine levels were measured in plasma samples and culture supernatants using commer-
cially available ELISA systems. The following cytokinc levels were determined; IL-2 
(Pharmingcn, San Diego, CA; detection limit 300 pg/ml), IL-4 (Central Laboratory of the 
Blood Transfusion Service of the Dutch Red Cross, Amsterdam, The Netherlands; detection 
limit 7 pg/ml), IL-5 (Pharmingcn; dctection limit 20 pg/ml), IL-6 (Central Laboratory ofthe 
Blood Transfusiou Service ofthe Dutch Red Cross; detection limit 10 pg/ml), IL-8 (Ceutral 
Laboratory of the Blood Transfusion Service of the Dutch Red Cross; detection limit: 22 
pg/ml), TNF-a (Central Laboratory of the Blood Transfusion Service of the Dutch Red 
Cross; detectiou limit: 24 pg/ml), IFN-y (Medgeuix Diagnostics, Fleurs, Belgium; detection 
limit 25 pg/ml), IL-I 0 (Pharmingcn, San Diego, CA; detection limit 20 pg/ml). 
Ninety-six well ELISA plates (Costar plastics, Badhoevedorp, The Netherlands) were coat-
ed with capture antibody overnight at 4°C and blocked 30 minutes with PBS 5% milk pow-
der. Plasma samples were diluted 1:2 in CLB High Performance buffer (Central Laboratory 
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of the Blood Transflrsion Service oflhe Dutch Red Cross). 100 ~I of the diluted plasma was 
added to the wells and incubated for I hour at room temperature. After washing biotin 
labelled detection antibody was added to the wells and the plates were incubated 1 hour at 
room temperature. After washing streptavidine HRPO was added to the wells and incubat-
ed 1 hour at room temperature. Then the substrate, tctramethylbenzidine/II20 2 was added. 
The reaction was stopped after 10 minutes with 2 M H2S04. The optical density (00) was 
read at 450 11m. 
Concentrations of cytokines were calculated from the standard graph of duplicate standards 
included in the runs. 
JmlJ1une h;sfochemistlY staining procedure 
Staining of slides from nasophmyngeaJ washings was carried out by means of the long-
chain biotin streptavidine-alkaline phosphate method (supersensitive; BioGenex, Kiinipath, 
Duiven, The Netherlands). 
Nasopharyngeal washings (± I ml) were diluted with 5 ml DMEM, homogenated, and cen-
trifuged for 10 minutes at 1000 rpm. The pellet was spotted onto multi spot slides, dried at 
room temperature and fixed with acetone. Slides were stored at -20°C until use. 
The specimens were brought to room temperature, dried and fixed in PBS buffered forma-
lin 4% for 15 minutes at 4°C and rinsed in PBS pH 7.8. The slides were incubated for 10 
minutes with 0.5%-1 % bovine serum album (BSA; Sigma, Bornem, Belgium) in PBS and 
subsequently incubated with normal' goat serum (Central Laboratory of the Blood 
Transfusion Service of the Dutch Red Cross) for 10 minutes. After this the following mon-
oclonal antibodies were spotted onto the respective wells of the multi spot slides and incu-
bated for 60 minutes: Anti-CD3+ (UCHTI, I: 100; DAKO, Glostrup, Denmark), anti-CD8+ 
(leu2, I: I 00; BD, Dorset, UK), anti-CD 14+ (mon/1, I :500; Central Laboratory ofthe Blood 
Transfusion Service ofthe Dutch Red Cross), anti-CDl5 (80H5, 1:50; Coulterlmmunoteeh, 
Marseille, France), anti-MBP (BMKI3, 1:50; Sanbio, Uden, The Netherlands), anti-lgE 
(HM25M, 1:750; Central Laboratory of the Blood Transfllsion Service of the Duteh Red 
Cross), anti-t'Yptase (G3, 1:250; Chemicon, Temecula, CA), anti-eosinophilic cathionic 
protein (EG-2, 1:50; Kabi Phannacia, Woerden, The Netherlands). Subsequently, the slides 
were rinsed with PBS for 5 minutes and incubated with Link (goat anti-mouse long-chain 
biotinilated supersensitive AP, BioGenex AZOOOUM; Klinipath) for 30 minutes, rinsed with 
PBS for 5 minutes, incubated with streptavidine-alkaline phosphatase (BioGenex, 
AZOOOUM, Klinipath) for 30 minutes. They were then rinsed once more in PBS for 5 min-
utes and TRIS butfer (0.1 M pi r 8.5) for 5 minutes and incubated for 30 minutes with a New 
Fuchsin substrate (Chroma, Kongen, Germany). Finally, the sections were rinsed in distilled 
water, counterstained with Gills haematoxylin and mounted in glycerin-gelatin. 
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For all spots 1000 cells were counted and the number of positive cells/IOOO cells was 
scored. 
t:stablishmen! and RSV il?fectiol1 ofB-LeL 
B lymphoblastic cell lines (B-LCL) were generated trom PBMCs of patients by EBV trans-
formation essentially as described previollsly (40) using 2xl 05 PBMCs. 
B-LCL cultures were infected with the RSV-A2 strain (ATCC-VR 1322) with a multiplicity 
of infection of 100, in most cases leading to a persistent infection within two to six weeks 
(4). These persistently infected 8-LCL were Llsed as antigen presenting cells in T cell stud-
ies. Infection of 8-LCL with RSV was confirmed by immune fluorescence. To this end a 
sample of the cells was spotted 011 slides, dried at room temperature and fixed in acetone. 
After staining with FITC labelled RSV-speeifie monoclonal antibodies (DAKO, Ely, UK) 
fluorescent cells were scored with an epifluorescence microscope using a 620-nm filter. 
RSV infected cells were used as antigen presenting cells when at least 30% of the cells were 
found positive. Before use in T cell stimulation experiments RSV infected and control B-
LCL were UV irradiated essentially as described previously for measles infected B-LCL 
(302 nm, 2.5,10-2 flW/mm') (41). 
Bulk stimulation of PBMCs 
T ccl1 cullures were canied out in RPMI 1640 medium supplemented with penicillin (l00 
U/ml) streptomycin (100 flg/ml), L-glutamin (2 111M), 2-/3 mercapto-ethanol (10-5 M) and 
10% human pooled serum (HPS). The HPS was a pool of 8 donors, heat inactivated for 30 
minutes at 56°C and tissue culture tested. PBMCs (3 x I 04/well) were co-cultured with UV 
inadiated RSV infected autologous B-LCL (l04/well) in 96 well round bottom plates at 
37°C, 5% CO2, At day 3 recombinant human interleukin-2 (rIL-2; Eurocetlls, Amsterdam, 
The Netherlands) was added to a tinal concentration of 50 lU/ml. Fresh medium with rIL-
2 was added at day 7 and day 11. Twelve to 16 days after this bulk stimulation cells were 
harvested and counted. To expand further the T cell bulk cultures the cells were restimulat-
ed in medium containing 50 lU/ml rlL-2 and I flg/ml phytohaemagglutin-L (PHA-L; 
Boehringer Mannheim, Almcre, The Netherlands) 3xl04 per well in 96 well plates, As feed-
er cells each well received 105 gamma irradiated allogenic PBMCs (a pool of six donors) 
and 5,103 gamma irradiated of both the B-LCL APD (International Histocompatibility 
Workshop, IHW 9291) and BSM (IHW 9(32) as described previously (42). T cell bulks 
were cultured for another 14 days, adding fl'esh medium with rIL-2 evelY 3 to 4 days. 
Between day 28 and 32 after the first RSV specific stimulation, cel1s were harvested, count-
ed and used in experiments for cytokine measurements. 
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Atfeaslfremenf ofcytokines in cU/lure supernatants 
For measurement of cytokine levels in culture snpClnatant, cells were restimulated with 
autologolls RSV infected B-LCL, un infected 8-LCL or medium. Culture supernatants were 
harvested 48 hours after restimulation and tested for the presence ofIFN-y, IL-4 and IL-I O. 
Validity of detection of IFN-y and ILA in culture supernatants was tested using a measles 
virus specific CD8+ clone known to produce both IFN-y and IL-4 (R. van Binnendijk, 
unpublished results) and an RSV speeillc CD8+ T cell clone known to produce IFN-y. RSV 
specific cytokine production was determined by subtracting the cytokine production meas-
ured with un infected B-LCL from that with RSV infected B-LCL. RSV induced cytokine 
production was considered significant in bulk cultures when levels above 10 pg/ml were 
found. 
Intracellular c}Jtokine immul1ejluorescence 
Intracellular production of IFN-y and IL-4 in PBMCs bulk cultures, upon RSV stimulation, 
was measured by intracellular immune fluorescence. Six hours after restimulation with 
autologous RSV infected B-LCL, control B-LCL or medium, in the presence of monensin 
(0,5 [lM; Sigma, Zwijndrecht, The Netherlands), cells were collected, divided into two por-
tions and stained with RPE-Cy5 anti-CD4+ or anti-CD8+ (DAKO, Glostmp, Denmark) for 
1 hour on ice. After washing twice with PBS, cells were fixed in 4% paraformaldchydc for 
20 minutes on ice and washed subsequently twice with 0,5% glycine. Cells were then per-
meabilised with 0.1 % saponin in PBS supplemented with 1 % normal mouse serum and 5(10 
foetal calf serum. After permeabilising the cells were stained with anti-IFN-y FITC (DAKO, 
Glostmp, Denmark) and IL-4-PE (Pharmingen) for 30 minutes on ice. Fluorescence was 
measured by FACS analysis. Cells were gated on FSC/SSC prolile and CD4/CD8 expres-
sion. Proportions of CD4+ or CD8+ cells expressing IFN-y and IL-4 were measured using 
quadrant markers. Markers were set using the medium control to define 2% IFN-y and IL-
4 positive cells as shown in Figure 5.1.1. Validity of detection of intracellular of IFN-y and 
IL-4 was tested using a measles virus specific CD8+ clone known to produce both of IFN-
yand IL-4 and an RSV specific CD8+ T cell clone known to produce IFN-y. 
Statistical analyses 
Differences in number of cells, levels of soluble cytokines and percentages of cells express-
ing IFN-y between groups of different clinical severity were tested lIsing Mann-Whitney U 
test (MWU test). For testing of the relation between levels of cytokines in plasma and num-
ber of positive cells in immune histochemistry staining Kruskall Wallis one way anova was 
used. 
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Table 5.1.1. Clinical and virological data of selected patients for detailed T cell responses 
Palient Age VI' admission Ar(ilicial Respiratory pC,(}~ SaO:, Wllet,-:ing Apnea's Almormality 
No. in days ventilation rale!lllin (kPaj (%) Oil X-ray 
Severe RSV infection 
I. 6X RSV ICUb yes ND' 10.7 NO 110 no yes 
2. 96 RSV Normal ward no 70 6.9 93 yes yes yes 
3. 65 RSV ICU yes 50 7.7 70 no yes yes 
4. 60 RSV lCU no 64 8.1 87 yes yes yes 
5. 44 RSV leU yes 30 12.2 82 no yes yes 
6. 59 RSV ICU no 30 11.3 NO no no no 
7. 198 RSV Normal ward no 40 5.0 93 yes yes yes 
Mild RSV infection 
8. 198 RSV Not admitted 110 40 NO NO 110 no NO 
9. 98 RSV Not admittcd 110 32 4.5 96 yes no yes 
10. 79 RSV Not admitted no 56 5.0 96 no no no 
11. 79 RSV Not admitted 110 72 5.2 95 110 no yes 
12. 47 RSV Not admitted no 72 5.9 98 no no NO 
13. 161 RSV Normal ward no 30 4.8 NO no no NO 
RSV negative 
14. 71 negative Normal ward no 40 4.7 100 yes yes NO 
15. 47 pertussis ICU no 48 6.3 NO no no no 
a: VI virus isolation 
b: leU - intensive care unit 
c: NO = no data recorded or no data available before slart or oxygen therapy and/or artificial ven-
tilation 
Results 
Patients 
Of the 111 children included in the study 95 had a RSV infection as diagnosed by direct anti-
gen detection and virus isolation. Of the 16 RSV negative children one suffered ti'om aden-
ovirus infection and one from a Borde/ella pel'/lfssh; infection. No causative agent for the 
other 14 could be identitied. Of the RSV positive children fifty were defined as having a 
severe disease and 45 as having a mild disease by the predetermined criteria. Of the RSV 
positive children 60 were male and 35 were female. One child had a bronchopulmonary dys-
plasia, seven had an underlying heart abnormality and four children were born at 33 weeks 
gestation or less. In 84 children no underlying risk factors were identitied. Seventeen need-
ed no hospital admission, 41 were admitted to the medium care unit and 36 were admitted 
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Figure 5.1.2. Plasma concentrations of cytokines in patients with mild vs. severe RSV infec-
tion dllring the acute (ac.) and convalescent (conv.) stage of disease. Individual and mean levels 
arc shown. Levels of IL-6 and IL-8 in the acute phase were significantly higher in the severe 
group using MWU test. 
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to the intensive care unit. Of the children admitted to the intensive care twelve needed 
mechanical ventilation. Twenty-seven children had one or more apnoeas either before or 
during admission whereas 68 had no history of apnoea. 
Plasma levels of cytokincs and numbers of positive staining cells in nasopharyngeal wash-
ings were compared between RSV positive and negative patients and in RSV positive 
patients between those with severe versus mild disease. 
For characterisation of RSV specific T cell responses fifteen patients without underlying 
risk factors were selected and matched for age. Seven had a severe RSV infection, six had 
a mild RSV infection and two had a non-RSV related respiratory infection. Detailed clini-
cal and virological data of these fifteen children are shown in Table 5. L 1. 
C)!tokincs in plasma samples 
Plasma levels of cytokines related to a Type I or 2 response were either low or undetectable 
(Figure 5.1.2.). IL-2 and lL-5 could not be detected in auy ofthe plasma samples tested. IL-
4 was detected in 18 out of95 (19%) RSV positivc children aud one out of 16 (6%) RSV 
negative children in the acute phase and 22 out 0[88 (25%) RSV positive and one out of 14 
(7%) RSV negative children in the convalesccnt phase. IFN-y was detected in ninc out of 
93 (10%) RSV positive childreu and three out of 16 (19%) RSV negative childreu in the 
acute phase and five out of 83 (6%) RSV positive and none of the RSV negative children in 
the convalescent phase. IL-J 0 was detected in 23 Ollt of95 (24%) RSV positive children and 
one out of 16 (6%) RSV negative children in the acute phase and three out of 87 (3%) of 
RSV positive and none of the RSV negative children in the convalescent phase. Statistically 
significant differences using MWU test, were not found between RSV positive and negative 
patients or between RSV positive patients with infection of different clinical severity for 
plasma levels of cytokines related to a Type 1 or Type 2 response (Figure 5.1.2.). Also no 
statistically significant differences were found in MWU test when children with underlying 
risk factors were excluded and when Sa02, pC02 , or artificial ventilation was used as the 
single parameter for clinical severity and also when admission to hospital or admission to 
the intensive care unit was used as a parameter for clinical severity. 
IL-6 was detected in 44 out of93 (48%) RSV positive children and three out of 16 (19%) 
RSV negative children in the acute phase and ten out of84 (12%) RSV positive and two out 
of 14 (14%) RSV negative children in the convalescent phase. TL-8 was detected in 68 out 
of95 (72%) RSV positive children and five out of 15 (33%) RSV negative children in the 
acute phase and 46 out of 87 (53%) RSV positive and six out of 14 (45%) RSV negative 
children in the convalescent phase. TNF-<x was detected in ten out of 89 (11 %) RSV posi-
tive children and one out of 15 (7%) RSV negative children ill the acute phase and 21 out 
of 80 (26%) RSV positive and two out of 12 (16%) RSV negative children in the eonvales-
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cent phase. No statistical differences were found between RSY positive and negative chil-
dren. For RSV positive children IL-6 and IL-8 were found more often in children with more 
severe disease during the acute phase (p<O.Ol in MWU test). This finding was confirmed 
when children with underlying risk factors were excluded and when Sa02, pC02, or 31iifi-
cial ventilation was uscd as the single parameter for clinical severity and also when admis-
sion to hospital or admission to the intensive care unit was used as a parameter for clinical 
severity. During the convalescent phase and for TNF-a both during the acute and convales-
cent phase no differences in plasma levels were found (Figure 5.1.2.). 
Cellsf;<oJ11l1asophmYllgeal w(fs'hings 
Multispot slides from nasopharyngeal cells obtained in the acute phase of the infection were 
available from 68 of patients. Ofthese 59 were RSV positive and 9 were RSV negative. No 
statistical differences in numbers of inflammatory cells were found between RSV infected 
and RSV negative children. Results from immune histochemical staining in RSV positive 
children with sevcre vs. mild infection are shown in Table 5.1.2. 
The cellular infiltrates in RSV infected patients consisted mainly of polymorphonuclear 
cells (CDI5+) and monocytes (CDI4+). Tn the slides for mildly il1 patients more BMK-13 
positivc (eosinophilic granulocytes) and IgE positive cells were found. This was not con-
firmed however, when Sa02, pC02, or artificial vcntilation was used as the single parame-
ter for clinical scverity or when hospital admission or admission to the intensive care unit 
was used as a parameter for clinical severity. 
In part of the slides high numbers of cells stained positive for eosinophilic cathionic protein 
usually considered an eosinophilic marker, whereas only low numbers ofBMK-13 positive 
cells were found. These eosinophilic cathionic protein positive cells were not related to 
more severe clinical disease and were also not related to the presence of wheczing. In the 
26 children with wheezing a median number of 66 eosinophilic cathionic protein positive 
cells (range 0 - 680) was found. In the 37 chi1dren without wheezing a median number of 
43 eosinophilic cathionic protein positive cells (rangc 0 - 680) was found, p=O.86 in MWU 
test. 
Comparison of numbers of positive staining cells with plasma levels of IL-6 and IL-8 using 
Kruskall-Wallis one-way ANOYA showed no relationship. 
RS V specific T cell responses 
In the fifteen patients selected for characterisation of RSV specific T cell response IFN-y, 
IL-4 and IL-I 0 production in culture supernatants (Figure 5.1.3.) and intracellular expres-
sion ofIFN-y and IL-4 (Figure 5.1.4.) were measured upon re-stimulation with RSV infect-
ed and control B-LCL in pre-stimulated PBMCs bulk cultures cstablished from samples col-
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lectcd in the acute and the convalescent phases. 
RSV-induced IFN-y was found in the culture supernatant of six of the 13 RSV positive 
patients in the acute phase (patients 3, 5, 6 and 7 with severe and patients X and 11 with mild 
symptoms) and twelve of 13 patients in the convalescent phase (all seven with severe and 
patients 8,10, II, 12 and 13 with mild symptoms). In patient 9 RSV induced IFN-y was 
detected in the culture of the acute phase but not in that of the convalescent phase. In the 
latter, however, a relatively high background was found upon stimulation with non-infected 
cells. IL-4 and IL-I 0 were demonstrated in the culture supernatants at much lower concen-
trations than IFN-y. RSV-induccd IL-4 above 10 pg/ml was found in one patient (patient 8 
with mild symptoms) in thc acute phase and in four patients (patients 1,3,7 with severe, 
and patient 8 with mild symptoms) in the convalescent phase. RSV-induced IL-I0 above 10 
pg/ml was found in 2 patients (patients 8 and 11, both with mild symptoms) in the acute 
phase and in seven patients (patients 1,3,5 and 7 with severe, and patients 8, 11 and 13 with 
mild symptoms) in the convalescent phase. In the culture of one of the control patients RSV-
induced TFN-y was detccted at both time points in low concentrations. 
A representative example of a FACS analysis for RSV-induced intracellular TFN-y and IL-4 
is shown in Figure 5.1.1. No RSV specific TL-4 was measured above medium control back-
ground in any of these samples, whereas ILA is detectable in T cell clones using this 
method. Results of RSV-induced intracellular TFN-y expression in acute and convalescent 
phase samples of all 15 patients studied arc shown in Figure 5.1.4. Proportions of RSV-
induced IFN-y positive cells were higher in the CD8+ than in the CD4+ cells. RSV-induced 
IFN-y in CD4+ cells was found in four of the 13 patients in the acute phase (patient 5 with 
severe, and patients 8, 9 and 11 with mild symptoms) and in eleven of the 13 patients in the 
convalescent phase (patients 1,2,4,5,6 and 7 with severe, and patients 8, 9, la, II and 12 
with mild symptoms). IFN-y in CD8+ cells was found in six ofthe 13 patients (patients 6 
and 7 with severe, and patient 8, 9, II and 12 with mild symptoms) in the acute phase and 
in all 13 patients in the convalescent phase. 
No statistical ditferences in cytokine concentrations in culture supematants or proportions 
of RSV induced IFN-y positive cells were found between the mild and severe group in the 
acute or in the convalescent phase. 
Discussion 
Vims specific T cell responses have been shown to be involved in the clearance of RSV 
infection, but also in the induction of immune pathology (1,7,9,31,43). In the mouse model 
this immune pathology is associated with an eosinophilic lung infiltrate and a Type 2 medi-
ated T help response. Young children arc prone to develop a type 2 immune response upon 
infection (11,33) and higher levels of Type 2 cytokines have been found in children with a 
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Table 5.1.2. Number of inflammatory cellsllOOO counted cells found in nasopha-
ryngeal washings of children with RSV infection 
Mild Severea 
(n~21 ) (n~37) 
median (range) median (range) 
CD3 (T cells) 30(4-94) 21 (5 - 140) 
CDI4 (monocytes) 44 (0 - 156) 57 (0 - 249) 
CDI5 (PMN) 325 (10-900) 300 (0 - 900) 
IgE 7 (0 - 64) 1 (0 - 42) 
BMKI3 (eosinophils) 1.5 (0 - 9) 0.5 (0 - 11) 
Tryptase (mast cells) 0(0 - 9) o (0 - 32) 
Eg2 (ECP)' 42 (0 - 241) 66 (0 - 680) 
CDS o (0 - 19) 0(0-23) 
a Severe RSV infection was defined as meeting one or more of the following criteria: 
peo2 > 6,6kPa, Sa02 < 90%, artificial ventilation. 
b p value as tested in Mann-Whitney U test; 
c eosinophilic cathionic protein. 
d indicates signilicant dilTerem:e 
ph 
0.22 
0.78 
O.SI 
0.04d 
O.02d 
0.12 
0.56 
0.39 
RSV infection (34,37). Tn those studies, however, a comparison was made with healthy non-
infected children. In the present study it was shown that infants with clinically more severe 
RSV infection have higher levels of IL-6 and IL-8 in their plasma, indicating more inflam-
mation in the lungs, bullhey do not exhibit a more pronounced RSV-specific Type 2 like T 
cell response than intants with mild RSV infection. Only few eosinophilic granulocytes 
were detected in nasopharyngeal washings and a Type I-like T cell response characterised 
by the expression of mainly IFN-y and only low levels ofIL-4 and IL-I 0, were found in the 
supernatants of PBMCs cultures from both groups of infants after RSV-specific stimulation. 
Intracellular detection of cytokines confirmed these findings. IFN-y expression proved to be 
more prominent in CDS+ than in CD4+ cells upon RSV-specific stimulation. No RSV 
induced expression of IL-4 could be demonstrated while it was measurable in low levels in 
the culture supernatants. Apparently the intracellular measurement of cytokines, as stan-
dardised for measles and RSV-specific T cell clones, was not sensitive enough for the detec-
tion of these low levels in the PBMCs bulk cultures. 
For the characterisation of specific T cell immunity in these infants we have used a virus 
specific pre-stimulation protocol to expand the virus-specific T cells in the peripheral blood. 
Although it may be argued that such a protocol can intluence the ratios of the respective 
cytokines expressed, it is known that Type 2 responses in PBMCs for celiain antigens can 
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F;gure 5.1.3. Concentration:; of RSV specific IFN-y (white), IL-4 (grey) and IL-IO (black) 
measured in culture supernatants of pre-stimulated T cell bulk cultures of infants with a recent 
RSV inteelion of dit1erenL clinical severity. Samples were from the acute phase (A) and the con-
valescent phase (8). RSV-specific cytokine production was determined by subtracting the 
cytokine production in wells stimulated with control B-LCL from the cytokine production in the 
wells stimulated with RSV infected B-LCL. 
only be mcasured using restimulation protocols that allow for the expansion of T cells 
(21,28) and that Thl/Th2 responses measured in this way do show a relation to clinical 
responsc (12,23,36). Tn the severely iII patients a less pronounced T cell response was found 
in the acute phase. This is compatible with the lindings of De Weerd et a!. (10) that T cells 
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Figure 5.1.4. Proportions of intracel!ular lFN-y expression, as round in FACS analysis, in pre-
stimulated T eel! bulk cultures of infants with a recent RSV inlection of different clinical severi-
ty. Samples from the acute phase (\) and the convalescent phase (2) were stimulated with RSV 
infected (black) B-LCL or control B-LCL (white). 
arc relatively depleted from the peripheral blood in the acute phase and may be accumulat-
ed in the respiratory tract. 
Epithelial cells and also polymorphonuclear cells have been shown to produce IL-o and IL-
8 upon infection with RSV (2,3,5,26). Our findings that infants with more severe disease 
have higher levels of lL-6 and IL-8 in their plasma suggests that these infants had more 
extensive infection and more general inflammation in their respiratOlY tract. Our data are in 
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agreement with the recently published data of Bont et aL (6) who found higher plasma lL-
8 levels a marker for severe disease. The cellular infiltrates of the nasopharyngeal washings 
mainly consisted of polymorphonuclear cells and lTIonocytes. This is consistent with the 
findings of Everard et a1. (13) who identified cells in bronchoalveolar lavage fluids and 
nasopharyngeal washings of RSV infected children. Eosinophilic granulocytes and IgE 
expressing cells were found more hequently in infants with milder disease (Table 5.1.1.). 
However, the overall numbers of eosinophils and IgE positive cells were very low and when 
other criteria for clinical severity were tested, like peo2 or artificial ventilation as single 
determinant or hospital admission no statistical differences were found for these cells. 
Therefore we conclude that there is no relationship between these parameters and disease 
severity. 
Surprisingly in pmi of the nasopharyngeal washings relatively high numbers of cells stained 
positive for eosinophilic cathionic protein, that is known as an activation marker of 
eosinophilic granulocytes, whereas only few eosinophils were detected in the slides. It has, 
however, been documented that not only eosinophils but also neutrophilic granulocytes can 
express eosinophilic cathionic protein (38), that may therefore have been the source for the 
eosinophilic cathionic protein found. Although higher levels of soluble eosinophilic cathion-
ic protein in nasopharingeal samples have been associated with RSV bronchiolitis and 
wheezing (15,22), these eosinophilic cathionic protein expressing cells could not be related 
to clinical severity or wheezing in this study. 
In RSV infection there is a wide range of clinical appearance. So using a simple definition 
of mild versus severe disease may cause considerable overlap between the two groups. Also 
pre-existing risk factors, like prematurity or cardiopulmonary disease increase the chance of 
a severe clinical outcome and may influence the analysis. Therefore the data were also 
analysed excluding children with underlying illnesses, and other parameters related to clin-
ical severity were tested, like need for hospital admission, intensive care unit admission or 
artificial ventilation, that gavc the same results. 
For the detailed in vitro analysis of RSV-specific T cell responses patients without any of 
the pre-existing risk factors were selected. Also, because the age at which the first RSV 
infection takes place may influence clinical severity, the patients selected for these studies 
were matched for age between the two groups of different clinical severity (Table 5.1.1.). 
The data aflhese studies show that, although low levels of Type 2-like cytokincs were found 
in some infants, a predominant Type I-like RSV-induced T cell response was present in cul-
tures from infants irrespective of the clinical severity of the disease. Genetic variability both 
in the virus and the host may influence the analysis of the immune response in RSV infec-
tion. In the mouse model the Type 2 T cell response inducing lung eosinophilia has been 
associated with an eleven amino acid domain on the G protein. This response is influenced 
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by the genetic background and the route of exposure to the antigen (39). 
Taken together these data do not support the hypothesis that severe RSV infection is asso-
ciated with a Type 2-like T cell response in naturally occurring RSV bronchiolitis. 
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Summary 
Virus-specific cytotoxic T lymphocytes (CTL) playa major role in the clearance ofrespira-
tory syncytial virus (RSV) infection. We have generated cytotoxic T-cell clones CTee) from 
two infants who had just recovered from severe RSV infection. These Tee were function-
ally characterized and used to identify HLA class 1 (B57 and C12)-restricted CTL epitopes 
of RSV. 
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Respiratory syncytial virus (RSV) is a common cause of upper respiratory tract infections, 
but may - especially in young infants, the elderly, or i111l11U110Compromised individuals -
cause severe lower respiratory tract infections (12). In rodent models CD4+, as well as 
CD8+, RSV-spccific T lymphocytes proved to be involved in both recovclY from and 
immune pathogenesis of the infection (1,2,8,19). Therefore, a fine balance lllust exist in 
these models between protective and disease-enhancing effects of vir lis-specific T lympho-
cytes. RSV-specitic CD8+ cytotoxic T lymphocytes (CTL) against virtually all RSV pro-
teins have been demonstrated to circulate in humans after RSV infection (4,7,9). eTL may 
be expected to playa crucial role in the clearance of RSV infections, but their role in pro-
tection and immune pathology remains unclear. Therefore, the identification of CTL epi-
topes of human RSV may contribute to future studies concerning the role of CTL in patho-
genesis and protection fl'om RSV infection. Here we describe the functional characteriza-
tion ofCD8+ cytotoxic T-cell clones (TCC) generated from two infants who had just recov-
ered from severe RSV infection. These TCC were also used to identify, for the first time, 
HLA class I-restricted CTL epitopes of RSV. 
Peripheral blood mononuclear cells (PBMC) were collected from two infants, 4 weeks after 
a severe, laboratory-confirmed RSV infection. At the time of infection they were 1 and 2 
months old and had both been admitted to the intensive care unit. B-Iymphoblastic cell lines 
(B-LCL) werc generated by Epstein-Barr virus transformation (22), infected with RSV A2 
(ATCC VR 1322), and UV irradiated (24) to serve as autologous antigen-presenting cells 
(APC). PBMC (3"104/well in 96-well round-bottom plates) were stimulated with APC 
(104/well), and expanded in RPMI 1640 medium supplemented with antibiotics, 10% 
pooled and heat-inactivated human serum, and recombinant human interleukin-2 (IL-2, 50 
IU/ml). After 2 weeks, T cells were harvested and cloned by limiting dilution, using phyto-
hemagglutinin stimulation as previously described (25). TCC thus generated were expand-
ed and tested for RSV specificity by [3H]thymidine incorporation assays as previoLlsly 
described (22). All of the RSV-specitlc TCC proved to be of the CDX+ phenotype in tluo-
rescence-activated cell sorter analysis. TCC whosc specificity for RSV was confirmed by a 
second proliferation assay were tested for protein specificity by a gamma interferon (IFN-
'I) ELlspot assay (Mabteeh AB, Stockholm, Sweden). In this test, paraformaldehyde-t1xed 
autologous B-LCL that had been infected with recombinant vaccinia viruses (rVV) express-
ing different RSV proteins (F, G, N, P, M2, SH, M, IB, or IC) were used as APC. Brietly, 
TCC (5,104/wcll) were incubated with APC (1()4/well) for 4 h, transferred to anti-human 
IFN-y coated plates, and incubated for another 18 h. The ELlspot assay was further per-
formed in accordance to the kit manufacturer's instructions. The results are shown as nUlll-
bers ofIFN-y producing cells (spots) per well. 
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Figure 5.2. I. Responses of RSV-specific Tee /l'om patients 1 (A) and 2 (B) measured by an 
IfN-y ELlspOL assay using autologous 8-LCL infected with RSV A2 or rVV expressing the RSV 
F, 1 B, or 1 C protein. Results are indicated as number of spots per well. No responses againsl the 
8-LCL infected with the other rVV were found (data not shown). 
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Thirty-four RSV-specific Tee were generated from the PBMC of patient 1, as detected by 
a [3J I Jthymidine incorporation assay. Of these, 27 proved to be RSV-F specific and 7 were 
RSV-l B specific in an IFN-y ELI spot assay (Figure 5.2.1.A). Twenty-four RSV-speei[ic 
Tee were generated iI-om the PBMC of patient 2 as detected by a r3H]thymidinc incorpo-
ration assay. Of these, 10 were RSV-F specific and 14 proved to be RSVIC-spccific in an 
IFN-y ELIspot assay (Figure 5.2.1.B). None or the clones detected by the llHlthymidine 
incorporation assay was found to be negative by the IFN-y ELlspot assay. Since the F pro-
tein is considered to be a major CTL target (4,7,9), further efforts were focllsed on the iden-
tification of CTL epitopes in the F protein. To this end, lX-mer peptide amides overlapping 
by 12 amino acids, together spanning the entire F protein ofRSV A2 (11,18) (n = 94), were 
generated in an automated mUltiple-peptide synthesizer as previously described (26). The 
purity of the pep tides varied between 50 and 90%, as determined by analytical revcrse-
phase high-performance liquid chromatography (C::s column; gradient of 0.1 % trifluo-
roacetic acid in water to 0.1 % trifiuoroacetic acid in acetonitrile). Autologous B-LCL of 
patients 1 and 2 were pulsed overnight with land 3 mM peptide, respectively. RSV F-spe-
citic TCe or patient I reacted with peptides 17 and 18 (Figure 5.2.2.A). All of the RSV F 
Tce of patient 2 reacted with peptide 91 and marginally with peptide 90 (Figure 5.2.2.B). 
Subsequently, two additional sets of pmiially overlapping 8- to 12-mer pcptides (80 to 95% 
purity) were generated to determine the respective minimal epitopes. Autologous B-LCL of 
patients I and 2 were pulsed for 1 h with the different pepUdes at 1 and 3 ~lM respectively. 
All of the RSV F-speeitic TCe of patient 1 reacted with one nine-mer peptide (RARREL-
PRF) spanning residues 118 to 126 of the F protein (Figure 5.2.2.C). The RSV F TCe of 
patient 2 all reacted with one nine-mer peptide (lAVGLLLYC) spanning residues 551 to 559 
ofthe F protein (Figure 5.2.2.D). 
The HLA restriction of the recognition by the RSV F TCe was also determined by the lFN-
y ELispOI assay using a set of allogeneic B-LCL with partially matched HLA types loadcd 
with the respective minimal peptides, as shown in Figure 5.2.3. Recognition of the RSV F 
epitope of patient 1 proved to be HLA B57 restricted. Recognition of the epitope of patient 
2 proved to be C 12 restricted. 
Well-growing TCe of both specificities from each of the patients were arbitrarily selected 
and tested for cytotoxic activity by a chromium release assay as previously described (23). 
Brietly, autologous 5lCr-Iabe1ed, RSV-infected B-LCL and control B-LCL or, in the case of 
the F-specitic TCC of patient 2, minimal-peptide-Ioaded B-LCL or control (measles virus) 
peptide-loaded B-LCL were incubated with TCC for 4 h at 37°C at an effector-to-target cell 
ratio of 10: 1, which was found to be the most discriminative ratio in preliminary experi-
ments. Spontaneous 51Cr release (target cells plus medium) and maximum51 Cr release (tar-
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Figure 5.2.2. Fine mapping ofT-ceil epitopcs on the RSV F protein. Responsiveness ofTCC 
from patients 1 (A) and 2 (8) to partially overlapping IS-mer peptide amide::; (n =- 94) spanning 
the F protein was measured by an IFN-y ELlspot assay. Minimal peptide activation ofTCC from 
patients 1 (C) and 2 (D) was measured in an IFN-y ELIspot assay Llsing APC pulsed with two 
additional sets of overlapping 8- to 12-mer peptides. med, medium. 
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get cells plus Triton X-IOO) were determined in 12 identical wells. Supcmatants were har-
vested and analyzed in a gamma counter. Assay results were accepted only when the spon-
taneous-ta-maximum release ratio was <25%. All of the tested Tee showed RSV-specific 
lysis (Figure S.2A.A). Virus-specific production of cytokines in cell-free culture supernatant 
was measured as previously described (6). Tee were stimulated with RSV-infected B-LCL 
or control B-LCL or, in the case of the F-specific Tee of patient 2, minimal-peptide-loadcd 
or control B-LCL. for 48 h. The concentrations of the following cytokines were measured 
llsing commercially available sandwich enzyme-linked immunosorbent assay systems in 
accordance with the manufacturers' instructions: IL-4 (CLB, Amsterdam, The Netherlands; 
detection limit, 7 pg/ml), IFN-y (Medgenix Diagnostics, FlellI's, Belgium; detection limit, 25 
pg/ml), IL-IO (Pharmingen, San Diego, CA; detcction limit, 20 pg/ml). All of the TCC pro-
duced predominantly IFN-y, indicating a type 1 phenotype ;'1 vitro (Figure 5.2.4.B). 
In the present study, we identified two nine-mer CTL epitopes on the RSV fusion protein. 
To our knowledge, these are the first HLA class I-restricted CTL epitopes described for RSV 
in humans. We found CTL epitopcs with an HLA restriction with a low prevalence in the 
popUlation. But using the techniques described here on samples of more children with a 
recent RSV infection, CTL epitopes with more prevalent HLA restrictions may be identi-
fIed. 
The TCC found in the children studicd were all CD8+ CTL with a Type I-like cytokine pro-
file. No RSV-specific CD4+ T cells were detected in the samples of these infants, while the 
use of similar stimulation protocols did result in the identification of such cells in other sys-
tems (l4, 17,20,22). Virus-specific CTL responses playa major role in the clearance of RSV 
infections but may also be involved in pathogenesis (1,3,5,8,15). Tn mice, enhanced lung 
pathology induced by priming with formalin-inactivated RSV has been associated with the 
absence of a CTL response (l3,21). In young children, a CTL response against RSV has 
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Figure 5.2.3. Determination of HLA reslrietion of RSV F protein recognition by speci fie TCC 
using a set of aUlologous and paltially HLA cbss 1- 1l1fltched 8-LCL for patients 1 (A) and 2 (B), 
by an fFN-y ELIspol assay. 
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Figure 5.2.4. Cytotoxic responses (A) and cytokine production (B) of selected Tee with dif-
ferent protein specificities from patients I and 2. Tee were stimulated with aUlologous-RSV-
infected or control 8-LCL and in the case oflhe F-specific Tee of patient 2, minimal-peplide- or 
control (measles virus) peptide-loaded B-LCL. Cytotoxic responses were measured in a chromi-
um release assay using an effector-ta-target cell ratio of 10. Cytokincs in cell-free culture super-
natant (IFN-y, IL-4, IL-5, and lL-IO) were measured by enzyme-linked immullosorbent assay. 
Levels of cytokines in the sllpernMant ofTCC stimulated with control 8-LCL were all below the 
detection limit and are not shown. 
been described but poor responses were found in younger and more severely ill patients 
(10,16). The poor CTL response in young children has been suggested to be one of the pos-
sible causes of more severe disease. In these two patients, it was possible to detect RSV-spe-
cific cytotoxic TCC, showing that also in very young children with clinically severe infec-
tions, priming of a CTL response does occur, although we cannot say anything about the 
quantitative responses. 
In conclusion, usc of the IFN-y ELls pot assay to determine epitope specificity proved to be 
sensitive and convenient, since only small numbers ofT cells and APC were needed. This 
and similar studies may be impoliant for future studies conceming the role of CTL in the 
pathogenesis ofRSV infection in children. 
This study was financially suppOlied by the Sophia Foundation for Medical Research, 
Rotterdam, The Netherlands (grant 214). 
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Summary 
Respiratory syncytial virus (RSV) infection is the most prevalent cause of severe respirato-
ry disease in infants. It also causes considerable morbidity in older children and adults with 
underlying risk factors. RSV vaccine development has been complicated by the need to 
administer the vaccine at a very young age, and by enhanced disease observed after vaCCI-
nation with formalin inactivated RSV. 
For infants live attenuated vaccines, which may not be expected to predispose for vaccine 
induced enhanced pathology, hold the greatest promise. However the balance between atten-
uation and immunogenicity appears to be delicate. For older risk groups results with sub-
unit vaccines are most promising. 
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Introduction 
Infection with respiratory syncytial virus (RSV) is the most COllllllon cause of severe respi-
ratory disease in young children, leading to the hospitalisation of up to 2% of children in 
their tirst year oflifc (56,58,63,96,111). In fact up to 70'10 of hospital admissions of babies 
for respiratory infections during the winter season may be caused by RSV (54). Currently 
no licensed vaccine is available for this major cause of infant morbidity. 
The majority of RSV infections run a mild clinical course and only a minority of infected 
children (0,5 - 2%) has to be admitted to hospital. However, since RSV infections are so 
prevalent with an estimated 50%) of children being infected in their first year of life, RSV 
bronchiolitis is a common reason for hospital admission of young infants. Why RSV infec-
tion is complicated by lower respiratory tract involvement in part of the infected children is 
not understood, but an immune pathological mechanism has long been suspected. 
A better understanding of protective, but also of putative disease enhancing mechanisms in 
RSV infection - upon both natural and vaccine indueed responses - is crucial to prevent the 
recurrence of the vaccination debacle with a formalin inactivated RSV (fI-RSV) vaccine 
(47,90,10R) and to determine approachcs which result in the induction ofa safe and effec-
tive immune response against RSV. 
The virus 
RSV is a member of the genus Pneumovirus, of the family Paramyxoviridae. Other mem-
bers of this genus are bovine RSV - which causes respiratory tract disease in calves similar 
to human RSV in infants - pneumonia virus of miee and the turkey rhino-tracheitis virus 
(27). 
The viruses of the genus Pneumovirus differ f)'om the other Paramyxoviridae in that they 
have a second matrix protein (M2) (27) and envelope glycoproteins with no hemagglutinin 
or neuraminidase activity. One ofthe surface glycoproteins, the fusion (F) protein, mediates 
both viral penetration and cell to cell spread by fusion of membranes. This protein contains 
N-linked oligosaeharide groups and is composed of two disulphide-linked subunits of47kD 
(FI) and 20k!) (F2) respectively (76). The larger envelope protein G serves a function cor-
responding to the host cell attachment of the hemagglutinin of other paramyxoviruses. It is 
heavily glycosylated with both 0- and N-linked oligosaeharide groups. Tn fact more than 
60% of the molecular weight of the G protein consists of sugar moieties. 
Antigenic diversity in RSV isolates is largely determined by variation in the F and G gly-
coproteins. RSV can be divided into two major antigenic groups, A and B, by their reactiv-
ities with monoclonal antibodies (5,52,106) and nucleotide sequence differences 
(20,82,137,140). These two groups circulate independently in the population with group A 
being the most prevalent (3,70,105,148). Sequence diversity within the two groups can also 
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be extensive. This diversity is mainly found in the G protein (83). G protein amino acid 
homology between different G proteins can be as low as 53% and antigenic homology as 
low as 5%, making the G protein, the protein most tolerable to mutations without loss of 
function, known in nature (27). Several lineages within the groups A and B also seem to co-
circulate independently (l8,137). Studies on heterogeneity in RSV strains show an accu-
mulation of amino acid changes over the years, suggesting antigenic drift based immune 
mediated selection (19,20,48,81,117). 
Epidemiology 
RSV infections have a world-wide distribution. In temperate climates infections are largely 
confined to the winter season. In tropical climates RSV infections lllay be found during the 
whole year, with a concentration in the rainy season in some geographical areas 
(77,133,152). Although infection can be estahlished in several laboratory animals, natural 
infection with RSV seems to be limited to humans and apes (17,27). Transmission occurs 
through direct close contact or contact with surfaces contaminated with respiratory secre-
tions (62). The incubation time for RSV infection ranges between 2 and 7 days (62,102). 
RSV infections are highly prevalent in the population and reinfections arc common. In a 
study of Hall et al. about 25% of adult volunteers could be reinfected with RSV of the same 
group two months after natural infection (65). Over 5Q!;/o of children are infected in their 
first winter season. By two years of age almost all children have been infected and over 50% 
will have been infected twice (69). 
RSV causes respiratory tract infections in patients of all ages. The highest morbidity ofRSV 
disease is seen below the age of 6 months (56,58,63,116) and in children with underlying 
risk factors such as prematurity (l11), bronchopulmonary dysplasia (59), congenital hemi 
disease with increased pulmonary circulation (95) or immune deficiency (64). Clinically 
severe RSV infections occur mainly in the very young but also in illlmunocompromised 
adults (42,159). In the elderly significant morbidity induced by RSV infection has been 
found (45,67). 
An estimated 0.5 - 2% of all inlants with RSV infection are hospitalised (56,58,63,96,111) 
and 7% - 21 % of these hospitalised infants will develop respiratory insufficiency and 
require respiratory support (96,145). The proportion of infants, in the industrialised world, 
eventually dying from RSV infection has been estimated at 0.5-1.5% of hospitalised RSV 
infected infants. However, higher mortality rates have been found in infants with underly-
ing disease (93-95). 
Factors influencing clinical severity 
Although recent data suggest that RSV is also an important pathogen for the elderly 
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(45,159), severe problems related to RSV infections are mainly found in young infants 
probably during their first infection. In up to 40% of infected children, involvement of the 
lower respiratory tract may be detected (57,87,135) but only in a minority this leads to prob-
lems necessitating hospitalisation. Many factors related to the virus, the environment and 
the patient involved, may influence the clinical outcome. This renders studies concerning 
the relative impOiiance of these different factors in naturally occurring RSV bronchiolitis 
complicated. 
Identification of the two virus groups (RSV-A and -B) has led to studies investigating the 
possible relationship between virus group and clinical severity. In about half of these stud-
ies group A was found to cause more severe disease, whereas no such differences were 
found by others (91,153). Only two studies ever reported group B to be more severe 
(72,138). Strain variation within groups A and B, as defined by nucleotide sequence an~"y­
sis, have also been suggested to influence disease severity (15,46,153). However, no con-
clusive data to suppOli this notion have been published. 
Also environmental circumstances may influence the outcome of RSV infection. The age at 
which first RSV infection takes place influences the chance of developing lower respirato-
ry tract infection and thus factors which increase the chance of early exposure, like number 
of siblings, attendance of day care centres and socio-economic status (116), may all increase 
the risk of developing lower respiratory tract disease. Tn addition factors like geographical 
area (13), parental smoking (98,131,162) and use of wood-burning stoves (131) have been 
associated with an increased risk of severe RSV infections. 
Individual patient factors like underlying illnesses associated with compromised respirato-
ry function like bronchopulmonary dysplasia (BPD) (59) Of congenital heali disease with 
increased pulmonary circulation (95) significantly enhance the risk to develop severe RSV 
infection. However, also subclinical, reduced lung function has been associated with an 
increased risk for the development of lower respiratory tract disease in young children (97). 
Finally, RSV specific immunity may, besides being protective, also be involved in an 
immune pathological mechanism leading to severe lower respiratory tract disease. This 
hypothesis is largely based on experimental animal data and the observation that vaccina-
tion of infants with FI-RSV candidate vaccines resulted in an enhanced susceptibility to 
develop severe lower respiratory tract involvement upon subsequent natural infection 
(25,47,90). 
Humoral immune response 
In response to RSV infection antibodies to most RSV proteins are generated (53,149,154). 
Antibodies against the F- and G-prolcins are probably most important in the host defence 
against RSV infection. Protection is however incomplete and reinfection, especially of the 
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upper respiratory tract, is readily possible even in the presence of high levels of virus neu-
tralising (VN) antibodies (65). In young infants the antibody response to RSV is limited, 
because of immaturity of the immune system and interference by matemal antibodies (12). 
Loeal antibodies in the respiratory tract appear to be related to protection against reinfec-
tion: presence of VN antibodies in the respiratory tract correlates with relative protection 
against experimental infection in adults (102,110) and production of local IgA coincides 
with virus clearance (99). 
Severe RSV lower respiratory tract infection is predominantly seen in infants between six 
weeks and six months of age, when 1110st of them still have RSV specific maternal serum 
antibodies. Vaccination with FI-RSV vaccine, inducing high titres ofRSV specific antibod-
ies, gave rise to more severe clinical disease upon subsequcnt exposure to the virus 
(25,108). Therefore, in the past, antibodies have often been incriminated as a factor inl110rc 
severe clinical outcome of the infection. However it has become clear that VN antibodies 
are in fact protective against RSV infection provided that high titres arc present (123): chil-
dren with higher maternally derived antibody titres were found to be more protected against 
developing bronchiolitis (56). Although virtually all children have measurable RSV specif-
ic antibodies at birth, titres drop relatively fast to unprotective levcls (12). Intravenous 
administration of normal gamma globulin did not induce protection against severe RSV 
infection (100) whereas administration of immune globulins with a high titre ofVN anti-
bodies against RSV (RSVIG) decreased the incidence of severe lower respiratory tract 
involvcment in high-risk children (61,68,129). RSVIG has been licensed for prophylaxis in 
high-risk children and similarly, a VN monoclonal antibody preparation directed against the 
RSV-F protein has been registered for prophylaxis in high-risk children (1,2, 101,126,139). 
Cellular immune response 
Virus specific T cell responses have a major impact on the clinical outcome of RSV infec-
tion. T cell responses have been shown to playa role in clearance of the virus (7,9). Whilst 
in normal children, virus excretion stops within 1-3 weeks, children who have no adequate 
cellular immune response may shed the virus for prolonged periods of time (44). It has been 
shown that in humans after RSV infection virus specific HLA class-I restricted CD8+ CTL 
are present in circulation (7,8,21,24) and that RSV infection in mice can be abOlted by trans-
fer of RSV-specitic CD4+ and CDR+ T cells (4,22,23). In contrast to this apparent protec-
tive role, RSV specific cellular immunity has also bcen shown to be involved in the induc-
tion of enhanced pathology in rodent models. Vaccination of rodents with FI-RSV prepara-
tions was associated with enhanced lung pathology upon challenge. This pathology was 
characterised by an eosinophilic infiltrate, which correlated with a type 2 immune response 
(22,112, ISS). Passively transferred CD4+ and to a lesser extent CDS+ cell lines ii'om thus 
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vaccinated animals to RSV infected mice, reduced virus titres in the lungs but also aug-
mented lnng pathology (4,33). This lung pathology could be abrogated by the administra-
tion of anti-1L-4 and anti-IL-IO but not of anti-1FN-y or lL-2 (32). The inability to induce 
virus specific CTL with FI-RSV has been associated with this type 2 mediated enhanced 
pathology in a mouse model (33,134). 
Much less is known about the natural immune response to RSV infection in humans. 
Whether a similar immune pathological mechanism does indeed playa role in naturally 
occurring RSV bronchiolitis in infants, as has often been suggested, remains unclear. A 
study concerning the RSV specific memory T cell response in normal adults and children 
showed a predominant type I like cytokine pattern (6). We have recently shown that IFN-y 
is the most prevalent cytokinc produced by RSV specific T cells in young infants, regard-
less of clinical severity (14). Also comparison of cytokine profiles in nasopharyngeal wash-
ings between children with mild and severe disease showed increased production of IFN-y 
in severely affected children (I51). However, type 2 cytokines have been detected in PBMC 
of normal adults when stimulated in vitro with RSV. 11-5 was for instance measured at high-
er levels in RSV infected than in un infected PBMC cultures (144). In vitro stimulation of 
PBMC with different RSV antigen preparations showed a type 1 like response upon stimu-
lation with live RSV and RSV-F protein, whereas a type 2 like response was found after 
stimulation with FI-RSV or RSV-G protein (80). 
Collectively these data indicate that RSV infections may induce both type I and type 2 like 
T cell responses. However, whether indeed a skewing towards type 2 like response in part 
of infected infants is at the basis of the more severe manifestations of RSV related disease 
remains elusive. 
Pathogenesis 
Alier infection, RSV primarily replicates in the epithelial cells of the nasophmynx (66). The 
exact mechanism by which RSV may spread to the lower respiratory tract is unknown. This 
may either occur through direct cell-to-cell spread or by aspiration of nasopharyngeal secre-
tions. RSV infection is considered to be limited to the respiratOlY tract (27,49). No cultur-
able virus is found in blood samples of immunologically normal subjects, although the pres-
ence ofRSV RNA may be demonstrable in blood (39,124). Signs oflower respiratory tract 
involvement may develop 1 to 3 days after the onset of upper respiratory symptoms (27). 
Severe lower respiratory tract disease in RSV infection is, at least in part, caused by direct 
cytopathic changes. An aberrant immunological response, ocellning in some of the infect-
ed children, has been suspected to contribute to the severity of the inflammatory process. 
The role played by the virus specific immune response in the pathogenesis of lower respi-
ratory tract infection is still unclear. Type 2 T cell mediated enhanced lling pathology has 
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been described in rodent models after vaccination with FT-RSV or RSV-G protein express-
ing vectors (112,134,155). RSV lower respiratOlY tract infection in infants is thought to 
occur predominantly in the course of their first RSV infection, when they have not been 
exposed to RSV antigens before. This argues against an early virus specific cellular immune 
pathological mechanism in naturally occurring severe RSV infection, as has been found in 
the FI-RSV vaccinees. On the other hand, several observations in favour of the involvement 
of an immune pathological mechanism in humans have been reported. Very young children 
are known to be more prone to produce a type 2 like immune response upon intection (38). 
Higher type 2 cylokines in supernatants of PBMC from children who experienced a RSV 
bronchiolitis at an early age have been found (125), although in these cases RSV infected 
patients were compared with non-infected patients. Furthermore type 2 cytokines have also 
been found ;/7 vitro in culture supernatants of PBMC from normal adults when stimulated 
with FI-RSV or RSV-G protein (80). 
Direct measurement of cytokines in plasma samples has shown higher levels of systemic 
sCD25 and TCAM in RSV intected than in control children, but no relation with clinical 
severity was found (132). In a recent study we also failed to relate clinical severity of RSV 
disease in young infants to a predominant type 1 or 2 like cytokine profile in plasma sam-
ples (14). Not unexpectedly the general pro-inflammatory cytokines IL-6 and IL-8 were 
found more often in children with more severe disease (11,14). However, because RSV 
infections are llsually restricted to the respiratory tract, the amount of cytokines measured 
systemically, may not be a reliable reflection of the local process. Direct measurement of 
cytokines and other soluble tactors in samples from the respiratOlY tract, as has been stud-
ied by certain groups (50,128,143,151) may be more informative in studying RSV patho-
genesis. Finally, in the mouse model enhanced disease upon RSV infection is characterised 
by a striking eosinophilia in the lungs. In studies investigating cellular infiltrates of respira-
tory secretions of children with naturally occurring RSV intection, the cellular infiltrates 
mainly consisted of polymorphonuclear granulocytes andlor monocytes (14,43,128). This 
observation indicates that the pathogenesis of natural RSV lower respiratory tract infection 
in infants does not parallel that of the cnhanced disease observcd in rodent models after FI-
RSV priming. 
Animal models in RSV research 
Over the past decades several animal 111odels, using rodents, calves, sheep, terrets, hamsters, 
dogs and several primate species including chimpanzees have been used in RSV research 
with varying degrees of success (for review see (17». Perhaps with the exception of RSV 
infection of chimpanzees, no animal model combines all aspects of RSV related disease in 
humans. 
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Many studies on the mechanism of FI-RSV mediated enhanced disease have been carried 
out in mice and cotton rats (78,79,109,112,119,155). The mouse model has been shown to 
be useful for studying RSV specific imll1une responses and RSV-rclated immunopathogen-
csis. Although this was largely due to the absence or alternative animal models in which the 
pathogenesis of RSV infection more closely resembled that in man, the model has con-
tributed substantially to our current understanding ofFI-RSV-rclated immune pathogenesis. 
Cotton rats are more permissive to RSV than mice and show higher RSV specific antibody 
responses. Studies in the RSY-cotton rat model showed that high titrcs of \TN antibodies 
were protective against RSV lower respiratory tract disease (122,123). This ultimately 
resulted in the development of the passive immunisation strategies for high-risk children 
(1,61,68). Ilowever, lack of reagents to characterise the immune response of cotton rats 
have considerably hampered studies of the cellular immune response and immune patho-
genesis in cotton rats. 
Bovine RSV induces a disease in calves that is quite similar to that caused by human RSV 
in infants. The major advantage of the bovine RSV infection model is the use of a natural 
infection in its natural host. Also the observation of immunopathological effeds in calves 
after Fl- bovine RSV vaccination and subsequent challenge with bovine RSV makes this an 
attractive, although expensive model (51,158). However, until recently it has been impossi-
ble to perform detailed immunological studies such as those carried out in the mouse model, 
due to lack of reagents (92,103,161). 
The close genetic relatedness between humans and other primates has led to the develop-
ment of several primate models, using chimpanzees (28,160), African green monkeys (86) 
and macaques (157). Although chimpanzees arc naturally infected with RSV, and develop a 
disease that closely resembles that in humans, their use is largely limited by fmancial and 
ethical constraints. RSV infection in Athcan green monkeys is also quite similar to that in 
humans and enhanced lung pathology has been observed following FI-RSV vaccination 
(86). However, due to lack of specific immunological reagents, this model also has clear 
1 imitations. The description of a human RSV challenge model in macaques (157), for which 
more immunological reagents are available, does offer some promise for the future. 
However, no clinical disease has been observed in this species upon experimental RSV 
infection. 
Vaccine development 
Since RSV is the most prevalent infectious agent causing severe respiratOlY disease in 
infants, the development of a vaccine against RSV is high on the list of priorities of the 
Global Program for Vaccines of the World Health Organisation (35). However, the devel-
opment of a safe and effective RSV vaccine has been severely hampered by a combination 
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of complicating factors. Severe RSV infections occur at a very young age. Therefore, vac-
cination should preferably be carried out almost immediately after birth. This implies that a 
RSV vaccine would have to induce an effective response in a largely immature immune sys-
tem and usually in the presence ofmatemai antibodies. Another discouraging observation is 
that Irequent reinfections occur throughout life (57,65). Therelore it is probably not realis· 
tic to expect that a candidate RSV-vaccine would induce sterile immunity. Protection of the 
lower respiratory tract and therefore prevention of severe complications should probably be 
the primary goal. Perhaps the most worrying complication in RSV vaccine development at 
present is related to the enhanced disease that was observed after experimental vaccination 
with FI·RSY and subsequent natural RSY infection (25,47,88,90). For any tllture candidate 
RSV vaccine it should convincingly be shown that its use would not predispose for this 
enhanced disease upon infection with the virus. This may be hard to show since the under-
lying mechanism of enhanced disease is not understood. A preventive vaccine that could be 
incorporated in the current pediatric vaccination schedules would definitely be the approach 
of choice for protection of infants. 
Besides young infants, other groups at risk of developing complications when infected with 
RSV are the elderly, older children with chronic lung disease and the immune compromised. 
Requirements for RSV candidate vaccines may vary for the respective risk groups. Also 
vaccination of pregnant mothers has been suggested, aiming to enhance transpiacentaJly 
acquired VN antibodies in the new-bam and thereby prolonging the period during which 
protective levels of antibodies are present (41,55). 
Virtually all modern approaches for vaccine development are still being pursued cun-ently 
lor the development of a safe and effective RSY vaccine (Table 6. I. I.). 
Subunit vaccines 
Several candidate subunit vaccines based on the RSY·F andlor G proteins, the main targets 
for induction of neutralising antibodies, have been developed. These vaccines aim primal'i-
ly at the induction of an adequate VN antibody response resulting in significant protection 
of the lower respiratory tract. This goal has indeed been achieved with a number of such 
candidate vaccines in clinical trials in older children and adults belonging to several risk 
groups (10,31,156). RSY·F subunit vacciues PFp·I and 2 have been tested in healthy 
seropositive children (10, I IS, 146) and cystic Ii bros is· (118) as well as older BPD (60) 
patients. These vaccines were found to be safe and to reduce respiratory problems upon 
RSV infection. 
A recently developed candidate peptide vaccine, BBG2Na, a fusion protein between the 
130-230 residues of the G protein and the albumin-binding domain (BB) of streptococcal G 
protein (34,120) has proven highly immunogenic in mice (130) and is currently under eval-
Table 6.1.1. RSV vaccination approaches 
Vaccine candidates 
Non-replicating 
fOnl13ldehyde inactivated RSV 
Subunits: 
- purified proteins (PFP 112) 
- peptide (BBG2Na) 
- iscom 
Replicating' 
live attenuated 
vector delivery systems: 
- adenoviruses 
- poxviruses: 
classical vaccinia viruses 
replication deficient vaccinia viruses 
(ALVAC"', NYVAC"', MVA) 
Major advantages 
controlled manufacturing 
safe in the elderly 
controlled manufacturing 
safe in the elderly 
induction of VN antibody and CTL, also 
in the presence of maternal antibodies 
mimics natural infection 
induction of VN antibody and CTL 
induction of VN antibody and CTL 
induction of VN antibody and CTL 
Major disadvantages 
predisposition for enhanced disease 
predisposition for enhanced disease not ruled out 
no CTL response 
predisposition for enhanced disease not ruled out 
no CTL response 
only preclinical data 
over/under attenuation 
reversion to wild type 
limited immunogenicity in primates 
limited immunogenicity in primates 
safety concems 
only preclinical data 
n 
0: 
» 
" -; 
'" 
" 
'" 
:;;: 
'" 
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uation in phase 1 and 2 human clinical trials. 
Since subunit vaccines may generally not be expected to induce a HLA class-l restricted 
CTL response the induction by these vaccines of enhanced pathology related to the absence 
ofCTL in immune narve children cannot fully he excluded at present. In rodent models both 
the presence and absence of enhanced pathology to cetiain subunit vaccines containing the 
G protein has been reported (31, 109,156). Although also the BBG2Na peptide vaccine has 
been shown to induce a type 2 like response in mice, subsequent challenge with wild type 
RSV did not result in lung pathology or type 2 responses (34,121). Therefore such subunit 
and peptide vaccines may probably be expected to be useful in immune non-narve individ-
uals at high risk of developing pulmonaIY complications upon RSV infection. 
Antigens presented in immune stimulatory complexes (iscoms) have been described to 
induce both good antibody and T cell mediated immune responses including HLA class-l 
restricted CTL, even in the presence of maternally derived antibodies (for review sec (114)). 
Because the lack of development of CD8+ CTL has been associated with enhanced disease 
in RSV infection (33,134), iscom vaccines expressing RSV proteins may be of major inter-
est for evaluation, even in immune naIve children. lscoms presenting both human and 
bovine RSV glycoproteins have been shown to induce both VN antibodies and a CTL 
response in rodent models (74,75,147). 
Live attenuated vaccines 
Live attenuated vaccines have the advantage of mimicking the natural infection most close-
ly. Therefore antigen delivery takes place by the natural route inducing a response resem-
bling the natural response after RSV infection. Consequently, no enhanced pathology may 
be expected. Tfthe vaccine is delivered via the mucosal route, also a balanced, both systemic 
and local immune response will develop including mucosal antibodies and a cytotoxic T cell 
response, which are both known to be impoliant in protection against infection and clear-
ance of the virus. A disadvantage of the live attenuated vaccine approach however, is that 
maternal antibodies may interfere with induction of immunity by neutralising the vaccine 
virus. This may preclude an effective response in the vety young upon parenteral adminis-
tration, as is observed after vaccination with live attenuated measles vaccine in children less 
than one year of age (113). 
The classical Jennerian approach has initially been evaluated for RSV, by using bovine RSV 
as a vaccine. However bovine RSV did not protect chimpanzees against RSV infection ren-
dering this approach unsuitable for further evaluation in humans (35). 
Attenuated RSV strains of both groups (A and B) have been generated by several research 
groups in the past by repeated passages of the virus at low temperature followed by passage 
in the presence of mutagenic agents (36,107). Tn pre-clinical and clinical trials with these 
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candidate vaccines it became clear that the balance between attenuation and immunogenic-
ity is delicate. These vaccines proved to be either over- or under-auenuated and also rever-
sion to wild type was not uncommon. Enhanced disease however, was never found in chim-
panzees or infants upon infection after vaccination with slIch candidate vaccines (40). More 
recently so-called further attenuated cold passaged temperature sensitive (cpts) RSV prepa-
rations were developed and tested in chimpanzees, adult volunteers and also in RSV 
seropositive and seronegative children (89). These candidate vaccines proved to be more 
stable and no reversion to the wild type has been detected. ImpOliantly, no enhanced disease 
was found upon infection in the subsequent season but respiratory symptoms upon vacci-
nation were not uncommon. Protective efficacy against lower respiratory tract involvement 
upon repeated vaccination, in combination with other pediatric vaccines is currently evalu-
ated. 
Recently it has become possible to recover infectiolls virus hom cONA clones ofRSV (26). 
This technology may have a major impact on RSV vaccine development. It has become pos-
sible to identify the exact mutations responsible for attenuation by introducing point muta-
tions, and studying these mutant viruses in vivo (84,85). Also induction of combinations of 
mutations may make it possible to rationally design a genetically stable candidate vaccine 
combining sufficient attenuation with adequate immunogenic potential (29). Moreover it 
may become possible to prepare vimses expressing glycoproteins [rom the different RSV 
groups or, as has recently been shown, a vaccine candidate based on bovine RSV that 
expresses human-RSV F and G proteins (16). 
Live vector vaccines 
Live vectors presenting RSV antigens may be expected to induce both good VN antibody 
and HLA class-1 restricted CTL responses. Vaccinia- and adenoviruses expressing RSV pro-
teins have in the past been developed and encouraging responses were found in several non-
primate animal models (30,73). However the poor responses found in chimpanzees for both 
vector delivery systems (28,37,73) and concerns about safety of vaccinia virus make them 
less suitable vector candidates to deliver RSV antigens. More recently, recombinant 
poxvirus constructs have been developed based on replication-deficient poxviruses, like 
canarypox (ALVAC@)), highly attenuated vaccinia (NYVAC(R)) virus and modified vaccinia 
virus Ankara (MVA). These are all known to replicate not at all, or only limitedly in mam-
malian cells (104). Compared with replication competent strains of vaccin ia virus, MVA is 
found safe (136), allows similar expression levels of the recombinant genes (141), and can 
induce equal or better antibody and T cell responses, including COX+ CTL responses, in ani-
mals (71,127,142,163). MVA expressing RSV glycoproteins has been shown to be stable 
and to induce good serological responses in mice (164). 
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Concluding remarks 
Although recently encouraging results have been obtained with preventive passive immune 
therapy against RSV infection in high-risk children, the most cost effective and practical 
approach to prcvent RSV lower respiratory tract infection would undoubtedly be preventive 
vaccination. 
In the mouse model pathogcnesis of enhanced disease after vaccination with FI-RSV is 
related to a type 2 mediated T cell (112) reaction, which is also associated with the virtual 
absence ofa CTL response (134). Data in mice (150) and humans (14) however, did so far 
not convincingly show that a similar pathogenesis occurs in naturally occurring severe man-
ifestations of RSV infection. Other factors, like disturbed respiratory functions and epi-
demiological as well as geographical factors may playa major role in RSV pathogenesis. 
Studies aimed at a better understanding of the pathogenesis of RSV lower respiratory tract 
disease in previously healthy infants are of importance for the rational design of pediatric 
RSV candidate vaccines. 
Because even naturally occurring RSV infection fails to induce complete protection, the 
most realistic aim for a RSV vaccine should be the prevention of lower respiratory tract dis-
ease. For risk groups, like the elderly and oldcr children with BPD or cystic fibrosis, the 
priming for enhanced disease upon natural RSV infection is not expected to be a major 
problem, because of the pre-existing immunity. Boosting of the VN antibody titre is associ-
ated with a reduced risk of developing complications upon infection with RSV infection and 
current results with subunit vaccines are promising in this respect. Moreover, in the future, 
the combination of RSV subunit vaccines with influenza vaccines may be attractive for 
these risk groups. 
For the induction of protective immunity by vaccination in immune naIve children, the issue 
of predisposition for enhanced pathology upon natural RSV infection is of great concern. 
Since at present for candidate subunit vaccines the induction of enhanced disease cannot 
convincingly be ruled out, these non-replicating vaccines are not likely to be used first in 
immune naIve children. Reccnt data, however, obtained with new generations of adjuvant 
and antigen presentation systems - like the iscom presentation system - indicate that also 
with subunit preparations even in the presence of neutral ising antibodies, good VN antibody 
and HLA class-l restricted CD8+ CTL responses may be induced (113,114). Live attenuat-
ed vaccines may be the most promising in the ultimate target group: newborn children. With 
these vaccines antigen delivery resembles natural infection most closcly and consequently, 
no enhanced pathology upon re-infection may be expected. Moreover, taking advantage of 
the recently developed reversed genetics technology it may be possible to rationally design 
sufficiently attenuated and immunogenic vaccine viruses, expressing antigens from both 
RSV A and B (29). Similar results may be obtained with the novel generation of live vector 
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vaccines, based on replication deficient poxviruses. A problem associated with the live 
attenuated and live vector vaccine approaches in very young infants may be the relative 
immaturity of the immune system of the infant and the presence of maternal antibodies, 
which may interfere with replication of the vaccine vims. The latter problem may perhaps 
be overcome by application via the mucosal route. 
New insights in the pathogenesis of RSV infections, as well as the rapid developments in 
the molecular and immunological fields of modern vaccinology, will be of major impor-
tance for the further development of safe and efficacious RSV vaccination approaches. 
These approaches may be expected to differ for different target groups. 
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Concluding remarks and summary 
For more than 40 years RSV has been recognized as the most prevalent cause of severe res-
piratory infection in young infants. Despite considerable research still no causative thera-
peutic strategy and no effective vaccine are available. The limited knowledge on the patho-
genesis oflower respiratory tract involvement in RSV infection, both in naturally occulTing 
and in enhanced disease following experimental FI-RSV vaccination, has hampered the 
development of therapeutic and preventive strategies. It has been shown in recent years that 
enhanced pulmonary disease arrer FI-RSV vaccination ~ at least in the mouse model - is 
associated with an aberrant type 2 like immune response. Whether this also is the case in 
naturally occurring RSV associated lower respiratory tract disease remains elusive. Studies 
on the immune-pathogenesis of RSV associated lower respiratory tract infection in human 
infants are more complicated, since several factors, related to the virus, the environment or 
the individual patient may also have an impact on the clinical outcome of naturally occur-
ring RSV infection in young children (see table 6.2.1.). 
Variation in the RSV strain involved may be a factor influencing clinical severity by as yet 
unknown virulence factors in certain strains or by less cross protective maternal antibodies, 
thus increasing the chance of becoming severely infected at a younger age. Tn chapter 2 we 
studied RSV strain variation in relation to clinical severity. Differences in clinical outcome 
between infections with the two RSV groups A and B were studied in a group of232 chil-
dren with a RSV infection, who were either admitted to, or visited the outpatient department 
of the Sophia Children's Hospital Rotterdam between 1992 and 1995. By analyzing a set of 
standardized clinical data collected fi'om these children we found no relationship between 
clinical severity and the group of RSV involved. 
Several studies have been published concerning the association between clinical severity 
and the RSV group involved. In about half of these studies infections with group A were 
found to be more severe (26,27,40,45,53,58,60) whereas in other studies no ditferences 
were detected between the infections with either of the groups (30,35,42,44,52,59-61). Only 
two studies ever reported group B to be more severe (31,57). Whether certain strains with-
in the two groups are more virulent is not known but it has been suggested that some virus 
variants within group A may induce more severe disease (15,26,60). To address this ques-
tion we selected 28 group A strains ii'om three consecutive winters and subjected them to 
sequence analyses of pmi of the G protein. In the season 1994/95 a high incidence of RSV 
infections during a relatively short period was [oLlnd which were all group A viruses. We 
studied whether this peak represented infection with one, possibly more virulent, strain of 
RSV. Several lineages circulated repeatedly and simultaneously during the respective sea-
sons. This was also the case during the 1994/95 season and no one dominant strain was 
Table 6.2.1. Factors influencing the clinical outcome ofRSV infection. 
Factors related to the Disease severity 
Virus 
Strain variation 
Environment 
crowding (siblings, day care centers) 
socia-economic status 
parental smoking 
wood-buming stoves 
geographic area 
Individual patient 
young age 
gender 
prematurity 
underlying illnesses 
- lung disease (BPD, cystic fibrosis) 
- congenital heart defects 
- T cell immune deficiency 
Immune response 
- Humoral: matemallpassively administered 
- Cellular 
no influence on disease severity 
group A more severe 
increased disease severity 
increased disease severity 
increased disease severity 
increased disease severity 
varying disease severity 
increased disease severity 
boys> girls 
increased disease severity 
increased disease severity 
increased disease severity 
increased disease severity 
protective 
protective 
enhanced in the mouse model 
references 
(30,35,42,44,52,59-61 ) 
(26,27,39,40,45,53,58,60 ) 
(50) 
(18) 
(41,55,63) 
(55) 
(6,32,61) 
( 18,20,23,46,50) 
(13,17,18) 
(47) 
(21,47) 
(36-38,47) 
(24) 
(18,22,28,51,54) 
(3-5,7,8,10) 
(9,48,49,62) 
n 
I 
» 
0' 
" a, 
N 
a, 
V> 
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found. Also no relationships were found between circulating RSV lineages on the one hand 
and clinical severity or age of the infected infants on the othcr hand. Taken together, the 
studies in chapter 2 showed no relationship between clinical severity and the RSV strain 
involved. 
Environmental factors have been described to influence the clinical outcome ofRSV infec-
tion. Circumstances related to crowding like number of siblings, attendance of day care cen-
ters and socioeconomic status, which increase the chance of early infection, arc all associ-
ated with a higher chance of becoming severely affected (18,50). In addition factors, possi-
bly influencing lung function, like parental smoking (41,55,63) and use of wood-burning 
stoves (55) have been associated with an increased risk of severe RSV infections. Difference 
in severity ofRSV associated disease has been reported for different areas. Tn chapter 3 we 
assessed the possible influence of geographical differences in disease severity between two 
university hospitals in cities in different pmis of Europe. RSV infections are considered a 
serious disease in the Sophia Children's Hospital (Rotterdam, The Netherlands) but gener-
ally more benign in the Geneva Children's Hospital (Switzerland). We studied J 51 infants, 
55 from Geneva and 96 from Rotterdam, primarily admitted for a RSV infection. Analysis 
of clinical data collected in a standardized way confirmed that the course of RSV infections 
was indeed more benign in Geneva than in Rotterdam: infants admitted in the Geneva 
Children's Hospital less often presented with apnea or respiratory insufficiency and thus less 
often required ICU admission or respiratory suppmi. This was also reflected by a shmier 
length of hospitalization. We could not identify epidemiological factors explaining the dif-
ferences bern'een the two cities. Studies including more different geographical areas will 
probably be required to identify factors responsible for the differences in disease severity in 
different areas. We did conclude that geographical differences might influence the RSV 
associated disease pattern and thus may complicate the interpretation of multi-center stud-
ies aiming at the development of prophylactic and therapeutic strategies. 
Individual patient characteristics are well known to influence the chance of becoming 
severely infected with RSV. Most severe RSV infections arc seen when children are 
between six weeks and six months of age. The younger a child encounters its first RSV 
infection, the higher is its chance of lower respiratory tract involvement and apnea. Also 
boys have a higher hospitalization rate for RSV infection (13,17,18). Prematurely born chil-
dren arc at higher risk of becoming severely affected by RSV, possibly because they receive 
less matemal antibodies (47). Several underlying illnesses such as bronchopulmonary dys-
plasia, congenital heaJi disease with increased pulmonary circulation and immune deficien-
cy significantly increase the risk of becoming severely ill when infected with RSV 
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(21,24,36-38,47). Also subclinical, reduced lung tunction has been associated with an 
increased risk for the development of lower respiratory tract disease in young children (39). 
So apart from the individual's immune responsiveness, anatomical and physiological condi-
tions in the lungs influence the clinical outcome of RSV infection. 
Immunity to RSV infection is incomplete and/or very short-lived and reinfections occur tl"e-
quently throughout life (25,29). The way in which RSV evades the immune response is still 
unlrnown but the frequent reinfections in the whole population enable RSV to reach infants 
at an early age, when they arc most vulnerable for severe lower respiratory tract involve-
ment. 
Antibodies have often been incriminated as playing a role in the pathology of RSV lower 
respiratory tract infection mainly on the basis of two observations. (i) Most severe infections 
are seen at an age when most children still have maternally derived antibodies (19,33), and 
(ii) the FI-RSV candidate vaccine - which predisposed for more severe disease upon sub-
sequent infection - induced high levels of antibodies (11,16,34). However, it has become 
clear that virus neutralizing antibodies - albeit at high titers - are in fact protective against 
RSV lower respiratory tract disease (18,51). 
In chapter 4 we studied the decline of maternally derived antibodies in and the response to 
RSV infection in young infants. In all children RSV neutralizing antibodies could be 
demonstrated at bilih, which declined with a half-life of about 26 days. Given this half-life 
time and the relatively high titers necessary for protection, the observed antibody levels may 
be expected to drop relatively fast to non-protective levels. Furthermore, in a group of 38 
children with a suspected RSV infection, all younger than six months of age upon admis-
sion, the value of serological assays to diagnose a RSV infection was evaluated. Tn 32 of 
these children RSV infection was confirmed by virus isolation, direct immune fluorescence 
and RT-PCR analyses. All serological tests together studied in chapter 4a identified only 13 
(41 %) of the 32 RSV infected infants. In chapter 4b a subtype specific ELISA using pep-
tides from the central conserved region of the G protein detected 67% of infections making 
this peptide based ELISA more sensitive than all other serological tests combined, for this 
age group. Taken together we concluded that in children under six months of age the diag-
nostic value of RSV serology is limited and by far inferior to the direct detection methods 
for RSV antigen or viral RNA. 
With the exception of pC02 levels, which were higher in children with higher VN titers 
upon admission, none of the parameters of clinical severity conelated with antibody levels 
upon admission. The conelation ofpC02 leveis with VN titers can be explained by the high-
er pC02 usually found in younger infants with RSV infection (46), at which age also high-
er maternal antibody levels are expected. Thus no causal relationship between RSV specif':. 
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ic antibody titers and severity of infection was detected. 
Virus specific T cell responses have been described to be involved in the clearance of RSV 
infection, as well as in the induction of immune pathology in mouse models: upon vaccina-
tion with FI-RSV, a predominant type 2 T help response was fOLind (2,9,12,49,62). 
Moreover, in this respect it should be considered that young children, having a relatively 
immature immune system, are prone to develop a type 2 like immune response upon infec-
tion. Whether a type 2 like immune response does indeed playa role in naturally occurring 
RSV lower respiratory tract infection in infants remains elusive. In chapter 5.1 we studied 
intlammatory responses in infants, younger than six months of age, with RSV infections of 
different clinical severities. We found that infants with clinically more severe RSV infec-
tions have higher plasma levels of IL-6 and IL-S, which is probably a reflection of more 
extensive inflammation of the lungs in these children. The cellular components ofnasopha-
ryngeal washings of these infants mainly consisted of polymorphonuclear cells and mono-
cytes and only few eosinophilic granulocytes were detected. A type 1 like T cell response 
characterized by the expression of mainly IFN-y and only low levels of IL4 and lLiO was 
found in PBMC cultures of 15 children after RSV specific stimulation, regardless of clini-
cal severity. Using FACS analysis, RSV specific IFN-yexpression proved to be more promi-
nent in CD8+ than in CD4+ cells, indicating a virus specific HLA class-l restricted CTL 
response in these children, which is usually associated with vil1ls clearance (3,4,14). 
Moreover, in the mouse model, the absence of a CTL response was associated with the 
induction of enhanced disease following vaccination with FI-RSV (12,56). On the other 
hand CD8+ T cells - although to a lesser extent than CD4+ T cells - were also found to be 
associated with more lung inflammation in the mouse model (1,2). Therefore detailed iden-
tification and characterization of CTL responses against RSV in humans will contribute to 
the development of candidate vaccine targets and also to future studies concerning the role 
of CTL in the immnne pathogenesis of RSV infection. In chapter 5.2 T cell clones (TCC), 
generated from two infants who had just recovered from severe RSV infection, were stud-
ied. These TCC were used to identify, for the first time, HLA class-T restricted CTL epitopes 
on the RSV fusion protein in humans. In the samples from these two children, only HLA 
class-l restricted CD8+ TCC and no CD4+ TeC were detected, whereas high frequencies 
of type 2 cytokine producing CD4+ T cells have been found in different animal models of 
FI-RSV mediated immune-pathogenesis. 
Taken together the data presented in chapter 5 do not support the hypothesis that severe 
RSV infection is associated with a type 2 like T cell response in naturally occurring RSV 
bronchiolitis. 
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Future directions 
Recently passive immune prophylaxis against RSV infection has proven useful in high-risk 
children. However, the most cost effective and practical approach to prevent RSV lower res-
piratory tract infection will undoubtedly be vaccination. As has been discLissed in chapter 
6.1 the development of a safe and effective vaccine will require detailed lmowlcdge of both 
protective and disease enhancing mechanisms in RSV infection. 
In recent years several new techniques have become available, which will allow studying 
the immune response in more detail. For instance ELlspot techniques have shown to be sen-
sitive and cOllvenient tools to study T cell responses using only small amounts of patient 
material. Also DNA alTay assisted mRNA profiling technology is becoming available, mak-
ing it possible to determine for example the expression levels of many mRNAs of cytokines 
and their receptors in a parallel fashion. 
These and other techniques will significantly contribute to our knowledge of the RSV 
immune response in young infants and will hopefully show the way towards the most effec-
tive approach for the induction of safe and effective preventive and therapeutic strategies. 
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RNA 
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RT-PCR 
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TNF-a 
URTI 
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VN 
immune stimulating complex 
international units 
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lower respiratory tract infection 
monoclonal antibody 
milliliter 
modified vaccinia virus Ankara 
optical density 
peripheral blood mononuclear cells 
phosphate buffered saline 
carbon dioxide pressure 
polymerase chain reaction 
purified F protein 
picogram 
polymOl]Jhonuclear cells 
ribonucleic acid 
R.Phycoerythrin 
R -phycoerythrin-Cyaninc 5 
respiratory syncytial virus 
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oxygen saturation 
soluble CD25 
side scatter 
T cell clones 
tumor necrosis factor alpha 
upper respiratory tract infection 
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virus neutralizing 
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Algemene conclusies en samenvatting 
RSV is de meest voorkomende verwekker van ernstige luehtweginfeeties bij jonge 
kinderen. De meeste RSV-infeeties verlopen mild en maar eell kleine minderheid van ge"in-
fecteerde kinderen (0,5 - 2%) behocft ziekenhuisopname. RSV-infCcties komen echter 
veelvuldig in de populatie voor ell gesehat wordt dat minstens 50(10 van aile kinderen hun 
eerste RSV-infectie oploopt tijdens het eerste levensjaar (31). Hierdoor is ernstig veriopende 
RSV-intectie een bclangIijke oorzaak van ziekenhuisopname bij baby's. 
Infecties met RSV komen wereldwijd voor. III gematigde streken komen RSV-infecties 
aileen in de winterperiode voor, waar ieder jaar een epidemiologisehe verheffing gezien 
wordt met de piek rond december/januari. In tropischc gebieden worden infecties het hele 
jaar door gevandcn met in sommige streken pieken tijdens het natte seizoen (33,57,61). 
Dc overdracht van het virus vindt plaats via direct contact met een geInfecteerde persoon, 
via grate druppelinfectie of via contact met besmette oppervlakken (23). RSV kan cnkelc 
men averleven op bijvoorbecld tafeioppervlakken, handschoenen, stethoscopen en kleding 
en ongcveer een halfuur op llUid (6,24). Infectie via kieinc druppclaerasolen over grotere 
afstanden zoals bij influenza, is voor RSV nooit gevonden. 
Op dit moment is er geen veilig en eiIectief vaecin tegen RSV beschikbaar. In de zestiger 
jaren taen het virus pas ontdekt was is een formaline-geInactiveerd RSV-vacein (FI-RSV) 
ontwikke!d. Dit vaecin induceerde hoge antistoftiters tegen RSV, eehter na toediening van 
dit vaccin aan een groep kinderen bleek dal ze niet beschermd waren tcgen RSV, integen-
deel, ze haddcn een vee! gratere kans op het ontwildcelen van een ernstig verloop van de 
infectie en er zijn zelfs enkele gevaccineerdc kinderen overleden (12,17,35). 
De beperkte kennis van de pathogenese van bgcre luchtweginfectics met RSY, zowe! bij 
natLiuriijke infeeties als bij vaccin ge"inducecrde verstcrkte pathologie, hebben de ontwik-
keling van preventieve en thcrapeutischc strategicen bij RSV-intecties in de weg gestaan. 
Rccentc1ijk is in muizenexperimenlen gevonden dat door vaccin ge"induceerde versterkte 
pathologie geassocicerd is met een type 2-achtige cellulaire il1lmuunrespons (49). Of dit bij 
natuurlijk optrcdende RSV-intecties van de lagere luchtwegen bij kinderen ook het geval is, 
is onbekend. Evaluatie van ondcrzoek naar een J11oge!ijke iJ11munologische component in 
het ontstaan van crnstige RSV-intectics bij kindcren is gecompliceerd omdat meerdere fac-
toren, gerelateerd aan het virus, aan de omgcving en aan de ol11standigheden in de indi-
viduele patient van grate invlocd kunncn zijn op de ernst van de infectie (zie ook tabel 1). 
Variatie in circulerende virusstaml11en zou de ernst van de RSV-infectie kunnen beYnvloc-
den door op dit moment onbckende virulentiefactoren in het virus of door maternale anti-
Tabel 1. Factoren die de ernst van de RSV-infectie kUl1l1en beYnvloeden. 
Factoren gerelateerd aan 
Het virus 
Variatie in virusstam 
De omgeving 
Crowding (meer broertjes en zusjes, 
Ernst van de ziekte 
Geen invloed op ernst van de ziekte 
Groep A ernstiger 
Emstiger ziektebeeld 
en'::chebezoek, lagere sociaal-economische status) 
Rokende ouders Emstiger ziektebeeld 
Gebruik van houtkachels 
Geografiscb gebied 
De individuele patient 
jonge leeftijd 
geslacht 
prematuriteit 
onderliggende ziekte 
long ziekte (BPD, Cystische fibrose) 
congenitale bartafwijking 
T eel immuun deficientie 
Immunologische respons 
Humoraal: maternaallpassief toegediend 
Cellulair 
Emstiger ziektebeeld 
Varierende ernst van de ziekte 
Emstiger ziektebeeld 
jongens ernstiger dan meisjes 
Ernstiger ziektebeeld 
Ernstiger ziektebeeld 
Emstiger ziektebeeld 
Ernstiger ziektebeeld 
Beschennend 
Besehennend 
Ernstiger ziektebeeld in muizenmodel 
referenties 
(32,36,43,45,53,60,62,63 ) 
(28,29,40,41,46,54,59,62) 
(19,51) 
(42,56,65) 
(56) 
(7,34,63) 
(l9,20,25,47,SI) 
(14,18,19) 
(48) 
(21,48) 
(37-39,48) 
(26) 
(l9,22,30,S2,55) 
(3-5,8,9,11) 
(10,49,50,64) 
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stoffen die minder kruisreageren met andere virus stammen waardoor kinderen al jonger 
gevoelig zijn voor lagere luchtweginfecties. In hoofdstuk 2 wordt de variatie in virLlsstam 
vergeleken met de ernst van infectie. Verschillen in ernst tussen de twee bekende RSV 
groepen A en B werden bestudeerd in een groep van 232 kinderen met een RSV-infectie die 
gezien werden in het Sophia kinderziekenhuis Rotterdam gedurende de periode 1992 -
1995. Er werd geen relatie gevonden tussen de emst van de infeetie en de RSV-groep 
waarmee de kinderen geYnfecteerd waren. 
In de literatuur zijn verschillende studies gepubliceerd waarin de relatie tussen de emst van 
infectie en de twee RSV-groepen werd vergeleken. In ongeveer de helft van deze studies 
werd gevonden dat infectie met RSV-A ernstiger verliep dan infectie met RSV-B 
(28,29,4\,46,54,59,62). In de andere heltl werd geen verschil in ernst gevonden 
(32,36,43,45,53,60,62,63). Of er bepaalde stammen binnen de 2 groepen zijn die ernstiger 
infecties veroorzaken is onbekend maar cr is gesuggereerd dat bepaalde RSV-A stammen 
meer pathogeen zijn (16,28,62). 
Gedurende het wintcrseizoen 1994/95 werd een groot aantal kinderen opgcnomen met cen 
RSV-infectie, welke allemaal tot groep-A behoorden, gedurende een rclatief kotie periode. 
Om te bestuderen of deze pick cen enkele, mogelijk meer pathogene stam, vertegenwoor-
digde, werden 28 RSV-A stammen geseleeteerd uit de 3 seizoenen 1992 - 1995 en 
bestudeerd via sequentieanalyse van een varia bel deel van het RSV-G eiwit. Gedurende aile 
3 seizoenen circuleerden er verschillende stammen gelijktijdig. Ook gedurende het seizocn 
1994/95 werd niet een enkele, dominante virLlsstam gevonden. Er werd ook geen relatie 
gevonden tussen de klinische ernst van de infectie en de verschillende stammen. 
Samenvattcnd geven de studies in hoofdstuk 2 geen aanwijzing voor cen relatie tussen de 
ernst van infectie en de bctrcffende virusstam. 
Omgevingsfactoren kunnen van invloed zijn op de ernst van RSV-infecties. 
Omstandigheden die gerelateerd zijn aan "crowding!!, zoals oudere broertjes en zusjes, 
creche bezoek en lagere sociaal-economische status verhogen de kans op een ernstiger RSV-
infectie (19,51). Ook factoren die van invloed kunnen zijn op de longfunctic, zoals rokende 
ouders en het gebruik van houtkachels zijn geassocieerd met een hogere kans op een ern-
stiger verloop van een RSV-infeetie (42,56,65). Tn hoofdstuk 3 wordt de \1logclijk invloed 
van het geografisch gebied op de ernst van de ziekte bestudeerd. Er werd een gestandaardi-
seerde set klinische gegevens verzameld van RSV-gernfecteerde kinderen, jonger dan 12 
maanden, in twee universiteitsziekenhuizen in versehillende delen van Europa. Tn het 
Sophia kinderziekenhuis (Rotterdam, Nederland) worden RSV-infecties bcschouwd als een 
ernstige ziekte terwijl in het kinderziekenhuis Geneve RSV-infecties ais een milde ziekte 
worden beschouwd. Er werden 151 kinderen, 55 uit Geneve (Zwitserland) en 96 uit 
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Rotterdam, primair opgenomen voor een RSV-infectie, in de studie geYnc1udecrd. Analyse 
van de vcrzamelde klinische data van de kinderen bevestigde dat het klinisch verioop van 
de infectic inderdaad milder was in kinderen nit Geneve dan in kindercn nit Rotterdam. 
Kinderen in Geneve hadden minder vaak apneu's en hocfden minder vaak beademd te wor-
den. Zij waren gemiddeid ook minder lang opgcnomen dan Rotterdamse kinderen. Er wer-
den gecn epidemiologische factoren gevonden die dit verschil konden verklaren. 
Waarschijnlijk zijn studies die mecr verschillende geografische gebieden binnen ccn studie 
bestuderen noodzakelijk om onderliggende factoren, verantwoordclijk voor verschil in ernst 
van de ziekte, te detecteren. Er werel weI geconcludeerd dat een verschil in klinische ernst 
kan bestaan tussen verschillende gebieden en dat dit van invloed lean zijn op de interpretatie 
van uitkomsten van trials die mogclijke profyiactische of therapeutischc strategieen bestu-
deren. 
lndividnele patient-factoren zijn duidelijk van invloed op de kans op ernstige ziekte bij een 
RSV-infectie. De meest emstige infecties worden gezien bij zeer jonge kinderen, wanneer 
zij tussen 6 wekcll en 6 maanden oud zijn. Hoe jonger een kind is bij de eerstc RSV-infec-
tie hoe groter de kans op een ernstig verloop. Jongetjes lopen een hogere kans om 
opgenomen te worden met een RSV-infectie dan meisjes (14,18,44). Prematuur geboren 
Idnderen hebben een hogere kans op een ernstige infcctie, mogclijk omdat zij minder mater-
naie antistoffen meegckregen hebben (48). Verschillende onderliggende ziektes zoals bron-
chopulmonale dysplasie, congenitale hartafwijkingcn met verhoogde bloedcirculatie in de 
longen en T-cel-immuunstoornissen verhogen allemaai de kans op een ernstig verloop van 
een RSV-infectie (21,26,39,48). Behalvc de individuele immuunrespons zijn anatomische 
en fysiologische condities in de patient dus zeker van invloed op het klinisch verloop van 
een RSV-infectie. 
De natuuriijke immuniteit tegen RSV is incompleet. Herinfecties komen veelvnldig voor 
gedurende het hele leven (27,31). Hierdoor kan het virus zich zeer effectief onder de bevol-
king vcrspreiden en het overgrote deel van de baby's ai in het eerste levensjaar besmettcn, 
op de leeftijd dat ze het meest gevoelig zijn voor RSV-infectic. De manier waarop RSV het 
immuunsystecm omzcilt en steeds herintecties kan veroorzaken is onbekcnd. 
Lang is gedacht dat antistoffen een rol spelcn in de pathogenese van lagere luchtweginfec-
ties met RSV. Dit werd voornamelijk gedacht op basis van twee observaties: (i) De mcest 
ernstige intecties worden gezien op een leeftijd dat kinderen nog maternalc antistoffen 
bezitten en (ii) het formaline-ge1nactiveerdc RSV-vaccin induceerde hoge antistoftiters en 
predisponeerdc ook voor een crnstige verloop van een RSV-infectic. Het is de laatste jaren 
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echter duideIijk geworden dat virus-neutraliserende antistoffen juist bcschermend werken 
tegen lagere luchtwcginfectie met RSV. Hiervoor zijn weI relatief hoge virus-neutrali-
serende antistofiitcrs nodig. 
In hoofdstuk 4 wordt het vedoop van maternaal verkregcn antistofiiters in kinderen 
bestudeerd. In aIle kinderen werden bij geboorte RSV-specifieke antistoffen aangetoond. 
Deze antistoftiters verminderden met een hal:t\vaardetijd van ongeveer 26 dagen. Bij deze 
halfwaardetijd en de relatief hoge titers die Ilodig zijn voor bescherming van de lagere 
luchtwegen, is het waarschijnlijk dat antistoftitcrs snel tot beneden de beschermende waarde 
dalen. 
Verder werd de waarde van serologische testen bij RSV infecties onderzocht in een groep 
van 38 kinderen jonger dan 6 maanden, met een acute luchtweginfectie, waarbij RSV als 
verwekkcr waarschijnlijk werd geacht. Bij 32 van deze kinderen werd een acute RSV-infec-
tic vastgesteld met directe antigeendetectie, vira1e kweck en RT-PCR. In aile serologische 
testen samen in hoofdstuk 4A we I'd maar in 13 (41 %) van de kinderen een signiftcante anti-
stofrespons gevonden. In hoofdstuk 4B werd cen subtype specifieke ELISA getest, waarbij 
pcptiden van het centraal geconserveerde deel van het G-ciwit als antigcen werden gebruikt. 
In deze ELISA werd bij 67% een significante res pons gevonden. Ook differentieerde de 
peptide ELISA goed tussen RSV-A en B infecties. Geconcludeerd werd dat de peptide 
ELISA zoals beschreven gevoeliger was dan de hoofdstuk 4A beschrcven serologische tests. 
Echter serologic als diagnostiek bij RSV-intecties is duidelijk ongevoeliger dan detectie van 
het virus of componenten hiervan bij jonge kinderen. 
Met uitzondering van de pC02 , die gemiddeld hoger was bij kinderen met een hogere titer 
aan virus neutraliserende antistofl'en bij opname, werd er geen verband gevondell tussen kli-
nische parameters en antistottiters. De con'elatic tussen pC02 en virus-neutraliserendc anti-
stoftiters kan worden verklaard door de bekende relatie tussen jongere leeftijd en hogere 
pCO, bij RSV-infectic (47), op welke leetlijd ook gcmiddeld hogcr antistoftiters gevonden 
wordell. In hoofdstuk 4 werd dLIS geen relatie tussen virus-ncutraliserende antistoftiter en 
emst van de intectie aangetoond. 
Dc virusspecifieke T-cel-respons speelt een 1'01 in zowcl bescherming tcgen infectie als bij 
de inductie van il11111UUnpathologische respons in het l11UiZCllll1odeL Na vaccinatie met FI-
RSV werd een type 2 cellulaire iml11uunrespons gevonden in lTIuizen (2,10,13,49,64). Zeer 
jonge kinderen hebbcn een onrijp immuunsysteem en een predispositie tot het vormen van 
een type 2-achtige immuunrespons. Of een type 2-cellulaire imll1uunrespons cen rol speelt 
bij het ontstaan van een ernstig klinisch bceid bij een dcel van de RSV-gcInfectcerde jonge 
kinderen is echter onbekend. In hoofdstuk 5.1 werd de afweerrespons gemeten in relatie lot 
de klinischc ernst bij kinderen,jonger dan 6 maanden, met een acute RSV-infectie. In plas-
NEDERLANDSE SAMENVATllNG 181 
mamonsters van kinderen met een ernstiger klinisch beeld werden hogere conccntraties I L6 
en IL8 gevonden, passcnd bij meer ontstekingsreactie in de longen van deze kinderen. De 
cellulairc component van nasopharynx-spoelsels bestond voomamelijk uit polymorfkemige 
granulocyten en l11onocyten bij zowel emstig zieke kinderen als bij kinderen met een mild 
ziektebeeld. Er werden slechts weinig eosinofIele granulocytcn gevonden, ook bij de ernstig 
zieke kinderen. In een subgroep van 15 kindercn werd de virusspecifieke T-cel-respons 
gemeten in perifere bloedmonsters. Er werd een type l-achtige T-cel-respons gevonden, 
gekarakteriseerd door expressie van voornamelijk IFN-y en slechts wcinig IL4 en ILIO, bij 
zowel kinderen met een emstig als met een mild ziektcbeeld. Met gebruik van FACS-
analyse werd cxpressic van IFN-y l11cer in CD8+ T-cellen gevonden dan in CD4+ T-cellen. 
Oit impliceert een virusspecifieke cytoloxische-T-ceI-respons (CTL-respons), over het aJge-
meen geassocieerd met ldaring van de virusinfectie (3,4,15). In het muizcnmodel wordt het 
niet induceren van een CTL-respons na vaccinatie met FI-RSV geassocieerd met de ver-
sterkte ontstekingsreaktie in de longen (13,58). Aan de andere kant worden virusspecifieke 
CD8+ T- cell en, hoewelminder sterk dan C04+ T-cellen, geassocieerd met meer ontsteking 
in de Iongen bij muizen (1,2). Gedctailleerde identiticatie en karakterisering van de CTL-
respons tegen RSV-infectic kan dam'om van belang zijn voor studies die de mogelijk 
immuunpathogenese van RSV bestuderen en voor de ontwikkeling van mogelijke vaccins 
tegen RSV. In hoofdsluk 5.2 worden T-cel kloon8 bestudeerd, die gegenereerd zijn uit 
bloedmonsters van 2 kinderen die recentelijk hersteld waren van een ernstige RSV-infectie. 
Oeze T-celkloons werden gebruikt om HLA klasse-I gerestricteerde CTL-epitopen op het 
RSV fusie proteIne, voor het eerst bij de mens te idenlificeren. In de bloedmonsters van deze 
kinderen werden aIleen CD8+ en geen CD4+ T eel k100ns gedetecteerd, terwijI in dierlllo-
dell en na FI-RSV-vaccinatic hoge frequenties van type 2-cytokine producerende CD4+ 
cellen gedetccteerd werden. 
Gezamenlijk zijn de data in hoofdstuk 5 geen ondersteuning voor de hypothese dat een 
abberante, type 2-achtige, il11muunrespons ten grondslag Jigt aan de pathogenese van ern-
stige natuurlijk optredende RSV-infecties van de lagere luchtwegen. 
Toekomstige richtingen voor RSV research 
Reeentelijk is passieve il11munoprofylaxe bij kinderen met een hoog risico zinvol gebleken 
in de vorm van maandelijkse toediening van intravenells gallllllaglobuline of een gehu-
maniseerd anti-RSV-monoklonaal. De Illeest kosten-effectieve en praktische opJossing ter 
preventie van el11stige RSV-infccties blijft natuurlijk de ontwikkeling van een effectiefvac-
cin. Zoals bediscussiecrd in hoofdstuk 6.1 is voor het ontwikkelen van een vcilig en effec-
tief vaccin gedetailleerde kennis noodzakelijk van beschermende en ziekte versterkende 
l11cchanismen bij RSV-infectics. 
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Er komcn steeds mccr technieken beschikbaar waarmee de immllllnrespons in detail 
bestudcerd kan worden. De ELIspot tcchniek is bijvoorbeeld cen gevoelige en tcchnisch 
goed bruikbare methode om de T eel respolls te bestllderen wanneer maar kleine hoevcel-
heden patientmateriaal beschikbaar zijn. De recent beschikbaar gekomcn. Een andere voor-
beeld is de DNA-array technologie. Hiermce is het l110gelijk 0111 l11essenger-RNA-profielen 
van vele cytokines en hun rcceptoren uit een monster te bepalen, waarmec de immllllolo-
gisehe rcspons gedetaillccrd gekarakteriseerd kan worden. 
Dezc en andere technieken kllnncn een bijdrage lcveren aan onze kennis van de RSV-speci-
fieke immuunrespons en aan het bepalen van de meest veelbelovende richting voor het 
ontwikkelcn van veilige en cffectieve stratcgieell ter voorkol11ing van RSV-infectics. 
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